metformin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antihyperglycaemics, phenformin derivatives 1725 657-24-9

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • metformin
  • metformin hydrochloride
  • glucophage
  • LA-6023
  • LA 6023
  • N,N-dimethylguanylguanidine
  • metformin HCl
A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
  • Molecular weight: 129.17
  • Formula: C4H11N5
  • CLOGP: -1.43
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 4
  • TPSA: 88.99
  • ALOGS: -1.97
  • ROTB: 0

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
2 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 99 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 387.10 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 52 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.64 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 7.40 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 1 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 1.70 hours Lombardo F, Berellini G, Obach RS
S (Water solubility) 100 mg/mL Bocci G, Oprea TI, Benet LZ

Approvals:

DateAgencyCompanyOrphan
March 3, 1995 FDA BRISTOL MYERS SQUIBB
July 28, 2006 EMA CHEPLAPHARM Arzneimittel GmbH
Jan. 1, 1961 PMDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Lactic acidosis 15268.58 9.90 6357 360186 31930 63090549
Acute kidney injury 4034.17 9.90 6179 360364 257236 62865243
Hypoglycaemia 3384.52 9.90 2791 363752 57274 63065205
Metabolic acidosis 3180.93 9.90 2392 364151 42677 63079802
Diabetic ketoacidosis 2288.60 9.90 1444 365099 19061 63103418
Blood glucose increased 1988.43 9.90 2434 364109 81322 63041157
Ketoacidosis 1117.57 9.90 533 366010 3845 63118634
Diabetes mellitus inadequate control 1100.09 9.90 818 365725 14308 63108171
Glycosylated haemoglobin increased 1056.06 9.90 738 365805 11660 63110819
Euglycaemic diabetic ketoacidosis 1038.74 9.90 480 366063 3194 63119285
Hyperkalaemia 991.14 9.90 1386 365157 52817 63069662
Hyperglycaemia 903.81 9.90 1161 365382 40706 63081773
Pemphigus 884.51 9.90 42 366501 183684 62938795
Systemic lupus erythematosus 881.68 9.90 91 366452 208827 62913652
Glossodynia 794.80 9.90 63 366480 178813 62943666
Hand deformity 734.82 9.90 47 366496 159410 62963069
Hypoglycaemic coma 598.41 9.90 294 366249 2281 63120198
Drug ineffective 584.59 9.90 3595 362948 1041170 62081309
Drug intolerance 567.73 9.90 567 365976 308094 62814385
Synovitis 567.21 9.90 186 366357 186732 62935747
Contraindicated product administered 562.01 9.90 277 366266 217371 62905108
Arthropathy 556.49 9.90 333 366210 234459 62888020
Pericarditis 545.48 9.90 61 366482 131518 62990961
Infusion related reaction 510.29 9.90 402 366141 245119 62877360
Shock 505.22 9.90 650 365893 22813 63099666
Wound 477.09 9.90 173 366370 163090 62959389
Duodenal ulcer perforation 471.25 9.90 6 366537 87203 63035276
Hyperlactacidaemia 468.74 9.90 258 366285 2591 63119888
Alopecia 458.23 9.90 778 365765 336758 62785721
Swelling 450.11 9.90 557 365986 274821 62847658
Anuria 444.45 9.90 450 366093 12101 63110378
Pancreatitis acute 437.02 9.90 654 365889 26512 63095967
Blood glucose decreased 434.83 9.90 570 365973 20382 63102097
Treatment failure 428.72 9.90 314 366229 198729 62923750
Renal failure 426.60 9.90 1571 364972 116081 63006398
Pancreatitis 418.54 9.90 895 365648 48160 63074319
Joint swelling 407.45 9.90 797 365746 326869 62795610
Helicobacter infection 397.47 9.90 38 366505 92747 63029732
Discomfort 388.58 9.90 243 366300 167131 62955348
Diarrhoea 387.14 9.90 6030 360513 709336 62413143
Diabetic metabolic decompensation 372.95 9.90 187 366356 1523 63120956
Therapeutic product effect decreased 359.33 9.90 351 366192 192836 62929643
Blood glucose abnormal 353.32 9.90 322 366221 7570 63114909
Rheumatoid factor positive 347.58 9.90 40 366503 84366 63038113
Hypersensitivity 332.59 9.90 749 365794 291936 62830543
Folliculitis 325.96 9.90 20 366523 70297 63052182
Dehydration 319.88 9.90 1900 364643 171454 62951025
Vomiting 314.29 9.90 4749 361794 554868 62567611
Muscle injury 310.87 9.90 16 366527 65329 63057150
Pemphigoid 310.08 9.90 290 366253 7054 63115425
Rash 301.93 9.90 1949 364594 558922 62563557
Irritable bowel syndrome 279.65 9.90 66 366477 82346 63040133
Rheumatoid arthritis 278.24 9.90 662 365881 253157 62869322
Abdominal discomfort 269.89 9.90 949 365594 319936 62802543
Product use issue 265.60 9.90 546 365997 219974 62902505
Drug level increased 264.76 9.90 473 366070 22263 63100216
Sleep disorder due to general medical condition, insomnia type 264.55 9.90 8 366535 52209 63070270
Toxicity to various agents 260.77 9.90 2371 364172 244879 62877600
Pain 259.20 9.90 2883 363660 737745 62384734
Infection 257.34 9.90 590 365953 228583 62893896
Off label use 254.71 9.90 2579 363964 671883 62450596
Hypothermia 252.11 9.90 350 366193 13231 63109248
Haemodialysis 248.38 9.90 282 366261 8665 63113814
Impaired healing 230.90 9.90 154 366389 102388 63020091
Musculoskeletal stiffness 228.35 9.90 450 366093 184168 62938311
Drug interaction 225.87 9.90 2166 364377 226965 62895514
Diabetes mellitus 212.07 9.90 757 365786 55053 63067426
Blood lactic acid increased 211.57 9.90 232 366311 6854 63115625
Rhabdomyolysis 210.69 9.90 645 365898 43306 63079173
Stomatitis 209.63 9.90 297 366246 138428 62984051
Rheumatic fever 206.83 9.90 10 366533 43101 63079378
Hepatic enzyme increased 205.11 9.90 549 365994 201779 62920700
Maternal exposure during pregnancy 201.97 9.90 626 365917 219436 62903043
Continuous haemodiafiltration 187.11 9.90 99 366444 912 63121567
Pancreatic carcinoma 171.56 9.90 216 366327 7412 63115067
Ill-defined disorder 169.43 9.90 134 366409 81621 63040858
Vitamin B12 deficiency 167.74 9.90 179 366364 5124 63117355
Blood glucose fluctuation 167.38 9.90 167 366376 4409 63118070
Weight decreased 157.00 9.90 2355 364188 274443 62848036
Blister 155.68 9.90 322 366221 129492 62992987
Pyrexia 152.91 9.90 1860 364683 468618 62653861
Completed suicide 150.84 9.90 1392 365151 144281 62978198
Febrile neutropenia 148.74 9.90 286 366257 118163 63004316
Arthralgia 146.22 9.90 2362 364181 567348 62555131
Overdose 146.21 9.90 1151 365392 113927 63008552
Neurologic neglect syndrome 145.85 9.90 123 366420 2598 63119881
Hypomagnesaemia 142.67 9.90 427 366116 28310 63094169
Carotid artery thrombosis 140.99 9.90 122 366421 2672 63119807
Hip arthroplasty 138.20 9.90 51 366492 47595 63074884
Contusion 135.35 9.90 430 366113 149614 62972865
Drug hypersensitivity 135.31 9.90 1145 365398 309542 62812937
Fatigue 131.59 9.90 4017 362526 884011 62238468
Personality disorder 131.41 9.90 165 366378 5646 63116833
Tachypnoea 128.76 9.90 299 366244 17003 63105476
Intentional overdose 127.86 9.90 799 365744 73353 63049126
Acidosis 127.33 9.90 231 366312 11002 63111477
Adjustment disorder 125.60 9.90 121 366422 3057 63119422
Sinusitis 125.37 9.90 780 365763 225873 62896606
Nausea 124.38 9.90 6073 360470 848398 62274081
Hemiplegia 123.00 9.90 205 366338 9118 63113361
Psoriasis 120.67 9.90 888 365655 86069 63036410
Polyuria 119.68 9.90 193 366350 8349 63114130
Renal impairment 119.61 9.90 897 365646 87458 63035021
C-reactive protein abnormal 116.81 9.90 60 366483 46036 63076443
Mobility decreased 115.11 9.90 339 366204 120820 63001659
Myocardial infarction 114.42 9.90 976 365567 98917 63023562
Blood creatinine increased 107.94 9.90 872 365671 86972 63035507
Blood bicarbonate decreased 106.96 9.90 107 366436 2834 63119645
Cardiac arrest 106.41 9.90 905 365638 91640 63030839
Hypotension 102.00 9.90 2172 364371 270432 62852047
Ketosis 99.43 9.90 55 366488 558 63121921
Liver injury 97.02 9.90 124 366419 60396 63062083
Acetonaemia 94.66 9.90 34 366509 103 63122376
Therapeutic product effect incomplete 94.44 9.90 386 366157 124670 62997809
Therapy non-responder 92.90 9.90 186 366357 75715 63046764
Urine ketone body present 92.76 9.90 92 366451 2411 63120068
Neutropenia 92.27 9.90 611 365932 174394 62948085
Fibromyalgia 91.80 9.90 205 366338 80215 63042264
Injection site nodule 91.71 9.90 112 366431 3723 63118756
Anion gap increased 90.59 9.90 80 366463 1802 63120677
MELAS syndrome 89.99 9.90 33 366510 108 63122371
Knee arthroplasty 87.99 9.90 110 366433 54096 63068383
Product residue present 86.84 9.90 111 366432 3868 63118611
Diabetic neuropathy 80.92 9.90 107 366436 3857 63118622
Affect lability 78.95 9.90 189 366354 10962 63111517
Angioedema 78.44 9.90 510 366033 47455 63075024
Postprandial hypoglycaemia 77.83 9.90 25 366518 47 63122432
Hyponatraemia 77.50 9.90 987 365556 110913 63011566
Tubulointerstitial nephritis 77.32 9.90 272 366271 19631 63102848
Blood cholesterol increased 76.27 9.90 282 366261 93750 63028729
Nasopharyngitis 74.69 9.90 1026 365517 253231 62869248
Psoriatic arthropathy 73.88 9.90 275 366268 91245 63031234
Hypoglycaemic encephalopathy 73.62 9.90 36 366507 276 63122203
Dysarthria 72.84 9.90 459 366084 42252 63080227
Hepatic steatosis 72.60 9.90 344 366199 28425 63094054
Motor dysfunction 72.57 9.90 179 366364 10582 63111897
Bradycardia 71.37 9.90 691 365852 72536 63049943
Circulatory collapse 71.21 9.90 283 366260 21655 63100824
Drug level above therapeutic 70.67 9.90 111 366432 4694 63117785
Condition aggravated 70.36 9.90 1776 364767 400441 62722038
Myopathy 70.08 9.90 181 366362 11010 63111469
Urinary tract discomfort 69.92 9.90 45 366498 615 63121864
Diabetic retinopathy 69.14 9.90 76 366467 2251 63120228
Ketonuria 67.89 9.90 44 366499 609 63121870
Microalbuminuria 67.43 9.90 37 366506 369 63122110
Oliguria 67.41 9.90 157 366386 8944 63113535
Bone erosion 66.77 9.90 11 366532 17706 63104773
Glomerular filtration rate decreased 66.03 9.90 199 366344 13242 63109237
Coma acidotic 65.34 9.90 25 366518 95 63122384
Renal tubular necrosis 65.22 9.90 183 366360 11695 63110784
Sensory loss 64.54 9.90 166 366377 10072 63112407
Insulin resistance 62.74 9.90 47 366496 831 63121648
Bursitis 62.42 9.90 73 366470 36968 63085511
Hypovolaemic shock 61.62 9.90 121 366422 6120 63116359
Atrioventricular block 61.17 9.90 136 366407 7511 63114968
Glycosylated haemoglobin decreased 60.97 9.90 39 366504 527 63121952
Anaemia vitamin B12 deficiency 60.94 9.90 35 366508 384 63122095
Eating disorder 60.68 9.90 244 366299 18772 63103707
Unresponsive to stimuli 60.55 9.90 368 366175 33448 63089031
Product prescribing error 60.37 9.90 306 366237 25983 63096496
Foot deformity 59.80 9.90 44 366499 27809 63094670
Cerebrovascular accident 58.75 9.90 913 365630 107111 63015368
Product use in unapproved indication 58.72 9.90 706 365837 178374 62944105
Cerebral venous thrombosis 58.64 9.90 66 366477 2008 63120471
Vasoplegia syndrome 58.48 9.90 60 366483 1639 63120840
Glycosylated haemoglobin abnormal 57.93 9.90 25 366518 138 63122341
Alveolar osteitis 57.30 9.90 45 366498 856 63121623
Peripheral swelling 57.06 9.90 1137 365406 264805 62857674
Product odour abnormal 56.30 9.90 52 366491 1244 63121235
Haemodynamic instability 55.87 9.90 147 366396 9043 63113436
Adverse event 55.84 9.90 201 366342 67358 63055121
Macular degeneration 55.67 9.90 36 366507 24340 63098139
Accidental overdose 55.42 9.90 274 366269 23035 63099444
Blood potassium increased 55.32 9.90 231 366312 18078 63104401
Intentional product use issue 55.26 9.90 472 366071 127420 62995059
Polydipsia 54.74 9.90 84 366459 3480 63118999
Dialysis 54.67 9.90 158 366385 10269 63112210
Facet joint syndrome 54.63 9.90 4 366539 12134 63110345
Joint range of motion decreased 54.54 9.90 64 366479 32364 63090115
Blood ketone body increased 54.46 9.90 29 366514 271 63122208
Suspected suicide 53.89 9.90 118 366425 6450 63116029
Inflammation 53.67 9.90 268 366275 82005 63040474
Hyperglycaemic hyperosmolar nonketotic syndrome 53.61 9.90 45 366498 944 63121535
Multiple organ dysfunction syndrome 53.57 9.90 532 366011 56220 63066259
Anaemia megaloblastic 53.48 9.90 33 366510 417 63122062
Cytomegalovirus infection 52.00 9.90 28 366515 20924 63101555
Lower respiratory tract infection 51.64 9.90 501 366042 131806 62990673
Prerenal failure 51.45 9.90 56 366487 1640 63120839
Hemiparesis 51.37 9.90 268 366275 23014 63099465
Choreoathetosis 50.99 9.90 34 366509 495 63121984
Blood creatine phosphokinase increased 50.64 9.90 325 366218 30105 63092374
Disease progression 50.41 9.90 459 366084 122299 63000180
Abdominal pain 50.21 9.90 2122 364421 291334 62831145
Parkinsonism 49.82 9.90 153 366390 10286 63112193
Cholelithiasis 49.12 9.90 427 366116 43498 63078981
Immune-mediated myositis 49.10 9.90 49 366494 1294 63121185
Macroangiopathy 48.94 9.90 20 366523 94 63122385
Anhidrosis 48.27 9.90 20 366523 98 63122381
Grip strength decreased 48.12 9.90 35 366508 22252 63100227
Pancreatic carcinoma metastatic 47.91 9.90 61 366482 2117 63120362
Death 47.86 9.90 1724 364819 372657 62749822
Amylase increased 47.59 9.90 110 366433 6235 63116244
Lip dry 47.56 9.90 15 366528 15455 63107024
Tunnel vision 47.49 9.90 46 366497 1170 63121309
Toothache 47.30 9.90 228 366315 18971 63103508
Blood triglycerides increased 47.08 9.90 169 366374 12319 63110160
Acute coronary syndrome 47.02 9.90 147 366396 9979 63112500
Aphasia 46.90 9.90 339 366204 32661 63089818
Migraine 46.64 9.90 377 366166 102969 63019510
Athetosis 45.93 9.90 16 366527 43 63122436
Osmolar gap increased 45.71 9.90 19 366524 94 63122385
Osmolar gap 45.23 9.90 19 366524 97 63122382
Thrombocytopenia 45.05 9.90 608 365935 150549 62971930
Pneumonia 44.74 9.90 2168 364375 454599 62667880
Latent autoimmune diabetes in adults 44.66 9.90 13 366530 14 63122465
Distributive shock 44.30 9.90 47 366496 1336 63121143
Polymyalgia rheumatica 44.29 9.90 79 366464 3712 63118767
Leukopenia 44.23 9.90 263 366280 77027 63045452
Diabetic nephropathy 44.09 9.90 48 366495 1406 63121073
Suicide attempt 43.73 9.90 541 366002 60377 63062102
Blindness transient 43.72 9.90 78 366465 3666 63118813
Bladder pain 43.61 9.90 60 366483 2248 63120231
Lipase increased 43.49 9.90 141 366402 9759 63112720
Sopor 43.42 9.90 247 366296 21917 63100562
Chorea 43.07 9.90 50 366493 1574 63120905
Myelosuppression 42.93 9.90 44 366499 23659 63098820
Breast cancer stage III 42.55 9.90 5 366538 10381 63112098
White blood cell count decreased 42.37 9.90 557 365986 138547 62983932
Transplant rejection 42.21 9.90 6 366537 10774 63111705
High density lipoprotein decreased 41.89 9.90 57 366486 2113 63120366
Exposure during pregnancy 41.74 9.90 1185 365358 154362 62968117
Electrocardiogram T wave peaked 41.73 9.90 22 366521 201 63122278
Animal scratch 41.59 9.90 46 366497 1372 63121107
Prescribed overdose 41.52 9.90 84 366459 34069 63088410
Blood pressure systolic increased 41.25 9.90 437 366106 46960 63075519
Gastroenteritis 41.22 9.90 279 366264 26311 63096168
Lung disorder 41.07 9.90 202 366341 62059 63060420
Gastrointestinal disorder 40.89 9.90 523 366020 130716 62991763
Pollakiuria 40.86 9.90 289 366254 27648 63094831
Cleft lip 40.76 9.90 18 366525 106 63122373
Device expulsion 40.68 9.90 88 366455 34834 63087645
Pharyngitis 40.47 9.90 226 366317 19917 63102562
Coronary artery disease 40.07 9.90 322 366221 32055 63090424
Diabetic ketosis 40.00 9.90 23 366520 253 63122226
Pneumocystis jirovecii pneumonia 39.98 9.90 24 366519 16890 63105589
Pregnancy 39.54 9.90 97 366446 36739 63085740
Adjustment disorder with depressed mood 39.21 9.90 6 366537 10198 63112281
Adenocarcinoma pancreas 38.80 9.90 39 366504 1039 63121440
Cytokine release syndrome 38.76 9.90 17 366526 14297 63108182
Night sweats 38.52 9.90 148 366395 48666 63073813
Persistent cloaca 37.73 9.90 20 366523 185 63122294
Left ventricular hypertrophy 37.53 9.90 90 366453 5225 63117254
Malignant mediastinal neoplasm 37.48 9.90 44 366499 1402 63121077
Coordination abnormal 37.19 9.90 168 366375 13605 63108874
Multiple sclerosis relapse 36.97 9.90 149 366394 48329 63074150
Asthenia 36.95 9.90 2630 363913 380974 62741505
Loss of personal independence in daily activities 36.45 9.90 372 366171 96918 63025561
Cold sweat 36.40 9.90 152 366391 11895 63110584
Tenosynovitis 36.40 9.90 17 366526 13778 63108701
Kussmaul respiration 36.36 9.90 21 366522 233 63122246
Neurotoxicity 36.27 9.90 27 366516 16963 63105516
Exposure via ingestion 35.77 9.90 62 366481 2847 63119632
Autoimmune disorder 35.77 9.90 28 366515 17149 63105330
Hypovolaemia 35.71 9.90 139 366404 10534 63111945
Blood pH decreased 35.63 9.90 58 366485 2529 63119950
Vitamin B12 decreased 35.52 9.90 70 366473 3550 63118929
Muscle necrosis 35.40 9.90 30 366513 638 63121841
Peripheral venous disease 35.15 9.90 23 366520 15454 63107025
C-reactive protein increased 35.12 9.90 363 366180 94344 63028135
Decreased appetite 35.07 9.90 1779 364764 249273 62873206
Hypophagia 35.02 9.90 304 366239 30955 63091524
Dysentery 35.02 9.90 35 366508 926 63121553
Blood iron decreased 34.96 9.90 173 366370 14548 63107931
Haemofiltration 34.87 9.90 9 366534 3 63122476
Neutrophil count decreased 34.39 9.90 188 366355 56218 63066261
Lupus-like syndrome 34.37 9.90 23 366520 15272 63107207
Arthritis 34.27 9.90 467 366076 115454 63007025
Incorrect route of product administration 33.81 9.90 67 366476 27385 63095094
Ischaemic stroke 33.80 9.90 198 366345 17759 63104720
Hospitalisation 33.68 9.90 321 366222 84760 63037719
Joint stiffness 33.65 9.90 126 366417 41743 63080736
Malaise 33.32 9.90 2811 363732 413143 62709336
Bone marrow failure 33.14 9.90 75 366468 29215 63093264
Seizure 33.14 9.90 552 365991 132082 62990397
Injection site reaction 33.03 9.90 200 366343 58324 63064155
Bladder sphincter atony 32.94 9.90 17 366526 148 63122331
Angina pectoris 32.91 9.90 291 366252 29787 63092692
Acute myocardial infarction 32.71 9.90 306 366237 31818 63090661
Product substitution issue 32.49 9.90 180 366363 15816 63106663
Chronic sinusitis 32.11 9.90 17 366526 12826 63109653
Pancreatitis chronic 31.94 9.90 54 366489 2430 63120049
Headache 31.89 9.90 3186 363357 630055 62492424
Pulmonary fibrosis 31.87 9.90 120 366423 39689 63082790
Drug resistance 31.81 9.90 52 366491 22881 63099598
Haemophagocytic lymphohistiocytosis 31.45 9.90 11 366532 10616 63111863
Body mass index increased 31.42 9.90 37 366506 1183 63121296
Malignant neoplasm progression 31.18 9.90 313 366230 81808 63040671
Glucose urine present 31.08 9.90 29 366514 703 63121776
Intestinal malrotation 30.91 9.90 22 366521 358 63122121
Lower limb fracture 30.80 9.90 58 366485 24163 63098316
Mechanical ventilation complication 30.75 9.90 8 366535 3 63122476
Dysuria 30.74 9.90 314 366229 33424 63089055
Osteoporosis 30.28 9.90 200 366343 57138 63065341
Wound infection 30.21 9.90 48 366495 21362 63101117
Osteoarthritis 30.05 9.90 379 366164 94964 63027515
Urine albumin/creatinine ratio abnormal 29.89 9.90 9 366534 12 63122467
Anovulatory cycle 29.82 9.90 16 366527 152 63122327
Breast cancer stage II 29.62 9.90 7 366536 8729 63113750
Blood pressure systolic decreased 29.52 9.90 102 366441 7295 63115184
Albuminuria 29.34 9.90 18 366525 225 63122254
General physical health deterioration 29.31 9.90 912 365631 200490 62921989
Enthesopathy 29.01 9.90 7 366536 8607 63113872
Allergic reaction to excipient 28.98 9.90 21 366522 352 63122127
Disability 28.98 9.90 38 366505 18309 63104170
Pancreatic mass 28.75 9.90 31 366512 898 63121581
Wrong patient received product 28.41 9.90 48 366495 2159 63120320
Epstein-Barr virus infection 28.20 9.90 6 366537 8044 63114435
Pain in jaw 28.18 9.90 142 366401 43354 63079125
Wound complication 28.15 9.90 65 366478 3682 63118797
Infective pulmonary exacerbation of cystic fibrosis 28.10 9.90 8 366535 8809 63113670
Maternal exposure timing unspecified 27.62 9.90 4 366539 7083 63115396
Necrotising myositis 27.46 9.90 24 366519 533 63121946
Insulin C-peptide decreased 27.34 9.90 9 366534 19 63122460
Posterior reversible encephalopathy syndrome 27.32 9.90 36 366507 17309 63105170
Haematotoxicity 27.25 9.90 10 366533 9366 63113113
Blood lactic acid 27.22 9.90 13 366530 94 63122385
Eosinophilic myocarditis 27.17 9.90 25 366518 595 63121884
Skin haemorrhage 27.16 9.90 123 366420 9971 63112508
Anaemia macrocytic 27.15 9.90 61 366482 3393 63119086
Swollen tongue 27.14 9.90 314 366229 34486 63087993
Conjoined twins 27.00 9.90 18 366525 262 63122217
Anion gap abnormal 26.94 9.90 21 366522 395 63122084
Diabetic hyperosmolar coma 26.87 9.90 20 366523 350 63122129
Injection site erythema 26.82 9.90 329 366214 82845 63039634
Blood urea increased 26.72 9.90 251 366292 26128 63096351
Mouth ulceration 26.68 9.90 99 366444 32885 63089594
Ear congestion 26.65 9.90 53 366490 2706 63119773
Fall 26.63 9.90 2620 363923 389714 62732765
Breast cancer stage I 26.59 9.90 4 366539 6885 63115594
Urinary tract infection 26.55 9.90 1821 364722 262863 62859616
Aspergillus infection 26.44 9.90 7 366536 8086 63114393
Blood phosphorus increased 26.37 9.90 57 366486 3088 63119391
Injury 26.24 9.90 283 366260 72964 63049515
Cholecystitis chronic 26.22 9.90 124 366419 10237 63112242
Sedation 26.12 9.90 125 366418 38684 63083795
Progressive multifocal leukoencephalopathy 25.94 9.90 22 366521 12949 63109530
Platelet count decreased 25.92 9.90 493 366050 115629 63006850
Therapeutic response decreased 25.70 9.90 229 366314 61296 63061183
Red blood cell sedimentation rate increased 25.51 9.90 149 366394 43833 63078646
Fungal infection 25.40 9.90 325 366218 36549 63085930
Retinitis 25.34 9.90 3 366540 6193 63116286
Shock hypoglycaemic 25.31 9.90 13 366530 112 63122367
Pleural effusion 25.26 9.90 382 366161 92828 63029651
Syncope 25.07 9.90 870 365673 116515 63005964
Inappropriate antidiuretic hormone secretion 25.03 9.90 164 366379 15298 63107181
Diabetic foot 24.94 9.90 36 366507 1411 63121068
Hepatic function abnormal 24.78 9.90 120 366423 37022 63085457
Azotaemia 24.66 9.90 69 366474 4402 63118077
Malabsorption 24.62 9.90 65 366478 4007 63118472
Bone density decreased 24.40 9.90 29 366514 14583 63107896
Neutrophilia 24.30 9.90 68 366475 4338 63118141
Temperature perception test abnormal 24.27 9.90 8 366535 17 63122462
Glomerular filtration rate abnormal 24.23 9.90 27 366516 812 63121667
Pancreatic injury 24.20 9.90 9 366534 31 63122448
Hyperventilation 24.11 9.90 84 366459 6032 63116447
Foreign body aspiration 24.08 9.90 15 366528 193 63122286
Blood pressure increased 23.98 9.90 1155 365388 160907 62961572
Apolipoprotein A-I decreased 23.96 9.90 8 366535 18 63122461
Joint dislocation 23.92 9.90 45 366498 18755 63103724
Hypoglycaemic seizure 23.85 9.90 21 366522 471 63122008
Renal abscess 23.82 9.90 26 366517 764 63121715
Drug abuse 23.70 9.90 286 366257 72232 63050247
Hyperinsulinaemia 23.70 9.90 12 366531 100 63122379
Non-alcoholic steatohepatitis 23.57 9.90 38 366505 1643 63120836
Macular oedema 23.55 9.90 62 366481 3815 63118664
IIIrd nerve paresis 23.33 9.90 13 366530 134 63122345
Base excess decreased 23.22 9.90 11 366532 78 63122401
Autoimmune myositis 23.16 9.90 13 366530 136 63122343
Myalgia 23.11 9.90 1051 365492 145478 62977001
Drug tolerance decreased 22.97 9.90 41 366502 17432 63105047
Postmenopausal haemorrhage 22.96 9.90 43 366500 2099 63120380
Sleep disorder 22.89 9.90 332 366211 81234 63041245
Electrolyte imbalance 22.88 9.90 196 366347 19880 63102599
Immunodeficiency 22.80 9.90 52 366491 20202 63102277
Oedematous pancreatitis 22.73 9.90 22 366521 559 63121920
Cholestatic liver injury 22.68 9.90 48 366495 2562 63119917
Blood growth hormone increased 22.66 9.90 20 366523 450 63122029
Mucosal inflammation 22.66 9.90 168 366375 46760 63075719
Unintentional medical device removal 22.59 9.90 4 366539 6111 63116368
Needle issue 22.59 9.90 119 366424 10257 63112222
Congenital absence of bile ducts 22.58 9.90 8 366535 23 63122456
Atrioventricular block complete 22.55 9.90 101 366442 8150 63114329
Cardiac failure 22.49 9.90 674 365869 88468 63034011
Urine output decreased 22.46 9.90 127 366416 11243 63111236
Cytomegalovirus viraemia 22.46 9.90 3 366540 5646 63116833
Hypoglycaemic unconsciousness 22.44 9.90 25 366518 752 63121727
Thrombotic microangiopathy 22.26 9.90 17 366526 10544 63111935
Insulin-like growth factor increased 22.24 9.90 27 366516 892 63121587
Hypertriglyceridaemia 22.16 9.90 83 366460 6176 63116303
Sinus disorder 22.12 9.90 228 366315 24325 63098154
Atrial fibrillation 22.12 9.90 853 365690 115783 63006696
Incorrect dose administered 22.10 9.90 477 366066 59491 63062988
Pulseless electrical activity 22.03 9.90 94 366449 7427 63115052
Deformity 21.95 9.90 21 366522 11663 63110816
Base excess negative 21.92 9.90 6 366537 4 63122475
Blood insulin decreased 21.85 9.90 7 366536 13 63122466
Carcinoid tumour of the stomach 21.78 9.90 13 366530 154 63122325
Hypertensive crisis 21.70 9.90 157 366386 15129 63107350
Hypercholesterolaemia 21.49 9.90 58 366485 21276 63101203
Hyperinsulinaemic hypoglycaemia 21.45 9.90 10 366533 68 63122411
Body temperature decreased 21.41 9.90 195 366348 20124 63102355
Mitochondrial enzyme deficiency 21.41 9.90 8 366535 28 63122451
Increased appetite 21.35 9.90 111 366432 9519 63112960
Blood ketone body 21.26 9.90 9 366534 47 63122432
Diabetic ulcer 21.16 9.90 14 366529 201 63122278
Thirst 20.97 9.90 146 366397 13895 63108584
Hypoglycaemia neonatal 20.96 9.90 27 366516 948 63121531
Lactate pyruvate ratio abnormal 20.80 9.90 5 366538 0 63122479
Multiple cardiac defects 20.80 9.90 5 366538 0 63122479
Hepatosplenomegaly neonatal 20.80 9.90 5 366538 0 63122479
Overweight 20.80 9.90 58 366485 3693 63118786
Stevens-Johnson syndrome 20.76 9.90 74 366469 24876 63097603
Congenital bladder anomaly 20.62 9.90 13 366530 171 63122308
Oral herpes 20.61 9.90 79 366464 25995 63096484
Orbital swelling 20.52 9.90 9 366534 52 63122427
Coma scale abnormal 20.51 9.90 71 366472 5082 63117397
Drug ineffective for unapproved indication 20.51 9.90 114 366429 33949 63088530
Sedation complication 20.45 9.90 30 366513 13792 63108687
Calculus urinary 20.39 9.90 32 366511 1352 63121127
Blood calcium decreased 20.36 9.90 81 366462 26370 63096109
Hyperhidrosis 20.29 9.90 788 365755 107048 63015431
Medication error 20.28 9.90 419 366124 51865 63070614
Eyelid bleeding 20.21 9.90 8 366535 34 63122445
Jaundice hepatocellular 20.21 9.90 8 366535 34 63122445
Cardiovascular disorder 20.17 9.90 127 366416 11685 63110794
Anion gap 20.17 9.90 31 366512 1286 63121193
Rheumatoid nodule 20.17 9.90 43 366500 17112 63105367
Urachal abnormality 20.11 9.90 13 366530 179 63122300
Pathogen resistance 20.03 9.90 6 366537 6392 63116087
Musculoskeletal pain 19.91 9.90 394 366149 91883 63030596
CD30 expression 19.85 9.90 8 366535 36 63122443
Liver disorder 19.81 9.90 206 366337 53481 63068998
Clostridium difficile infection 19.78 9.90 97 366446 29825 63092654
Metabolic syndrome 19.73 9.90 34 366509 1554 63120925
Prothrombin consumption time prolonged 19.68 9.90 8 366535 37 63122442
Skin turgor decreased 19.53 9.90 20 366523 545 63121934
Osmolar gap abnormal 19.51 9.90 8 366535 38 63122441
Metastases to retroperitoneum 19.42 9.90 12 366531 152 63122327
Musculoskeletal disorder 19.42 9.90 58 366485 20586 63101893
Bronchopulmonary aspergillosis 19.38 9.90 13 366530 8622 63113857
Febrile bone marrow aplasia 19.37 9.90 9 366534 7316 63115163
Crush syndrome 19.36 9.90 11 366532 118 63122361
Transient ischaemic attack 19.35 9.90 316 366227 37437 63085042
Epileptic encephalopathy 19.25 9.90 15 366528 282 63122197
Decreased bronchial secretion 19.21 9.90 9 366534 62 63122417
Oxygen saturation immeasurable 19.13 9.90 6 366537 10 63122469
Urosepsis 19.13 9.90 177 366366 18347 63104132
Resuscitation 19.05 9.90 28 366515 1116 63121363
Bronchopulmonary aspergillosis allergic 19.02 9.90 41 366502 2217 63120262
Device dislocation 18.98 9.90 80 366463 25625 63096854
Congenital aortic valve stenosis 18.97 9.90 9 366534 64 63122415
Pulmonary toxicity 18.95 9.90 16 366527 9439 63113040
Blood immunoglobulin E increased 18.92 9.90 57 366486 3792 63118687
Female genital tract fistula 18.91 9.90 10 366533 7549 63114930
Coeliac disease 18.72 9.90 28 366515 12769 63109710
Impaired work ability 18.57 9.90 168 366375 17307 63105172
Bronchostenosis 18.52 9.90 18 366525 460 63122019
Accidental underdose 18.47 9.90 23 366520 780 63121699
Leukocytosis 18.47 9.90 230 366313 25705 63096774
Thyroglobulin increased 18.42 9.90 8 366535 45 63122434
Electrocardiogram QT prolonged 18.38 9.90 462 366081 59068 63063411
Renal injury 18.36 9.90 105 366438 9334 63113145
Sinus arrest 18.30 9.90 37 366506 1912 63120567
Basilar artery thrombosis 18.24 9.90 11 366532 133 63122346
Hypoparathyroidism 18.19 9.90 21 366522 657 63121822
Hyperphagia 18.18 9.90 35 366508 1744 63120735
Thalamic infarction 18.08 9.90 18 366525 474 63122005
Neuropathy, ataxia, retinitis pigmentosa syndrome 17.99 9.90 8 366535 48 63122431
Genital infection fungal 17.98 9.90 12 366531 175 63122304
Antipsychotic drug level increased 17.96 9.90 52 366491 3383 63119096
Pyelonephritis 17.92 9.90 169 366374 17609 63104870
Creatinine renal clearance 17.89 9.90 5 366538 4 63122475
Wound secretion 17.87 9.90 63 366480 4551 63117928
Herpes simplex 17.84 9.90 13 366530 8258 63114221
Device difficult to use 17.76 9.90 29 366514 12767 63109712
Decreased vibratory sense 17.51 9.90 15 366528 324 63122155
Heart sounds 17.49 9.90 25 366518 971 63121508
Joint effusion 17.48 9.90 46 366497 17014 63105465
Salivary hypersecretion 17.44 9.90 89 366454 7577 63114902
Bicuspid aortic valve 17.31 9.90 10 366533 111 63122368
Creatinine renal clearance abnormal 17.28 9.90 16 366527 384 63122095
Pulmonary hypoplasia 17.28 9.90 14 366529 279 63122200
Hypoaesthesia 17.27 9.90 795 365748 167598 62954881
Differential white blood cell count abnormal 17.27 9.90 22 366521 764 63121715
Muscular weakness 17.26 9.90 868 365675 121485 63000994
Glycosuria 17.24 9.90 27 366516 1139 63121340
Diabetic foot infection 17.09 9.90 12 366531 191 63122288
Prolonged expiration 17.07 9.90 26 366517 1070 63121409
Hormone receptor positive HER2 negative breast cancer 17.05 9.90 11 366532 151 63122328
Acute myeloid leukaemia 16.99 9.90 47 366496 17100 63105379
Antipsychotic drug level decreased 16.98 9.90 15 366528 338 63122141
Neurofibrosarcoma 16.93 9.90 11 366532 153 63122326
Herpes zoster 16.92 9.90 355 366188 82107 63040372
Dry eye 16.90 9.90 152 366391 40609 63081870
Lymphopenia 16.87 9.90 52 366491 18275 63104204
Immune reconstitution inflammatory syndrome 16.84 9.90 7 366536 6077 63116402
Poisoning 16.81 9.90 136 366407 13564 63108915
Nephrogenic systemic fibrosis 16.79 9.90 3 366540 4553 63117926
Blood pressure inadequately controlled 16.79 9.90 65 366478 4913 63117566
Persistent left superior vena cava 16.78 9.90 7 366536 35 63122444
Hypertensive heart disease 16.76 9.90 41 366502 2411 63120068
Oedema 16.75 9.90 432 366111 97190 63025289
Pruritus genital 16.69 9.90 43 366500 2611 63119868
Systemic infection 16.67 9.90 62 366481 4598 63117881
Heart rate increased 16.65 9.90 684 365859 93554 63028925
Congenital uterine anomaly 16.65 9.90 10 366533 120 63122359
Skinfold measurement 16.64 9.90 4 366539 0 63122479
Pleural mesothelioma 16.64 9.90 4 366539 0 63122479
Reactive psychosis 16.64 9.90 4 366539 0 63122479
Blood lactic acid abnormal 16.64 9.90 4 366539 0 63122479
Blood urine present 16.59 9.90 146 366397 14923 63107556
Flatulence 16.51 9.90 287 366256 34415 63088064
Laryngitis viral 16.51 9.90 8 366535 60 63122419
Thyroid cancer recurrent 16.47 9.90 7 366536 37 63122442
Constipation 16.43 9.90 1098 365445 223845 62898634
Vision blurred 16.43 9.90 668 365875 91256 63031223
Renal tubular disorder 16.41 9.90 43 366500 2639 63119840
Altered state of consciousness 16.39 9.90 220 366323 25010 63097469
Diet failure 16.32 9.90 7 366536 38 63122441
Cutaneous T-cell dyscrasia 16.29 9.90 8 366535 62 63122417
Lip swelling 16.29 9.90 261 366282 30802 63091677
Peritonitis 16.27 9.90 48 366495 17106 63105373
Metastases to kidney 16.27 9.90 12 366531 207 63122272
Pancreatic enzymes increased 16.22 9.90 21 366522 741 63121738
Diabetic complication 16.16 9.90 23 366520 890 63121589
Myxoedema coma 16.14 9.90 16 366527 419 63122060
Genital infection 16.11 9.90 11 366532 167 63122312
Skin disorder 16.04 9.90 102 366441 29405 63093074
Blood pressure diastolic decreased 16.01 9.90 201 366342 22505 63099974
Pyelonephritis acute 15.98 9.90 61 366482 4580 63117899
Device related infection 15.94 9.90 75 366468 23317 63099162
Creatinine renal clearance decreased 15.93 9.90 45 366498 16263 63106216
Tumour lysis syndrome 15.93 9.90 17 366526 8973 63113506
Multiple-drug resistance 15.92 9.90 5 366538 5165 63117314
Anal incontinence 15.71 9.90 133 366410 13443 63109036
Product complaint 15.64 9.90 127 366416 12682 63109797
Monoclonal B-cell lymphocytosis 15.61 9.90 7 366536 43 63122436
Blood cholesterol decreased 15.57 9.90 23 366520 921 63121558
Rales 15.56 9.90 126 366417 12571 63109908
Hyporesponsive to stimuli 15.54 9.90 25 366518 1079 63121400
Visceral congestion 15.47 9.90 14 366529 326 63122153
Osteonecrosis of jaw 15.44 9.90 129 366414 34994 63087485
Catheter site erythema 15.36 9.90 3 366540 4273 63118206
Hypocalcaemia 15.35 9.90 263 366280 31450 63091029
Hypokinesia 15.33 9.90 135 366408 13801 63108678
Electrocardiogram abnormal 15.25 9.90 98 366445 9081 63113398
Fluid intake reduced 15.22 9.90 51 366492 3590 63118889
Bradyarrhythmia 15.14 9.90 36 366507 2079 63120400
Eructation 15.11 9.90 91 366452 8242 63114237
Treatment noncompliance 15.09 9.90 301 366242 37024 63085455
Synovial cyst 15.09 9.90 23 366520 10410 63112069
Premature labour 14.99 9.90 31 366512 12473 63110006
Blood electrolytes abnormal 14.90 9.90 24 366519 1037 63121442
Myocardial ischaemia 14.90 9.90 126 366417 12733 63109746
Dyslipidaemia 14.88 9.90 83 366460 7310 63115169
PCO2 decreased 14.88 9.90 27 366516 1286 63121193
Injection site mass 14.84 9.90 169 366374 18487 63103992
No adverse event 14.82 9.90 160 366383 41245 63081234
Left atrial dilatation 14.78 9.90 33 366510 1828 63120651
Live birth 14.77 9.90 87 366456 25543 63096936
Food allergy 14.76 9.90 27 366516 11374 63111105
Lymphocyte count decreased 14.76 9.90 108 366435 30149 63092330
Hyperphosphataemia 14.74 9.90 37 366506 2211 63120268
Drug half-life increased 14.72 9.90 6 366537 28 63122451
Diabetic ketoacidotic hyperglycaemic coma 14.62 9.90 7 366536 51 63122428
Premature delivery 14.61 9.90 251 366292 30030 63092449
Gallbladder oedema 14.61 9.90 11 366532 196 63122283
Hyponatraemic encephalopathy 14.61 9.90 12 366531 244 63122235
Wheezing 14.60 9.90 430 366113 95165 63027314
Low density lipoprotein increased 14.60 9.90 74 366469 6283 63116196
Atelectasis 14.57 9.90 69 366474 21414 63101065
Respiratory tract infection 14.57 9.90 161 366382 41322 63081157
Staphylococcal infection 14.53 9.90 160 366383 41096 63081383
Blood chloride decreased 14.52 9.90 67 366476 5475 63117004
Retinopathy proliferative 14.50 9.90 7 366536 52 63122427
Mental disability 14.48 9.90 8 366535 81 63122398
Retinal artery thrombosis 14.48 9.90 8 366535 81 63122398
Sinus pain 14.47 9.90 48 366495 3362 63119117
Diabetes mellitus management 14.42 9.90 4 366539 3 63122476
Diabetic cheiroarthropathy 14.42 9.90 4 366539 3 63122476
Complication associated with device 14.37 9.90 50 366493 16928 63105551
Bladder cancer 14.37 9.90 67 366476 5499 63116980
Alkalosis hypochloraemic 14.36 9.90 10 366533 157 63122322
Flushing 14.32 9.90 327 366216 74760 63047719
Microcytic anaemia 14.31 9.90 48 366495 3381 63119098
Shock haemorrhagic 14.26 9.90 102 366441 9793 63112686
Leukocyturia 14.19 9.90 28 366515 1421 63121058
Metastases to fallopian tube 14.17 9.90 7 366536 55 63122424
Hypertensive angiopathy 14.15 9.90 8 366535 85 63122394
Scleritis 14.15 9.90 4 366539 4424 63118055
Bronchiectasis 14.12 9.90 149 366394 15993 63106486
Temperature regulation disorder 14.08 9.90 9 366534 6123 63116356
Blood growth hormone abnormal 14.07 9.90 6 366537 32 63122447
Catarrh 14.06 9.90 29 366514 1520 63120959
Bundle branch block left 14.05 9.90 79 366464 6980 63115499
Product administration error 14.01 9.90 194 366349 22203 63100276
Blindness 14.00 9.90 189 366354 21510 63100969
Necrotising fasciitis 13.98 9.90 44 366499 2997 63119482
Paraesthesia 13.97 9.90 752 365791 156214 62966265
Enterochromaffin cell hyperplasia 13.96 9.90 7 366536 57 63122422
Glucose urine 13.96 9.90 5 366538 15 63122464
Ear infection 13.94 9.90 147 366396 38066 63084413
Disturbance in social behaviour 13.94 9.90 3 366540 3990 63118489
Transcription medication error 13.93 9.90 11 366532 211 63122268
Adrenal adenoma 13.93 9.90 23 366520 1015 63121464
Proctitis 13.90 9.90 7 366536 5434 63117045
Hereditary angioedema with normal C1 esterase inhibitor 13.89 9.90 4 366539 4 63122475
Diaphragmatic spasm 13.89 9.90 4 366539 4 63122475
Venous aneurysm 13.89 9.90 4 366539 4 63122475
Pancreatic atrophy 13.83 9.90 10 366533 167 63122312
Hypocapnia 13.81 9.90 14 366529 377 63122102
Vascular purpura 13.81 9.90 28 366515 1450 63121029
Intestinal obstruction 13.80 9.90 113 366430 30786 63091693
Foetal hypokinesia 13.78 9.90 16 366527 504 63121975
Brain stem infarction 13.76 9.90 20 366523 789 63121690
Product blister packaging issue 13.76 9.90 11 366532 215 63122264
Genital swelling 13.74 9.90 9 366534 127 63122352
Peripheral circulatory failure 13.74 9.90 22 366521 946 63121533
Pelvic fracture 13.67 9.90 36 366507 13312 63109167
Dystonia 13.60 9.90 38 366505 13781 63108698
Status epilepticus 13.48 9.90 44 366499 15189 63107290
Hyperprolactinaemia 13.47 9.90 3 366540 3897 63118582
Rash erythematous 13.38 9.90 169 366374 42341 63080138
Empty sella syndrome 13.36 9.90 6 366537 37 63122442
Fat tissue increased 13.36 9.90 18 366525 661 63121818
Food craving 13.34 9.90 29 366514 1577 63120902
Prescription drug used without a prescription 13.33 9.90 37 366506 2349 63120130
Gastrointestinal toxicity 13.32 9.90 15 366528 7726 63114753
Colitis microscopic 13.30 9.90 96 366447 9243 63113236
Periorbital inflammation 13.27 9.90 7 366536 64 63122415
Respiratory acidosis 13.26 9.90 75 366468 6640 63115839
Ballismus 13.21 9.90 9 366534 136 63122343
Choking 13.19 9.90 100 366443 9779 63112700
Skin exfoliation 13.16 9.90 334 366209 42768 63079711
Bladder neoplasm 13.15 9.90 17 366526 599 63121880
Hypervolaemia 13.11 9.90 103 366440 28310 63094169
Hypereosinophilic syndrome 13.10 9.90 12 366531 284 63122195
Peripheral artery haematoma 13.10 9.90 6 366537 39 63122440
Benign pancreatic neoplasm 13.07 9.90 5 366538 19 63122460
Abnormal loss of weight 13.06 9.90 67 366476 5715 63116764
Generalised tonic-clonic seizure 13.01 9.90 106 366437 28910 63093569
Erythromelalgia 12.99 9.90 9 366534 140 63122339
Sensorimotor disorder 12.95 9.90 15 366528 471 63122008
Exostosis 12.93 9.90 56 366487 17806 63104673
Tachycardia 12.92 9.90 819 365724 117337 63005142
Embolic cerebellar infarction 12.87 9.90 5 366538 20 63122459
Loss of consciousness 12.77 9.90 818 365725 117303 63005176
Hypoperfusion 12.77 9.90 27 366516 1440 63121039
Genital rash 12.73 9.90 16 366527 548 63121931
Cortisol increased 12.73 9.90 14 366529 415 63122064
Retching 12.72 9.90 135 366408 14510 63107969
Disorientation 12.72 9.90 308 366235 39144 63083335
Vitamin B6 deficiency 12.71 9.90 8 366535 105 63122374
Blood pressure abnormal 12.70 9.90 139 366404 15059 63107420
Diffuse large B-cell lymphoma 12.69 9.90 12 366531 6700 63115779
Red cell distribution width abnormal 12.67 9.90 9 366534 146 63122333
Urine albumin/creatinine ratio increased 12.66 9.90 12 366531 297 63122182
Blood osmolarity abnormal 12.64 9.90 4 366539 7 63122472
Cutaneous vasculitis 12.57 9.90 62 366481 5207 63117272
Angioplasty 12.56 9.90 26 366517 1366 63121113
Abdominal distension 12.53 9.90 616 365927 85999 63036480
Nodular rash 12.52 9.90 10 366533 195 63122284
Tumour compression 12.49 9.90 6 366537 44 63122435
Ectopia cordis 12.49 9.90 7 366536 73 63122406
Gingival oedema 12.49 9.90 7 366536 73 63122406
Insulin resistant diabetes 12.48 9.90 3 366540 0 63122479
Non-high-density lipoprotein cholesterol decreased 12.48 9.90 3 366540 0 63122479
Vascular encephalopathy 12.41 9.90 14 366529 427 63122052
Palpitations 12.39 9.90 782 365761 111988 63010491
Hypergastrinaemia 12.39 9.90 8 366535 110 63122369
Neck pain 12.36 9.90 305 366238 69013 63053466
Demyelination 12.36 9.90 13 366530 6907 63115572
Psychogenic tremor 12.32 9.90 5 366538 23 63122456
Cholangiectasis acquired 12.29 9.90 4 366539 8 63122471
Metastases to central nervous system 12.19 9.90 37 366506 13068 63109411
Total cholesterol/HDL ratio abnormal 12.17 9.90 7 366536 77 63122402
Renal replacement therapy 12.17 9.90 7 366536 77 63122402
Coronary artery occlusion 12.13 9.90 85 366458 8106 63114373
Sprue-like enteropathy 12.11 9.90 18 366525 725 63121754
Pancreatic neoplasm 12.05 9.90 18 366525 728 63121751
Hidradenitis 12.02 9.90 40 366503 2806 63119673
Maximal voluntary ventilation abnormal 11.99 9.90 5 366538 25 63122454
Large intestine perforation 11.98 9.90 19 366524 8463 63114016
Blindness cortical 11.97 9.90 15 366528 512 63121967
Glycosylated haemoglobin 11.94 9.90 7 366536 80 63122399
Cytomegalovirus infection reactivation 11.90 9.90 4 366539 3959 63118520
Insulin-like growth factor decreased 11.88 9.90 13 366530 383 63122096
Cerebral infarction 11.88 9.90 199 366344 23694 63098785
Medullary thyroid cancer 11.87 9.90 10 366533 211 63122268
Small fibre neuropathy 11.86 9.90 14 366529 449 63122030
Pancreatic failure 11.85 9.90 21 366522 982 63121497
Neuroendocrine tumour 11.83 9.90 18 366525 740 63121739
Adverse drug reaction 11.82 9.90 360 366183 79354 63043125
Haemoglobin increased 11.80 9.90 47 366496 3599 63118880
Skin ulcer 11.80 9.90 176 366367 42869 63079610
Foreign body in reproductive tract 11.78 9.90 18 366525 743 63121736
Blood urea abnormal 11.77 9.90 17 366526 667 63121812
Large intestine polyp 11.71 9.90 84 366459 8073 63114406
Respiratory disorder 11.70 9.90 157 366386 38925 63083554
Hepatic failure 11.69 9.90 279 366264 35377 63087102
Neoplasm malignant 11.67 9.90 113 366430 29748 63092731
Vitreous haemorrhage 11.67 9.90 32 366511 2018 63120461
Hyperparathyroidism secondary 11.63 9.90 26 366517 1441 63121038
Duodenal ulcer haemorrhage 11.63 9.90 36 366507 2431 63120048
Thirst decreased 11.58 9.90 11 366532 273 63122206
Blood triglycerides abnormal 11.57 9.90 12 366531 332 63122147
Metabolic encephalopathy 11.55 9.90 65 366478 5744 63116735
Paranasal sinus discomfort 11.53 9.90 53 366490 4323 63118156
Radiculopathy 11.50 9.90 20 366523 8591 63113888
Incision site swelling 11.48 9.90 10 366533 221 63122258
Cardiac failure congestive 11.48 9.90 648 365895 91785 63030694
Vulvovaginal pruritus 11.48 9.90 43 366500 3200 63119279
Respiratory alkalosis 11.44 9.90 38 366505 2663 63119816
Hernia 11.44 9.90 117 366426 12457 63110022
Electrocardiogram P wave abnormal 11.41 9.90 10 366533 223 63122256
Binge eating 11.40 9.90 14 366529 468 63122011
Colitis ulcerative 11.39 9.90 96 366447 25995 63096484
Adrenal neoplasm 11.36 9.90 13 366530 403 63122076
Lactate pyruvate ratio increased 11.31 9.90 7 366536 89 63122390
Oral candidiasis 11.30 9.90 81 366462 22717 63099762
Thyroid cancer 11.30 9.90 63 366480 5548 63116931
Nephrolithiasis 11.29 9.90 320 366223 41664 63080815
Scleroderma 11.25 9.90 9 366534 5453 63117026
Device use error 11.24 9.90 10 366533 5751 63116728
Clostridium difficile colitis 11.24 9.90 71 366472 20498 63101981
Pulmonary haemorrhage 11.21 9.90 15 366528 7166 63115313
Autoimmune nephritis 11.20 9.90 13 366530 409 63122070
Urticaria 11.16 9.90 815 365728 164987 62957492
Hypertension 11.15 9.90 1427 365116 277876 62844603
Endometrial hyperplasia 11.14 9.90 19 366524 861 63121618
Wheelchair user 11.14 9.90 12 366531 6307 63116172
Barotrauma 11.12 9.90 9 366534 179 63122300
Product size issue 11.12 9.90 12 366531 348 63122131
Rash maculo-papular 11.12 9.90 124 366419 31772 63090707
Urine ketone body 11.10 9.90 8 366535 133 63122346
Fluid retention 11.08 9.90 261 366282 59425 63063054
Grandiosity 11.07 9.90 11 366532 289 63122190
Blood lactate dehydrogenase increased 11.04 9.90 83 366460 23033 63099446
Dizziness 11.04 9.90 2719 363824 427206 62695273
Malignant polyp 11.00 9.90 9 366534 182 63122297
Onychomycosis 10.99 9.90 18 366525 7914 63114565
Lymphadenopathy 10.98 9.90 156 366387 38302 63084177
Pneumonia viral 10.95 9.90 18 366525 7904 63114575
Multiple sclerosis 10.95 9.90 89 366454 24283 63098196
Aerophagia 10.93 9.90 4 366539 13 63122466
Ankylosing spondylitis 10.91 9.90 28 366515 10446 63112033
Blood insulin increased 10.90 9.90 8 366535 137 63122342
Vulvovaginal mycotic infection 10.88 9.90 62 366481 5504 63116975
Liver function test increased 10.87 9.90 129 366414 32682 63089797
Pancreatic duct stenosis 10.84 9.90 6 366537 61 63122418
Genital infection female 10.79 9.90 7 366536 97 63122382
Injection site hypertrophy 10.75 9.90 6 366537 62 63122417
Macrosomia 10.75 9.90 6 366537 62 63122417
Conjunctivitis 10.74 9.90 73 366470 20723 63101756
Biopsy skin abnormal 10.73 9.90 7 366536 98 63122381
Angina unstable 10.73 9.90 74 366469 7021 63115458
Purpura 10.70 9.90 32 366511 11353 63111126
Hypoplastic left heart syndrome 10.68 9.90 9 366534 190 63122289
Musculoskeletal toxicity 10.67 9.90 6 366537 63 63122416
Cardiac death 10.66 9.90 15 366528 574 63121905
Encephalitis 10.66 9.90 22 366521 8858 63113621
Central nervous system lesion 10.65 9.90 29 366514 10606 63111873
Blood sodium decreased 10.63 9.90 198 366345 24054 63098425
Pneumonia aspiration 10.62 9.90 138 366405 34402 63088077
Retinal vascular disorder 10.60 9.90 9 366534 192 63122287
Exercise tolerance decreased 10.60 9.90 61 366482 5436 63117043
Infective myositis 10.59 9.90 6 366537 64 63122415
Hypovitaminosis 10.58 9.90 18 366525 814 63121665
Vulvovaginal discomfort 10.56 9.90 34 366509 2344 63120135
Ulcer 10.54 9.90 98 366445 26009 63096470
Pernicious anaemia 10.51 9.90 16 366527 658 63121821
Cell death 10.49 9.90 36 366507 2565 63119914
Pancreatic pseudocyst 10.49 9.90 15 366528 583 63121896
Personality change 10.45 9.90 15 366528 6958 63115521
Coma 10.43 9.90 463 366080 63901 63058578
Clear cell endometrial carcinoma 10.42 9.90 3 366540 3 63122476
Castleman's disease 10.42 9.90 3 366540 3 63122476
Diffuse idiopathic skeletal hyperostosis 10.42 9.90 3 366540 3 63122476
Nipple swelling 10.42 9.90 3 366540 3 63122476
Aerococcus urinae infection 10.42 9.90 3 366540 3 63122476
CSF volume increased 10.42 9.90 3 366540 3 63122476
Sputum retention 10.41 9.90 15 366528 587 63121892
Foot operation 10.40 9.90 16 366527 7215 63115264
Osteonecrosis 10.38 9.90 91 366452 24439 63098040
Idiopathic angioedema 10.37 9.90 5 366538 37 63122442
Ascites 10.33 9.90 169 366374 40559 63081920
Blood sodium increased 10.32 9.90 37 366506 2695 63119784
Unevaluable event 10.31 9.90 222 366321 51164 63071315
Product solubility abnormal 10.30 9.90 18 366525 832 63121647
Urine output increased 10.28 9.90 24 366519 1369 63121110
Bradykinesia 10.28 9.90 58 366485 5130 63117349
Insulin C-peptide increased 10.28 9.90 6 366537 68 63122411
Blood magnesium decreased 10.25 9.90 119 366424 13079 63109400
Transfusion 10.25 9.90 49 366494 15168 63107311
Colitis 10.22 9.90 208 366335 48320 63074159
Transferrin saturation decreased 10.22 9.90 17 366526 755 63121724
Spinal compression fracture 10.21 9.90 45 366498 14238 63108241
Infected dermal cyst 10.15 9.90 13 366530 454 63122025
Gallbladder disorder 10.14 9.90 159 366384 18683 63103796
Intestinal transit time abnormal 10.13 9.90 6 366537 70 63122409
Micturition disorder 10.13 9.90 35 366508 2503 63119976
Drug specific antibody present 10.13 9.90 6 366537 4253 63118226
Prescribed underdose 10.12 9.90 116 366427 29573 63092906
Hypochloraemia 10.11 9.90 30 366513 1979 63120500
Cardio-respiratory distress 10.11 9.90 8 366535 154 63122325
Laryngitis 10.10 9.90 57 366486 16910 63105569
Cervical dysplasia 10.09 9.90 3 366540 3211 63119268
Complication of pregnancy 10.07 9.90 15 366528 605 63121874
Duodenal ulcer 10.07 9.90 78 366465 7678 63114801
Cardiotoxicity 10.05 9.90 21 366522 8417 63114062
Femur fracture 10.02 9.90 175 366368 41581 63080898
Vulvovaginitis 10.00 9.90 11 366532 326 63122153
Cerebral haematoma 10 9.90 45 366498 3638 63118841
Aortic disorder 9.98 9.90 17 366526 770 63121709
Bacteraemia 9.94 9.90 59 366484 17289 63105190
Breath sounds abnormal 9.93 9.90 102 366441 10871 63111608
Post procedural sepsis 9.93 9.90 9 366534 210 63122269
Cytopenia 9.93 9.90 34 366509 11567 63110912
Sudden visual loss 9.93 9.90 4 366539 18 63122461
Neuroglycopenia 9.91 9.90 13 366530 465 63122014
Blepharospasm 9.90 9.90 12 366531 5984 63116495

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Lactic acidosis 10902.89 11.05 5543 299849 29229 34622310
Acute kidney injury 2197.74 11.05 6730 298662 298258 34353281
Hypoglycaemia 2045.89 11.05 2453 302939 52187 34599352
Metabolic acidosis 1969.40 11.05 2159 303233 41521 34610018
Diabetic ketoacidosis 1561.18 11.05 1280 304112 16752 34634787
Blood glucose increased 1104.48 11.05 2042 303350 64676 34586863
Glycosylated haemoglobin increased 852.67 11.05 743 304649 10617 34640922
Euglycaemic diabetic ketoacidosis 847.99 11.05 458 304934 2764 34648775
Diabetes mellitus inadequate control 761.42 11.05 752 304640 12712 34638827
Hyperkalaemia 736.10 11.05 1771 303621 67618 34583921
Ketoacidosis 574.54 11.05 394 304998 3849 34647690
Off label use 477.44 11.05 1969 303423 417555 34233984
Pancreatitis 470.79 11.05 1046 304346 37845 34613694
Hyperglycaemia 459.09 11.05 1045 304347 38435 34613104
Hyperlactacidaemia 384.74 11.05 270 305122 2746 34648793
Drug abuse 366.13 11.05 205 305187 98891 34552648
Pancreatitis acute 363.43 11.05 777 304615 27364 34624175
Shock 287.67 11.05 646 304746 23533 34628006
Febrile neutropenia 278.35 11.05 480 304912 136369 34515170
Blood lactic acid increased 277.77 11.05 318 305074 6410 34645129
Completed suicide 268.29 11.05 1619 303773 96549 34554990
Diabetic metabolic decompensation 267.91 11.05 176 305216 1590 34649949
Pemphigoid 261.70 11.05 350 305042 8316 34643223
Hypoglycaemic coma 243.25 11.05 188 305204 2243 34649296
Drug ineffective 230.18 11.05 2721 302671 454030 34197509
Blood glucose abnormal 230.13 11.05 272 305120 5680 34645859
Death 225.62 11.05 2308 303084 395741 34255798
Pyrexia 209.72 11.05 1881 303511 331132 34320407
Neutropenia 208.02 11.05 689 304703 156089 34495450
Blood glucose decreased 195.02 11.05 386 305006 12851 34638688
Intentional overdose 181.62 11.05 810 304582 42864 34608675
Blood glucose fluctuation 180.36 11.05 199 305193 3845 34647694
Product use in unapproved indication 177.60 11.05 486 304906 117013 34534526
Pneumonia 165.86 11.05 2204 303188 360423 34291116
Vitamin B12 deficiency 160.47 11.05 187 305205 3844 34647695
Pancreatic carcinoma 159.12 11.05 282 305110 8619 34642920
MELAS syndrome 150.03 11.05 44 305348 18 34651521
Anuria 142.46 11.05 294 305098 10091 34641448
Disease progression 139.80 11.05 480 304912 107597 34543942
Platelet count decreased 135.82 11.05 561 304831 119156 34532383
Thrombocytopenia 133.84 11.05 808 304584 155439 34496100
Cytomegalovirus infection 133.50 11.05 32 305360 26103 34625436
Acidosis 133.03 11.05 295 305097 10650 34640889
Ketonuria 128.55 11.05 75 305317 536 34651003
Diabetic neuropathy 121.38 11.05 166 305226 4031 34647508
Renal failure 121.16 11.05 1704 303688 128853 34522686
Leukopenia 118.27 11.05 231 305161 62625 34588914
Pancytopenia 117.45 11.05 431 304961 94726 34556813
Type 2 diabetes mellitus 114.37 11.05 354 305038 15678 34635861
Toxicity to various agents 113.73 11.05 2416 302976 197946 34453593
Infusion related reaction 112.45 11.05 181 305211 52876 34598663
Drug resistance 112.11 11.05 43 305349 25884 34625655
Seizure 109.41 11.05 507 304885 104350 34547189
Anion gap increased 109.20 11.05 107 305285 1789 34649750
Continuous haemodiafiltration 108.71 11.05 81 305311 911 34650628
Hypomagnesaemia 108.55 11.05 428 304964 21423 34630116
White blood cell count decreased 105.90 11.05 451 304941 94994 34556545
Diabetes mellitus 105.78 11.05 737 304655 46136 34605403
Weight decreased 103.30 11.05 2136 303256 174165 34477374
Diarrhoea 100.44 11.05 4261 301131 385651 34265888
Drug dependence 100.10 11.05 43 305349 24174 34627365
Suspected suicide 98.85 11.05 161 305231 4587 34646952
Bone marrow failure 97.59 11.05 68 305324 29185 34622354
Vomiting 95.38 11.05 2834 302558 244787 34406752
Distributive shock 94.02 11.05 82 305310 1172 34650367
Ketosis 91.44 11.05 56 305336 442 34651097
Toxic epidermal necrolysis 85.46 11.05 41 305351 21605 34629934
Malignant neoplasm progression 83.60 11.05 440 304952 87606 34563933
Immune-mediated myositis 83.53 11.05 97 305295 1986 34649553
Stomatitis 81.91 11.05 154 305238 42360 34609179
Haemodialysis 81.27 11.05 239 305153 10287 34641252
Dehydration 80.82 11.05 1589 303803 128380 34523159
Pneumocystis jirovecii pneumonia 79.88 11.05 36 305356 19674 34631865
Product monitoring error 78.56 11.05 139 305253 4242 34647297
Injection site nodule 77.10 11.05 84 305308 1599 34649940
Treatment failure 76.74 11.05 185 305207 46512 34605027
Graft versus host disease 75.79 11.05 4 305388 10565 34640974
Overdose 75.17 11.05 1165 304227 89894 34561645
Myelosuppression 72.31 11.05 39 305353 19226 34632313
Diabetic retinopathy 71.84 11.05 84 305308 1733 34649806
Drug level increased 71.83 11.05 382 305010 21714 34629825
Polyuria 71.35 11.05 200 305192 8374 34643165
Lipase increased 70.99 11.05 212 305180 9204 34642335
Neutrophil count decreased 70.84 11.05 220 305172 50884 34600655
Intentional product use issue 69.84 11.05 277 305115 59539 34592000
Product residue present 69.63 11.05 102 305290 2644 34648895
Toe amputation 67.28 11.05 96 305296 2428 34649111
Glomerular filtration rate decreased 66.92 11.05 257 305135 12704 34638835
Blood lactic acid 66.33 11.05 40 305352 306 34651233
Urine ketone body present 64.65 11.05 64 305328 1084 34650455
Mucosal inflammation 64.26 11.05 152 305240 38470 34613069
Pancreatic carcinoma metastatic 62.99 11.05 101 305291 2839 34648700
Neuropathy peripheral 61.91 11.05 449 304943 82814 34568725
Myocardial ischaemia 61.47 11.05 308 305084 17100 34634439
Hypotension 59.02 11.05 2432 302960 219217 34432322
Macroangiopathy 58.65 11.05 17 305375 6 34651533
Myocardial infarction 58.54 11.05 1428 303964 119657 34531882
Coronary artery disease 57.71 11.05 661 304731 47644 34603895
Condition aggravated 57.58 11.05 1260 304132 190936 34460603
Bladder cancer 57.48 11.05 288 305104 15990 34635549
Anxiety 57.39 11.05 573 304819 98855 34552684
Posterior reversible encephalopathy syndrome 55.34 11.05 10 305382 9944 34641595
Aggression 55.24 11.05 166 305226 38798 34612741
Latent autoimmune diabetes in adults 55.08 11.05 21 305371 45 34651494
Product use issue 54.51 11.05 326 305066 62890 34588649
Sepsis 54.28 11.05 1077 304315 165484 34486055
Blood pH decreased 53.91 11.05 83 305309 2251 34649288
Transplant rejection 53.90 11.05 12 305380 10299 34641240
Diabetic nephropathy 53.89 11.05 79 305313 2049 34649490
Acetonaemia 53.71 11.05 27 305365 137 34651402
Hospitalisation 53.08 11.05 286 305106 56616 34594923
Anion gap 51.94 11.05 50 305342 817 34650722
Pathogen resistance 51.70 11.05 10 305382 9472 34642067
Anaemia vitamin B12 deficiency 51.54 11.05 36 305356 363 34651176
Glycosylated haemoglobin abnormal 51.06 11.05 27 305365 155 34651384
Hepatic function abnormal 50.80 11.05 207 305185 44156 34607383
Blood ketone body increased 50.40 11.05 37 305355 406 34651133
Bronchopulmonary aspergillosis 50.33 11.05 33 305359 14626 34636913
Kidney transplant rejection 50.32 11.05 4 305388 7493 34644046
Exposure via ingestion 49.59 11.05 77 305315 2104 34649435
Pancreatitis chronic 49.43 11.05 78 305314 2162 34649377
Drug intolerance 49.38 11.05 311 305081 59259 34592280
Hypothermia 48.98 11.05 205 305187 10543 34640996
Product odour abnormal 48.86 11.05 46 305346 730 34650809
Microalbuminuria 48.84 11.05 44 305348 658 34650881
Appendicitis 48.62 11.05 35 305357 14772 34636767
Therapy non-responder 48.46 11.05 177 305215 38969 34612570
Balanoposthitis 48.32 11.05 56 305336 1144 34650395
Immune reconstitution inflammatory syndrome 48.27 11.05 9 305383 8750 34642789
Progressive multifocal leukoencephalopathy 47.85 11.05 13 305379 9751 34641788
Infective pulmonary exacerbation of cystic fibrosis 47.46 11.05 3 305389 6798 34644741
Rash 47.35 11.05 1534 303858 221218 34430321
Aspergillus infection 47.18 11.05 24 305368 12230 34639309
Infection 47.18 11.05 537 304855 90378 34561161
Obesity 47.00 11.05 230 305162 12648 34638891
Renal tubular necrosis 46.22 11.05 264 305128 15416 34636123
Adenocarcinoma pancreas 45.37 11.05 58 305334 1316 34650223
Post transplant lymphoproliferative disorder 45.20 11.05 3 305389 6525 34645014
Acute graft versus host disease 44.99 11.05 3 305389 6500 34645039
Urine albumin/creatinine ratio abnormal 44.99 11.05 12 305380 0 34651539
Hypoxia 44.96 11.05 289 305103 54806 34596733
Cytomegalovirus viraemia 44.63 11.05 6 305386 7424 34644115
Drug interaction 43.89 11.05 2403 302989 223543 34427996
Epstein-Barr virus infection 43.87 11.05 7 305385 7621 34643918
Acute myocardial infarction 43.81 11.05 686 304706 53033 34598506
Deep vein thrombosis 43.73 11.05 362 305030 64886 34586653
Suicide attempt 43.51 11.05 528 304864 38588 34612951
Diabetic ketoacidotic hyperglycaemic coma 43.36 11.05 23 305369 133 34651406
Alanine aminotransferase increased 43.25 11.05 474 304918 80341 34571198
Cytokine release syndrome 43.07 11.05 84 305308 22793 34628746
Drug hypersensitivity 42.43 11.05 474 304918 80055 34571484
Pseudomonas infection 42.34 11.05 28 305364 12354 34639185
Genital infection fungal 42.25 11.05 25 305367 184 34651355
Hyperglycaemic hyperosmolar nonketotic syndrome 42.22 11.05 54 305338 1226 34650313
Psoriasis 41.92 11.05 521 304871 38291 34613248
Aspartate aminotransferase increased 41.91 11.05 384 305008 67399 34584140
Haemorrhage 41.64 11.05 270 305122 51100 34600439
Vitamin B12 decreased 40.88 11.05 53 305339 1220 34650319
Aplastic anaemia 40.55 11.05 17 305375 9699 34641840
Arthralgia 40.53 11.05 1153 304239 168888 34482651
Diabetic foot infection 40.38 11.05 39 305353 640 34650899
Haematotoxicity 39.99 11.05 11 305381 8183 34643356
Staphylococcal infection 39.97 11.05 149 305243 32611 34618928
Diabetic ketosis 39.79 11.05 21 305371 120 34651419
Ascites 39.70 11.05 241 305151 46330 34605209
Blood bicarbonate decreased 39.65 11.05 75 305317 2412 34649127
Pancreatic neoplasm 39.32 11.05 44 305348 864 34650675
Haemodynamic instability 39.09 11.05 176 305216 9347 34642192
Glycosylated haemoglobin decreased 38.87 11.05 30 305362 357 34651182
Blood phosphorus increased 38.37 11.05 10 305382 7711 34643828
Coma 38.27 11.05 586 304806 45092 34606447
Cardiac failure 38.20 11.05 1056 304336 90192 34561347
Septic shock 38.17 11.05 422 304970 71412 34580127
Interstitial lung disease 38.16 11.05 375 305017 64907 34586632
Blood cholesterol 38.02 11.05 24 305368 201 34651338
Drug reaction with eosinophilia and systemic symptoms 37.81 11.05 154 305238 32858 34618681
Plasma cell myeloma 37.71 11.05 214 305178 41823 34609716
Lumbosacral radiculoplexus neuropathy 37.68 11.05 14 305378 27 34651512
Hepatic steatosis 37.53 11.05 282 305110 18080 34633459
Osmolar gap increased 37.49 11.05 10 305382 0 34651539
Rheumatoid arthritis 37.44 11.05 189 305203 38049 34613490
Therapeutic product effect decreased 37.38 11.05 166 305226 34577 34616962
Haemophagocytic lymphohistiocytosis 37.22 11.05 35 305357 12938 34638601
Low density lipoprotein abnormal 36.85 11.05 28 305364 325 34651214
Cardiovascular disorder 36.27 11.05 179 305213 9877 34641662
Hallucination 36.22 11.05 282 305110 51216 34600323
BK virus infection 36.02 11.05 4 305388 5734 34645805
Clostridium difficile infection 35.92 11.05 69 305323 18829 34632710
Neoplasm progression 34.67 11.05 97 305295 23203 34628336
Multiple-drug resistance 34.60 11.05 3 305389 5236 34646303
Insomnia 34.37 11.05 670 304722 103237 34548302
Syncope 34.34 11.05 1044 304348 90407 34561132
Pernicious anaemia 34.34 11.05 17 305375 83 34651456
Chills 34.16 11.05 500 304892 80543 34570996
Sinusitis 33.36 11.05 218 305174 41184 34610355
Polydipsia 33.24 11.05 92 305300 3823 34647716
Neurotoxicity 33.15 11.05 67 305325 17943 34633596
Drug ineffective for unapproved indication 32.92 11.05 102 305290 23613 34627926
Depression 32.76 11.05 624 304768 96474 34555065
Urine ketone body 32.74 11.05 14 305378 45 34651494
Pancreatic neuroendocrine tumour 32.28 11.05 23 305369 240 34651299
Abdominal pain 32.09 11.05 1742 303650 161876 34489663
Haemoptysis 31.51 11.05 178 305214 34828 34616711
Glycosuria 31.44 11.05 46 305346 1191 34650348
Anaemia 31.28 11.05 1693 303699 231642 34419897
Neuropathy vitamin B12 deficiency 31.28 11.05 17 305375 104 34651435
Thirst 30.98 11.05 144 305248 7751 34643788
Obstructive pancreatitis 30.96 11.05 32 305360 572 34650967
Acute coronary syndrome 30.55 11.05 213 305179 13332 34638207
Blood ketone body 30.50 11.05 15 305377 72 34651467
5-hydroxyindolacetic acid in urine increased 30.46 11.05 22 305370 235 34651304
Osteonecrosis 30.41 11.05 52 305340 14838 34636701
Pneumothorax 30.29 11.05 77 305315 19015 34632524
Clostridium difficile colitis 30.27 11.05 57 305335 15673 34635866
Cholelithiasis 30.20 11.05 300 305092 20848 34630691
Tongue oedema 30.12 11.05 75 305317 2922 34648617
Blood mercury abnormal 29.96 11.05 21 305371 213 34651326
Therapy partial responder 29.95 11.05 24 305368 9592 34641947
Musculoskeletal stiffness 29.92 11.05 262 305130 46418 34605121
Starvation ketoacidosis 29.91 11.05 13 305379 44 34651495
Diabetic macroangiopathy 29.81 11.05 9 305383 5 34651534
Tumour lysis syndrome 29.29 11.05 66 305326 16993 34634546
Glucose urine present 29.11 11.05 41 305351 1024 34650515
Osteoporosis 28.97 11.05 41 305351 12627 34638912
Vitreous haemorrhage 28.88 11.05 64 305328 2309 34649230
Osmolar gap 28.86 11.05 13 305379 49 34651490
Bradyarrhythmia 28.85 11.05 61 305331 2130 34649409
Diabetic eye disease 28.66 11.05 13 305379 50 34651489
Myelodysplastic syndrome 28.56 11.05 80 305312 19128 34632411
Pollakiuria 28.54 11.05 280 305112 19394 34632145
Haemoglobin decreased 28.48 11.05 820 304572 119952 34531587
Product prescribing error 28.40 11.05 316 305076 22611 34628928
Naevus flammeus 28.18 11.05 19 305373 180 34651359
Hyperlipasaemia 28.06 11.05 28 305364 479 34651060
Dystonia 28.02 11.05 32 305360 10813 34640726
Immunosuppressant drug level increased 27.96 11.05 9 305383 6046 34645493
Therapeutic drug monitoring analysis incorrectly performed 27.77 11.05 23 305369 305 34651234
Peritonitis 27.54 11.05 64 305328 16301 34635238
Medication error 27.52 11.05 343 305049 25222 34626317
Therapeutic response decreased 27.51 11.05 147 305245 29166 34622373
Haematuria 27.41 11.05 601 304791 49465 34602074
Bladder transitional cell carcinoma 27.27 11.05 67 305325 2588 34648951
Rhabdomyolysis 27.17 11.05 784 304608 67379 34584160
Vitamin B1 deficiency 27.11 11.05 23 305369 316 34651223
Gangrene 27.09 11.05 95 305297 4491 34647048
Foetal exposure during pregnancy 27.09 11.05 208 305184 37893 34613646
Blood triglycerides increased 27.01 11.05 214 305178 13945 34637594
Dysphagia 26.93 11.05 383 305009 61998 34589541
No adverse event 26.86 11.05 106 305286 22821 34628718
Clear cell renal cell carcinoma 26.79 11.05 41 305351 1106 34650433
Cytomegalovirus infection reactivation 26.66 11.05 6 305386 5112 34646427
Cerebrovascular accident 26.63 11.05 948 304444 83863 34567676
Substance abuse 26.51 11.05 17 305375 7624 34643915
Cytopenia 26.38 11.05 44 305348 12679 34638860
Pleural effusion 26.30 11.05 528 304864 81018 34570521
Alveolar capillary dysplasia 26.24 11.05 7 305385 0 34651539
Diabetic foot 26.18 11.05 68 305324 2720 34648819
Angina pectoris 26.13 11.05 402 304990 30961 34620578
Migraine 25.83 11.05 73 305319 17405 34634134
Anaemia megaloblastic 25.81 11.05 18 305374 181 34651358
Drug level above therapeutic 25.81 11.05 89 305303 4172 34647367
Blood cholesterol abnormal 25.80 11.05 52 305340 1754 34649785
Exposure during pregnancy 25.75 11.05 24 305368 8910 34642629
Thrombotic microangiopathy 25.73 11.05 33 305359 10597 34640942
Needle issue 25.35 11.05 114 305278 6051 34645488
Stevens-Johnson syndrome 25.28 11.05 81 305311 18558 34632981
Staphylococcal bacteraemia 25.21 11.05 22 305370 8430 34643109
Pulmonary haemorrhage 24.93 11.05 32 305360 10272 34641267
Renal impairment 24.84 11.05 1036 304356 93477 34558062
Drug level below therapeutic 24.80 11.05 9 305383 5606 34645933
Epilepsy 24.79 11.05 100 305292 21395 34630144
Antipsychotic drug level decreased 24.67 11.05 37 305355 980 34650559
Abdominal discomfort 24.62 11.05 691 304701 59144 34592395
Coma scale abnormal 24.52 11.05 84 305308 3924 34647615
Flushing 24.48 11.05 174 305218 32246 34619293
Hyperoxaluria 24.43 11.05 15 305377 119 34651420
Malaise 24.39 11.05 1912 303480 183913 34467626
Lymphocyte count decreased 24.38 11.05 108 305284 22514 34629025
Productive cough 24.33 11.05 212 305180 37601 34613938
Acquired phimosis 24.26 11.05 13 305379 77 34651462
Nocardiosis 24.19 11.05 3 305389 3948 34647591
Hepatojugular reflux 24.12 11.05 28 305364 573 34650966
Alopecia 24.06 11.05 120 305272 24235 34627304
Epistaxis 23.98 11.05 361 305031 57890 34593649
Dizziness 23.76 11.05 2217 303175 216304 34435235
Pancreatic pseudocyst 23.74 11.05 33 305359 814 34650725
Unevaluable event 23.60 11.05 177 305215 32413 34619126
Type V hyperlipidaemia 23.55 11.05 32 305360 772 34650767
Enterococcal infection 23.46 11.05 28 305364 9278 34642261
Burkholderia pseudomallei infection 23.42 11.05 10 305382 32 34651507
Restlessness 23.24 11.05 129 305263 25353 34626186
Rectal haemorrhage 23.18 11.05 232 305160 40017 34611522
Thrombosis 23.14 11.05 306 305086 50152 34601387
Neuropathic arthropathy 23.10 11.05 16 305376 159 34651380
Acute myeloid leukaemia 23.01 11.05 82 305310 18188 34633351
Herpes zoster 22.97 11.05 191 305201 34208 34617331
Tongue disorder 22.84 11.05 9 305383 5330 34646209
Therapeutic product effect incomplete 22.64 11.05 308 305084 50233 34601306
Bacterial infection 22.56 11.05 75 305317 16988 34634551
Tenosynovitis 22.56 11.05 6 305386 4564 34646975
Bronchitis 22.48 11.05 246 305146 41717 34609822
Renal artery thrombosis 22.42 11.05 20 305372 295 34651244
Blood pressure fluctuation 22.39 11.05 129 305263 25120 34626419
Aplasia pure red cell 22.17 11.05 13 305379 6119 34645420
Glomerular filtration rate increased 21.95 11.05 23 305369 418 34651121
Respiratory arrest 21.91 11.05 149 305243 27894 34623645
Retroperitoneal fibrosis 21.88 11.05 22 305370 380 34651159
Disseminated intravascular coagulation 21.83 11.05 107 305285 21709 34629830
Drug-disease interaction 21.70 11.05 24 305368 465 34651074
Body temperature decreased 21.67 11.05 191 305201 12843 34638696
Generalised bullous fixed drug eruption 21.62 11.05 12 305380 77 34651462
Ileus 21.48 11.05 73 305319 16426 34635113
Anion gap abnormal 21.47 11.05 16 305376 180 34651359
Lymphopenia 21.46 11.05 72 305320 16263 34635276
Cytomegalovirus test positive 21.40 11.05 4 305388 3882 34647657
Expired product administered 21.31 11.05 71 305321 3270 34648269
Schizophrenia 21.17 11.05 139 305253 8527 34643012
Suicidal ideation 21.15 11.05 238 305154 40150 34611389
Hypogammaglobulinaemia 20.92 11.05 22 305370 7718 34643821
Pneumonitis 20.90 11.05 192 305200 33686 34617853
Pulmonary toxicity 20.88 11.05 14 305378 6133 34645406
Albumin urine present 20.87 11.05 21 305371 363 34651176
Neoplasm malignant 20.87 11.05 96 305296 19809 34631730
Sopor 20.78 11.05 179 305213 11957 34639582
Food aversion 20.69 11.05 22 305370 407 34651132
Conjunctivitis 20.65 11.05 33 305359 9672 34641867
Joint swelling 20.46 11.05 384 305008 59506 34592033
Genital candidiasis 20.41 11.05 11 305381 66 34651473
Colorectal cancer 20.41 11.05 8 305384 4753 34646786
Premature baby 20.40 11.05 95 305297 19538 34632001
Respiratory failure 20.40 11.05 759 304633 107813 34543726
Colitis 20.35 11.05 221 305171 37529 34614010
Vasoplegia syndrome 20.31 11.05 48 305344 1808 34649731
Large for dates baby 20.30 11.05 32 305360 886 34650653
Mydriasis 20.21 11.05 20 305372 7217 34644322
Hypoalbuminaemia 20.17 11.05 48 305344 12126 34639413
Actinic elastosis 20.17 11.05 10 305382 49 34651490
Basilar artery thrombosis 20.13 11.05 17 305375 232 34651307
Hypovolaemia 20.12 11.05 144 305248 9090 34642449
Balanitis candida 20.10 11.05 13 305379 114 34651425
Left ventricular dysfunction 20.06 11.05 153 305239 9854 34641685
Hypovolaemic shock 20.04 11.05 118 305274 6967 34644572
Drug withdrawal syndrome 20.01 11.05 97 305295 19737 34631802
Pneumonia aspiration 20.00 11.05 252 305140 41651 34609888
Device related infection 19.99 11.05 80 305312 17157 34634382
Renal oncocytoma 19.96 11.05 9 305383 34 34651505
Nasopharyngitis 19.96 11.05 462 304930 69506 34582033
Diabetic foetopathy 19.89 11.05 16 305376 203 34651336
Abnormal behaviour 19.84 11.05 132 305260 24837 34626702
Product commingling 19.61 11.05 8 305384 22 34651517
Nausea 19.56 11.05 3315 302077 336593 34314946
Blood creatinine increased 19.56 11.05 1016 304376 93960 34557579
Nipple inflammation 19.55 11.05 10 305382 53 34651486
Gastroenteritis 19.47 11.05 202 305190 14198 34637341
Body mass index abnormal 19.42 11.05 14 305378 149 34651390
Adrenal cyst 19.42 11.05 14 305378 149 34651390
Lymphoma 19.41 11.05 51 305341 12456 34639083
Herbal interaction 19.28 11.05 20 305372 359 34651180
Cornea verticillata 19.25 11.05 10 305382 55 34651484
Cystitis haemorrhagic 19.20 11.05 13 305379 5666 34645873
Intercapillary glomerulosclerosis 19.20 11.05 9 305383 38 34651501
Bundle branch block left 19.18 11.05 103 305289 5876 34645663
Status epilepticus 19.15 11.05 52 305340 12562 34638977
Klebsiella infection 19.12 11.05 28 305364 8503 34643036
Cytomegalovirus chorioretinitis 19.12 11.05 4 305388 3585 34647954
Leukocytosis 19.11 11.05 306 305086 23759 34627780
Psychotic disorder 19.06 11.05 130 305262 24322 34627217
Oxygen saturation decreased 19.03 11.05 343 305049 53475 34598064
Cardiotoxicity 19.01 11.05 13 305379 5635 34645904
Bacteraemia 18.99 11.05 98 305294 19619 34631920
Product administered to patient of inappropriate age 18.97 11.05 3 305389 3288 34648251
Intercepted product preparation error 18.94 11.05 6 305386 4072 34647467
Osteonecrosis of jaw 18.92 11.05 86 305306 17803 34633736
Tinnitus 18.81 11.05 101 305291 20017 34631522
Sedation 18.80 11.05 107 305285 20899 34630640
Pulmonary embolism 18.78 11.05 619 304773 89127 34562412
Birt-Hogg-Dube syndrome 18.75 11.05 5 305387 0 34651539
pH body fluid abnormal 18.68 11.05 7 305385 14 34651525
Tremor 18.64 11.05 564 304828 82023 34569516
Headache 18.51 11.05 1505 303887 199130 34452409
Respiratory syncytial virus infection 18.46 11.05 9 305383 4700 34646839
Abdominal pain upper 18.18 11.05 781 304611 70709 34580830
Intestinal perforation 18.17 11.05 32 305360 9028 34642511
Arthropathy 18.15 11.05 149 305243 26758 34624781
Pericardial disease 18.12 11.05 21 305371 429 34651110
Bradycardia 18.09 11.05 819 304573 74599 34576940
Brain natriuretic peptide abnormal 17.89 11.05 19 305373 351 34651188
Plasmapheresis 17.85 11.05 18 305374 312 34651227
Akathisia 17.80 11.05 27 305365 8082 34643457
Cleft lip and palate 17.74 11.05 30 305362 882 34650657
Ejection fraction decreased 17.71 11.05 250 305142 18904 34632635
Autoimmune pancreatitis 17.62 11.05 18 305374 317 34651222
Palmar-plantar erythrodysaesthesia syndrome 17.61 11.05 81 305311 16714 34634825
Inflammation 17.61 11.05 160 305232 28135 34623404
Liver palpable 17.60 11.05 17 305375 279 34651260
Erythromelalgia 17.55 11.05 9 305383 48 34651491
Mucosal dryness 17.46 11.05 37 305355 1294 34650245
Pulmonary valve disease 17.27 11.05 18 305374 325 34651214
Back pain 17.16 11.05 879 304513 120910 34530629
Incorrect route of product administration 17.15 11.05 69 305323 14776 34636763
Kussmaul respiration 17.15 11.05 11 305381 95 34651444
Hepatic vein dilatation 17.05 11.05 15 305377 217 34651322
Rales 17.04 11.05 146 305246 9737 34641802
Irritability 16.98 11.05 136 305256 24554 34626985
Atrioventricular block first degree 16.93 11.05 101 305291 5991 34645548
Echocardiogram abnormal 16.88 11.05 32 305360 1031 34650508
High density lipoprotein decreased 16.83 11.05 66 305326 3294 34648245
Mitral valve incompetence 16.74 11.05 202 305190 14741 34636798
Leukoencephalopathy 16.61 11.05 8 305384 4207 34647332
Hypersensitivity 16.58 11.05 406 304986 60629 34590910
Intentional self-injury 16.56 11.05 63 305329 13708 34637831
Hypoglycaemic unconsciousness 16.53 11.05 27 305365 771 34650768
Febrile bone marrow aplasia 16.46 11.05 29 305363 8180 34643359
Oedematous pancreatitis 16.44 11.05 21 305371 476 34651063
Ischaemic stroke 16.40 11.05 237 305155 18013 34633526
Hepatic enzyme decreased 16.31 11.05 9 305383 57 34651482
Liver disorder 16.29 11.05 197 305195 32800 34618739
Psychiatric decompensation 16.22 11.05 3 305389 2934 34648605
Pneumatosis intestinalis 16.15 11.05 7 305385 3916 34647623
Encephalitis toxic 16.12 11.05 16 305376 272 34651267
Poor venous access 16.06 11.05 13 305379 5170 34646369
Nail avulsion 16.04 11.05 7 305385 24 34651515
Psychomotor skills impaired 16.04 11.05 7 305385 3899 34647640
Small intestinal obstruction 16.00 11.05 71 305321 14795 34636744
Urine output increased 15.99 11.05 35 305357 1252 34650287
Tendonitis 15.99 11.05 35 305357 9105 34642434
Pulmonary tuberculosis 15.92 11.05 11 305381 4743 34646796
Dyspnoea at rest 15.90 11.05 71 305321 3757 34647782
Prostate cancer 15.87 11.05 247 305145 39402 34612137
Synovitis 15.87 11.05 66 305326 14000 34637539
Trisomy 18 15.85 11.05 26 305366 745 34650794
Scrotal cyst 15.84 11.05 5 305387 4 34651535
Central obesity 15.82 11.05 23 305369 592 34650947
Therapeutic drug monitoring analysis not performed 15.82 11.05 22 305370 543 34650996
Pancreaticoduodenectomy 15.81 11.05 9 305383 61 34651478
Atrial enlargement 15.67 11.05 24 305368 648 34650891
Viral infection 15.65 11.05 90 305302 17533 34634006
Haemolytic anaemia 15.62 11.05 150 305242 10329 34641210
Product appearance confusion 15.62 11.05 7 305385 26 34651513
Hypoglycaemic encephalopathy 15.61 11.05 16 305376 283 34651256
Insulin C-peptide decreased 15.55 11.05 8 305384 43 34651496
Pancreatitis haemorrhagic 15.55 11.05 17 305375 325 34651214
Drug dose titration not performed 15.55 11.05 17 305375 325 34651214
Chronic pigmented purpura 15.50 11.05 11 305381 114 34651425
Fixed eruption 15.49 11.05 41 305351 1659 34649880
Transferrin saturation decreased 15.47 11.05 20 305372 459 34651080
Malignant spinal cord compression 15.40 11.05 12 305380 145 34651394
Bradypnoea 15.39 11.05 3 305389 2826 34648713
Methaemoglobinaemia 15.38 11.05 6 305386 3575 34647964
Clostridium test positive 15.37 11.05 5 305387 3337 34648202
Paranoia 15.30 11.05 54 305338 12014 34639525
Product substitution issue 15.29 11.05 145 305247 9950 34641589
Wheezing 15.23 11.05 262 305130 41140 34610399
Hyperammonaemia 15.17 11.05 20 305372 6347 34645192
Anaphylactic reaction 15.13 11.05 195 305197 32106 34619433
Fibrillary glomerulonephritis 15.12 11.05 8 305384 46 34651493
Pneumonia cytomegaloviral 15.09 11.05 4 305388 3050 34648489
Oliguria 15.09 11.05 125 305267 8255 34643284
Cytomegalovirus colitis 15.04 11.05 3 305389 2781 34648758
Skinfold measurement 15.00 11.05 4 305388 0 34651539
Atrioventricular node dysfunction 15.00 11.05 4 305388 0 34651539
Blood insulin decreased 15.00 11.05 4 305388 0 34651539
Pain 14.89 11.05 1563 303829 203112 34448427
Torsade de pointes 14.88 11.05 25 305367 7184 34644355
Intraductal papillary-mucinous carcinoma of pancreas 14.86 11.05 5 305387 6 34651533
Prerenal failure 14.84 11.05 46 305346 2038 34649501
Chronic obstructive pulmonary disease 14.80 11.05 320 305072 48598 34602941
Peritonitis bacterial 14.75 11.05 19 305373 6091 34645448
Blood lactate dehydrogenase increased 14.74 11.05 129 305263 22861 34628678
Malnutrition 14.73 11.05 59 305333 12650 34638889
Ischaemic cardiomyopathy 14.72 11.05 101 305291 6288 34645251
Product complaint 14.71 11.05 95 305297 5795 34645744
C-reactive protein abnormal 14.71 11.05 34 305358 8676 34642863
Melaena 14.66 11.05 409 304983 34971 34616568
Choluria 14.62 11.05 12 305380 157 34651382
Hyperventilation 14.58 11.05 56 305336 2768 34648771
Blood bilirubin increased 14.52 11.05 241 305151 38055 34613484
Conduction disorder 14.50 11.05 46 305346 2064 34649475
Metabolic syndrome 14.50 11.05 40 305352 1659 34649880
Pancreatitis necrotising 14.49 11.05 55 305337 2703 34648836
Coma acidotic 14.43 11.05 5 305387 7 34651532
Microcytic anaemia 14.42 11.05 50 305342 2350 34649189
Cardiac discomfort 14.36 11.05 22 305370 594 34650945
Acute lung injury 14.35 11.05 37 305355 1473 34650066
Leukaemoid reaction 14.30 11.05 10 305382 101 34651438
Tachyarrhythmia 14.30 11.05 66 305326 3542 34647997
Product solubility abnormal 14.22 11.05 20 305372 499 34651040
Body temperature increased 14.21 11.05 91 305301 17277 34634262
Amylase increased 14.14 11.05 95 305297 5873 34645666
Atrial fibrillation 14.07 11.05 1247 304145 121146 34530393
Blood pressure systolic increased 14.02 11.05 280 305112 22672 34628867
Miosis 13.96 11.05 40 305352 9495 34642044
Blood alkaline phosphatase increased 13.95 11.05 190 305202 30985 34620554
Electrocardiogram QT interval 13.85 11.05 7 305385 36 34651503
Post-traumatic amnestic disorder 13.85 11.05 8 305384 56 34651483
Pneumonia bacterial 13.83 11.05 55 305337 11817 34639722
Diabetic coma 13.82 11.05 27 305365 890 34650649
Skin cancer 13.79 11.05 45 305347 10252 34641287
Paradoxical drug reaction 13.77 11.05 6 305386 3345 34648194
Gingival hypertrophy 13.73 11.05 41 305351 1780 34649759
Exercise tolerance decreased 13.70 11.05 85 305307 5113 34646426
Atrioventricular block complete 13.70 11.05 133 305259 9186 34642353
Hydrops foetalis 13.64 11.05 26 305366 841 34650698
Lip oedema 13.64 11.05 52 305340 2561 34648978
Periarthritis calcarea 13.64 11.05 9 305383 82 34651457
Neuralgia 13.52 11.05 77 305315 15036 34636503
Hepatic neoplasm 13.50 11.05 43 305349 1934 34649605
Foot amputation 13.46 11.05 24 305368 737 34650802
Erythema 13.43 11.05 636 304756 88144 34563395
Accidental overdose 13.43 11.05 249 305143 19891 34631648
Decreased appetite 13.41 11.05 1655 303737 164737 34486802
Hypertensive crisis 13.41 11.05 126 305266 8625 34642914
Blood lactic acid decreased 13.40 11.05 8 305384 60 34651479
Multiple sclerosis relapse 13.38 11.05 64 305328 13069 34638470
Articular calcification 13.37 11.05 9 305383 85 34651454
Skin injury 13.36 11.05 48 305344 2297 34649242
Cardiac arrest 13.35 11.05 994 304398 95165 34556374
Electrocardiogram Q wave abnormal 13.35 11.05 18 305374 431 34651108
Intentional product misuse 13.33 11.05 300 305092 45311 34606228
Atrioventricular block 13.32 11.05 118 305274 7945 34643594
Drug specific antibody present 13.31 11.05 6 305386 3279 34648260
Anhedonia 13.30 11.05 29 305363 7556 34643983
Insulin resistance 13.28 11.05 22 305370 636 34650903
Escherichia infection 13.27 11.05 33 305359 8212 34643327
Coma uraemic 13.26 11.05 7 305385 40 34651499
Graft versus host disease in skin 13.25 11.05 9 305383 3916 34647623
Faecal calprotectin increased 13.22 11.05 3 305389 2541 34648998
Scoliosis 13.17 11.05 4 305388 2789 34648750
Ultrasound antenatal screen 13.16 11.05 20 305372 536 34651003
Serotonin syndrome 13.16 11.05 111 305281 19822 34631717
Pseudomembranous colitis 13.15 11.05 4 305388 2787 34648752
Haematocrit decreased 13.13 11.05 200 305192 32016 34619523
Virologic failure 13.12 11.05 7 305385 3473 34648066
Hemiplegia 13.09 11.05 105 305287 6867 34644672
Body mass index increased 13.09 11.05 29 305363 1046 34650493
Pyonephrosis 13.08 11.05 8 305384 63 34651476
Orbital oedema 13.03 11.05 11 305381 150 34651389
Squamous cell carcinoma of skin 12.94 11.05 50 305342 10831 34640708
Stenosis 12.89 11.05 35 305357 1438 34650101
Upper respiratory tract infection 12.88 11.05 207 305185 32852 34618687
Hypoaesthesia eye 12.86 11.05 6 305386 25 34651514
Diabetic vascular disorder 12.86 11.05 7 305385 43 34651496
Stress 12.85 11.05 187 305205 30160 34621379
Amputation 12.84 11.05 23 305369 709 34650830
Macular oedema 12.83 11.05 55 305337 2859 34648680
Psychomotor retardation 12.83 11.05 8 305384 3642 34647897
Coronary artery bypass 12.82 11.05 80 305312 4822 34646717
Benign neoplasm of adrenal gland 12.78 11.05 4 305388 3 34651536
Hepatobiliary scan abnormal 12.78 11.05 4 305388 3 34651536
Pancreatic duct obstruction 12.78 11.05 4 305388 3 34651536
Sinus tachycardia 12.77 11.05 218 305174 17142 34634397
Full blood count decreased 12.73 11.05 99 305293 17989 34633550
Serum ferritin abnormal 12.73 11.05 13 305379 229 34651310
Constipation 12.69 11.05 1027 304365 135955 34515584
Hyperphosphataemia 12.69 11.05 12 305380 4425 34647114
Confusional state 12.69 11.05 1442 303950 142718 34508821
Cerebellar ischaemia 12.69 11.05 10 305382 123 34651416
Neonatal respiratory distress syndrome 12.65 11.05 10 305382 4024 34647515
Enthesopathy 12.59 11.05 13 305379 4600 34646939
Anaemia of malignant disease 12.59 11.05 18 305374 456 34651083
Dyslipidaemia 12.59 11.05 110 305282 7378 34644161
Pneumonia fungal 12.57 11.05 27 305365 7073 34644466
Injection site mass 12.56 11.05 100 305292 6526 34645013
Rheumatoid nodule 12.55 11.05 5 305387 2942 34648597
Vascular resistance systemic decreased 12.55 11.05 9 305383 95 34651444
Bladder papilloma 12.50 11.05 6 305386 27 34651512
Helicobacter gastritis 12.49 11.05 31 305361 1205 34650334
Diabetic complication 12.49 11.05 22 305370 669 34650870
Hemianopia homonymous 12.46 11.05 23 305369 726 34650813
Myasthenic syndrome 12.43 11.05 19 305373 512 34651027
Bundle branch block right 12.42 11.05 110 305282 7406 34644133
Loss of consciousness 12.41 11.05 860 304532 81807 34569732
Nipple disorder 12.37 11.05 12 305380 198 34651341
Oscillopsia 12.35 11.05 7 305385 47 34651492
Vitamin B1 decreased 12.33 11.05 15 305377 323 34651216
Folliculitis 12.32 11.05 13 305379 4553 34646986
Tricuspid valve incompetence 12.30 11.05 135 305257 9625 34641914
Cryptococcosis 12.28 11.05 3 305389 2416 34649123
Diffuse large B-cell lymphoma 12.26 11.05 29 305363 7341 34644198
Uveitis 12.25 11.05 30 305362 7505 34644034
Blood albumin decreased 12.22 11.05 69 305323 13503 34638036
Spondylolysis 12.20 11.05 8 305384 72 34651467
Mouth ulceration 12.16 11.05 58 305334 11852 34639687
Cardiac septal hypertrophy 12.12 11.05 14 305378 285 34651254
Coronary artery stenosis 12.12 11.05 133 305259 9483 34642056
Renal aplasia 12.09 11.05 23 305369 743 34650796
Red blood cell count decreased 12.06 11.05 180 305212 28910 34622629
Ureterolithiasis 12.05 11.05 45 305347 2194 34649345
Diabetic microangiopathy 12.01 11.05 6 305386 30 34651509
Antipsychotic drug level increased 12.00 11.05 66 305326 3799 34647740
Bacterial sepsis 11.99 11.05 17 305375 5233 34646306
Endometriosis male 11.95 11.05 5 305387 15 34651524
Subdural hygroma 11.91 11.05 15 305377 335 34651204
Peripheral arterial occlusive disease 11.88 11.05 90 305302 5784 34645755
Finger amputation 11.87 11.05 11 305381 171 34651368
Staphylococcal sepsis 11.86 11.05 45 305347 9799 34641740
Dry skin 11.83 11.05 197 305195 31090 34620449
Base excess decreased 11.81 11.05 12 305380 210 34651329
Postictal paralysis 11.79 11.05 13 305379 251 34651288
Drug effective for unapproved indication 11.78 11.05 4 305388 2598 34648941
Angioedema 11.78 11.05 418 304974 36956 34614583
Obsessive-compulsive disorder 11.76 11.05 19 305373 5545 34645994
Parainfluenzae virus infection 11.73 11.05 5 305387 2825 34648714
Alcoholic ketoacidosis 11.71 11.05 5 305387 16 34651523
Asthenia 11.65 11.05 2369 303023 242882 34408657
Leg amputation 11.62 11.05 44 305348 2160 34649379
Granuloma 11.60 11.05 7 305385 3244 34648295
Tachypnoea 11.58 11.05 225 305167 18127 34633412
Pyelitis 11.53 11.05 9 305383 109 34651430
Hepatic haematoma 11.53 11.05 16 305376 394 34651145
Brain oedema 11.52 11.05 72 305320 13749 34637790
Abnormal loss of weight 11.49 11.05 68 305324 4022 34647517
Pulmonary valve incompetence 11.43 11.05 25 305367 894 34650645
Dermatitis acneiform 11.41 11.05 23 305369 6166 34645373
Base excess negative 11.38 11.05 4 305388 6 34651533
Clostridial infection 11.36 11.05 9 305383 3618 34647921
Physical examination abnormal 11.35 11.05 14 305378 306 34651233
Anaphylactic shock 11.34 11.05 87 305305 15854 34635685
Tendon pain 11.33 11.05 6 305386 2989 34648550
Fistula 11.31 11.05 27 305365 6813 34644726
Lichen sclerosus 11.27 11.05 5 305387 18 34651521
Influenza virus test positive 11.27 11.05 9 305383 113 34651426
Thyroid C-cell hyperplasia 11.25 11.05 3 305389 0 34651539
Base excess 11.25 11.05 3 305389 0 34651539
Thyroid calcification 11.25 11.05 3 305389 0 34651539
Claudication of jaw muscles 11.25 11.05 3 305389 0 34651539
Dawn phenomenon 11.25 11.05 3 305389 0 34651539
Pancreatic enzymes abnormal 11.25 11.05 3 305389 0 34651539
Ureteral neoplasm 11.25 11.05 3 305389 0 34651539
Pure white cell aplasia 11.25 11.05 3 305389 0 34651539
Acquired mixed hyperlipidaemia 11.25 11.05 3 305389 0 34651539
Benign neoplasm of testis 11.25 11.05 3 305389 0 34651539
Diabetic encephalopathy 11.25 11.05 3 305389 0 34651539
Phimosis 11.24 11.05 24 305368 844 34650695
Chronic sinusitis 11.23 11.05 3 305389 2276 34649263
Eosinophilic colitis 11.16 11.05 12 305380 225 34651314
Myoclonus 11.13 11.05 79 305313 14646 34636893
Throat irritation 11.13 11.05 51 305341 10534 34641005
Product label issue 11.12 11.05 13 305379 268 34651271
Discoloured vomit 11.12 11.05 18 305374 510 34651029
Dermatosis 11.07 11.05 14 305378 314 34651225

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Lactic acidosis 25611.77 10.19 11672 559962 58687 79114067
Acute kidney injury 6251.11 10.19 12353 559281 507051 78665703
Metabolic acidosis 5123.91 10.19 4445 567189 78084 79094670
Hypoglycaemia 5047.32 10.19 4828 566806 96766 79075988
Diabetic ketoacidosis 3388.94 10.19 2426 569208 31696 79141058
Blood glucose increased 2177.58 10.19 3350 568284 111625 79061129
Hyperkalaemia 1849.65 10.19 3102 568532 111296 79061458
Euglycaemic diabetic ketoacidosis 1838.29 10.19 924 570710 5920 79166834
Diabetes mellitus inadequate control 1510.10 10.19 1310 570324 22954 79149800
Ketoacidosis 1476.30 10.19 836 570798 7018 79165736
Glycosylated haemoglobin increased 1422.50 10.19 1148 570486 18112 79154642
Hyperglycaemia 1207.25 10.19 1960 569674 68375 79104379
Hyperlactacidaemia 824.62 10.19 509 571125 5086 79167668
Shock 815.26 10.19 1263 570371 42285 79130469
Drug ineffective 787.35 10.19 4546 567088 1076367 78096387
Hypoglycaemic coma 773.48 10.19 461 571173 4299 79168455
Pancreatitis acute 703.06 10.19 1270 570364 48334 79124420
Off label use 673.38 10.19 3790 567844 903425 78269329
Pancreatitis 628.29 10.19 1466 570168 67109 79105645
Systemic lupus erythematosus 581.80 10.19 87 571547 121062 79051692
Pemphigoid 579.02 10.19 629 571005 14686 79158068
Renal failure 569.35 10.19 2897 568737 198071 78974683
Infusion related reaction 562.91 10.19 493 571141 229744 78943010
Drug intolerance 529.65 10.19 669 570965 263450 78909304
Pemphigus 528.64 10.19 51 571583 99531 79073223
Anuria 516.85 10.19 693 570941 20270 79152484
Hand deformity 509.79 10.19 70 571564 103849 79068905
Diabetic metabolic decompensation 506.03 10.19 309 571325 3023 79169731
Glossodynia 506.01 10.19 70 571564 103267 79069487
Blood lactic acid increased 489.82 10.19 528 571106 12216 79160538
Anti-cyclic citrullinated peptide antibody positive 485.73 10.19 27 571607 83116 79089638
Synovitis 481.55 10.19 239 571395 150495 79022259
Blood glucose decreased 462.06 10.19 740 570894 25494 79147260
Blood glucose abnormal 443.87 10.19 459 571175 10107 79162647
Arthropathy 435.53 10.19 377 571257 176734 78996020
Treatment failure 411.85 10.19 369 571265 170117 79002637
Toxicity to various agents 405.26 10.19 4711 566923 416829 78755925
Completed suicide 395.46 10.19 3065 568569 242702 78930052
Dehydration 390.42 10.19 3079 568555 245108 78927646
Duodenal ulcer perforation 388.32 10.19 21 571613 66190 79106564
Joint swelling 384.63 10.19 945 570689 287701 78885053
Pericarditis 381.53 10.19 135 571499 104101 79068653
Febrile neutropenia 372.41 10.19 679 570955 230320 78942434
Alopecia 355.45 10.19 700 570934 230655 78942099
Vitamin B12 deficiency 354.78 10.19 342 571292 6899 79165855
Therapeutic product effect decreased 354.06 10.19 391 571243 163472 79009282
Drug level increased 352.57 10.19 838 570796 38813 79133941
Vomiting 346.12 10.19 6693 564941 659135 78513619
Diarrhoea 337.39 10.19 8471 563163 872018 78300736
Helicobacter infection 337.06 10.19 49 571585 69655 79103099
Hypersensitivity 327.47 10.19 887 570747 261352 78911402
Intentional overdose 327.20 10.19 1566 570068 104394 79068360
Folliculitis 326.55 10.19 17 571617 55363 79117391
Pyrexia 306.69 10.19 3249 568385 675460 78497294
Stomatitis 304.24 10.19 362 571272 146395 79026359
Haemodialysis 301.65 10.19 499 571135 17669 79155085
Swelling 298.49 10.19 697 570937 216014 78956740
Drug abuse 296.82 10.19 441 571193 162250 79010504
Rheumatoid factor positive 296.57 10.19 39 571595 59800 79112954
Anion gap increased 287.98 10.19 228 571406 3492 79169262
Rash 287.20 10.19 2706 568928 575652 78597102
Sleep disorder due to general medical condition, insomnia type 278.72 10.19 7 571627 43549 79129205
Wound 275.12 10.19 256 571378 115923 79056831
Muscle injury 271.06 10.19 20 571614 48541 79124213
Contraindicated product administered 270.28 10.19 445 571189 157093 79015661
Continuous haemodiafiltration 268.47 10.19 172 571462 1844 79170910
Rheumatoid arthritis 266.35 10.19 697 570937 207773 78964981
Irritable bowel syndrome 263.92 10.19 61 571573 62180 79110574
Hypothermia 262.67 10.19 534 571100 22212 79150542
Drug interaction 262.24 10.19 4306 567328 410877 78761877
Pancreatic carcinoma 261.36 10.19 399 571235 13178 79159576
Drug hypersensitivity 260.79 10.19 1178 570456 297738 78875016
Blood glucose fluctuation 260.58 10.19 279 571355 6403 79166351
Neutropenia 259.37 10.19 1120 570514 286590 78886164
Acidosis 258.60 10.19 489 571145 19273 79153481
Infection 257.11 10.19 880 570754 240832 78931922
Overdose 252.45 10.19 2216 569418 181990 78990764
Arthralgia 250.92 10.19 2755 568879 569048 78603706
Product use in unapproved indication 248.06 10.19 939 570695 249420 78923334
Hypomagnesaemia 240.31 10.19 812 570822 46099 79126655
Product use issue 237.59 10.19 743 570891 209079 78963675
Musculoskeletal stiffness 225.15 10.19 583 571051 174425 78998329
Discomfort 214.36 10.19 356 571278 125261 79047493
MELAS syndrome 212.54 10.19 73 571561 135 79172619
Pain 210.80 10.19 3664 567970 700138 78472616
Sinusitis 207.69 10.19 712 570922 194789 78977965
Maternal exposure during pregnancy 205.39 10.19 418 571216 136120 79036634
Rhabdomyolysis 203.77 10.19 1352 570282 101779 79070975
Blood bicarbonate decreased 202.88 10.19 217 571417 4974 79167780
Diabetes mellitus 195.03 10.19 1091 570543 77299 79095455
Polyuria 189.66 10.19 366 571268 14648 79158106
Impaired healing 181.84 10.19 216 571418 87439 79085315
Hypotension 176.92 10.19 4267 567367 436050 78736704
Ketonuria 173.21 10.19 108 571526 1100 79171654
Diabetic neuropathy 169.54 10.19 216 571418 6000 79166754
Hepatic enzyme increased 163.14 10.19 713 570921 181897 78990857
Rheumatic fever 161.36 10.19 11 571623 28514 79144240
Ketosis 159.76 10.19 100 571534 1026 79171728
Cytomegalovirus infection 154.70 10.19 56 571578 42588 79130166
Weight decreased 151.73 10.19 3472 568162 351726 78821028
Suspected suicide 151.34 10.19 272 571362 10304 79162450
Blood pH decreased 146.70 10.19 175 571459 4536 79168218
Swollen joint count increased 145.51 10.19 4 571630 22923 79149831
Myocardial infarction 144.07 10.19 1982 569652 182147 78990607
Pneumonia 143.59 10.19 3620 568014 656626 78516128
Urine ketone body present 142.81 10.19 151 571483 3414 79169340
Blood creatinine increased 141.06 10.19 1716 569918 153341 79019413
C-reactive protein abnormal 139.49 10.19 87 571547 48280 79124474
Immune-mediated myositis 139.15 10.19 147 571487 3320 79169434
Ill-defined disorder 136.99 10.19 162 571472 65713 79107041
Contusion 135.87 10.19 576 571058 148200 79024554
Injection site nodule 135.51 10.19 151 571483 3629 79169125
Acetonaemia 134.31 10.19 60 571574 282 79172472
Distributive shock 133.70 10.19 128 571506 2559 79170195
Base excess decreased 133.55 10.19 62 571572 324 79172430
Thrombocytopenia 131.73 10.19 1240 570394 264019 78908735
Renal impairment 129.42 10.19 1713 569921 156070 79016684
Therapy non-responder 128.49 10.19 295 571339 92010 79080744
Condition aggravated 128.43 10.19 2678 568956 498446 78674308
White blood cell count decreased 127.91 10.19 807 570827 187481 78985273
Disease progression 125.33 10.19 790 570844 183572 78989182
Bone marrow failure 120.50 10.19 113 571521 50994 79121760
Diabetic retinopathy 119.90 10.19 129 571505 2977 79169777
Tachypnoea 119.30 10.19 501 571133 31562 79141192
Platelet count decreased 118.93 10.19 861 570773 193803 78978951
Glomerular filtration rate decreased 118.05 10.19 395 571239 22307 79150447
Neurologic neglect syndrome 118 10.19 124 571510 2783 79169971
Renal tubular necrosis 117.45 10.19 421 571213 24618 79148136
Fibromyalgia 114.77 10.19 177 571457 64163 79108591
Nasopharyngitis 114.72 10.19 1214 570420 252667 78920087
Hypovolaemia 114.37 10.19 332 571302 17359 79155395
Drug resistance 113.57 10.19 82 571552 42131 79130623
Abdominal discomfort 112.85 10.19 1200 570434 249527 78923227
Anaemia vitamin B12 deficiency 111.85 10.19 70 571564 718 79172036
Carotid artery thrombosis 111.24 10.19 123 571511 2930 79169824
Hemiplegia 109.03 10.19 293 571341 14646 79158108
Suicide attempt 108.51 10.19 988 570646 81944 79090810
Acute myocardial infarction 106.06 10.19 928 570706 76108 79096646
Leukopenia 105.19 10.19 453 571181 116060 79056694
Intentional product use issue 104.82 10.19 649 570985 151463 79021291
Blister 104.55 10.19 470 571164 119006 79053748
Drug level above therapeutic 104.54 10.19 208 571426 8515 79164239
Myelosuppression 103.64 10.19 82 571552 40214 79132540
Hip arthroplasty 103.54 10.19 64 571570 35692 79137062
Blood lactic acid 102.74 10.19 55 571579 408 79172346
Hypocapnia 101.16 10.19 61 571573 582 79172172
Cardiac arrest 101.08 10.19 1765 569869 170331 79002423
Haemodynamic instability 100.86 10.19 314 571320 17068 79155686
Blood ketone body increased 99.63 10.19 63 571571 659 79172095
Therapeutic product effect incomplete 98.82 10.19 602 571032 141043 79031711
Hepatic steatosis 98.37 10.19 532 571102 37206 79135548
Bradycardia 97.52 10.19 1438 570196 134119 79038635
Pneumocystis jirovecii pneumonia 97.21 10.19 56 571578 32452 79140302
Personality disorder 96.95 10.19 165 571469 5981 79166773
Headache 96.18 10.19 3773 567861 649999 78522755
Death 95.36 10.19 3216 568418 563298 78609456
Inflammation 95.11 10.19 348 571286 93405 79079349
Mobility decreased 94.54 10.19 502 571132 121673 79051081
Neutrophil count decreased 93.21 10.19 352 571282 93607 79079147
Macroangiopathy 92.68 10.19 37 571597 123 79172631
Exposure during pregnancy 92.03 10.19 392 571242 100740 79072014
Diabetic nephropathy 90.99 10.19 109 571525 2838 79169916
Lipase increased 90.55 10.19 292 571342 16174 79156580
Graft versus host disease 90.55 10.19 4 571630 15022 79157732
Transplant rejection 88.72 10.19 16 571618 19421 79153333
Seizure 88.53 10.19 895 570739 187939 78984815
Product prescribing error 86.97 10.19 585 571049 44228 79128526
Knee arthroplasty 86.08 10.19 110 571524 43138 79129616
Malignant neoplasm progression 85.71 10.19 596 571038 135394 79037360
Hyperglycaemic hyperosmolar nonketotic syndrome 84.28 10.19 93 571541 2210 79170544
Anaemia megaloblastic 84.12 10.19 54 571580 581 79172173
Adjustment disorder 83.34 10.19 122 571512 3878 79168876
Coronary artery disease 83.11 10.19 775 570859 64699 79108055
Bladder cancer 82.14 10.19 317 571317 19209 79153545
Hypovolaemic shock 81.89 10.19 233 571401 12043 79160711
Posterior reversible encephalopathy syndrome 81.89 10.19 43 571591 26238 79146516
Microalbuminuria 81.42 10.19 61 571573 857 79171897
Fatigue 81.06 10.19 5658 565976 924069 78248685
Exposure via ingestion 80.42 10.19 138 571496 5036 79167718
Migraine 80.31 10.19 338 571296 87155 79085599
Latent autoimmune diabetes in adults 80.18 10.19 29 571605 67 79172687
Product residue present 79.77 10.19 112 571522 3424 79169330
Glycosylated haemoglobin abnormal 78.55 10.19 37 571597 201 79172553
Mucosal inflammation 77.68 10.19 279 571355 75301 79097453
Polydipsia 77.37 10.19 156 571478 6449 79166305
Cerebrovascular accident 76.78 10.19 1551 570083 153741 79019013
Bursitis 75.75 10.19 87 571547 35757 79136997
Hypoglycaemic encephalopathy 74.92 10.19 51 571583 610 79172144
Pancreatic carcinoma metastatic 74.65 10.19 112 571522 3641 79169113
Product monitoring error 74.63 10.19 184 571450 8722 79164032
Cardiac failure 74.08 10.19 1539 570095 153303 79019451
Coma acidotic 73.99 10.19 30 571604 105 79172649
Angioedema 73.29 10.19 851 570783 75184 79097570
Vitamin B12 decreased 73.17 10.19 107 571527 3398 79169356
Infective pulmonary exacerbation of cystic fibrosis 72.56 10.19 5 571629 12846 79159908
Epstein-Barr virus infection 72.38 10.19 9 571625 14407 79158347
Acute coronary syndrome 71.56 10.19 321 571313 20812 79151942
Osmolar gap 70.54 10.19 32 571602 157 79172597
Vasoplegia syndrome 70.32 10.19 107 571527 3523 79169231
Cytokine release syndrome 70.16 10.19 93 571541 35905 79136849
Diabetic ketosis 69.92 10.19 44 571590 456 79172298
Aspergillus infection 69.77 10.19 25 571609 19136 79153618
Urine albumin/creatinine ratio abnormal 68.45 10.19 21 571613 21 79172733
Accidental overdose 68.20 10.19 502 571132 39079 79133675
Venoocclusive liver disease 68.19 10.19 4 571630 11767 79160987
Pathogen resistance 67.23 10.19 11 571623 14331 79158423
Oliguria 67.16 10.19 263 571371 16046 79156708
Product odour abnormal 66.83 10.19 64 571570 1280 79171474
Peripheral swelling 66.82 10.19 1448 570186 268169 78904585
Progressive multifocal leukoencephalopathy 66.74 10.19 32 571602 20568 79152186
Myocardial ischaemia 66.68 10.19 360 571274 25159 79147595
Psoriasis 66.64 10.19 956 570678 88631 79084123
Facet joint syndrome 64.99 10.19 4 571630 11298 79161456
Bronchopulmonary aspergillosis 64.42 10.19 40 571594 22254 79150500
Toe amputation 64.35 10.19 107 571527 3804 79168950
Postprandial hypoglycaemia 64.23 10.19 24 571610 63 79172691
Atrioventricular block 64.08 10.19 234 571400 13807 79158947
Insulin resistance 63.57 10.19 63 571571 1316 79171438
Post transplant lymphoproliferative disorder 63.19 10.19 5 571629 11459 79161295
Lower respiratory tract infection 62.83 10.19 607 571027 128613 79044141
Blood potassium increased 62.83 10.19 392 571242 28883 79143871
Toxic epidermal necrolysis 62.42 10.19 142 571492 44439 79128315
Cytomegalovirus viraemia 62.00 10.19 9 571625 12812 79159942
Anion gap 61.40 10.19 77 571557 2104 79170650
Pregnancy 61.40 10.19 61 571573 26790 79145964
Deep vein thrombosis postoperative 61.25 10.19 4 571630 10748 79162006
Angina pectoris 61.04 10.19 603 571031 51129 79121625
Syncope 60.77 10.19 1701 569933 177748 78995006
Haematotoxicity 60.47 10.19 18 571616 15501 79157253
Neurotoxicity 60.38 10.19 87 571547 32431 79140323
Lip dry 59.86 10.19 18 571616 15400 79157354
Immune reconstitution inflammatory syndrome 59.80 10.19 13 571621 13828 79158926
Circulatory collapse 59.44 10.19 468 571166 37200 79135554
Blood cholesterol increased 59.33 10.19 354 571280 83366 79089388
Adenocarcinoma pancreas 59.20 10.19 73 571561 1960 79170794
Osteoporosis 58.82 10.19 195 571439 53917 79118837
Diabetic ketoacidotic hyperglycaemic coma 58.81 10.19 30 571604 199 79172555
Joint range of motion decreased 57.98 10.19 93 571541 33189 79139565
Affect lability 57.74 10.19 195 571439 11064 79161690
Osteoarthritis 57.31 10.19 378 571256 86931 79085823
Abdominal pain 57.02 10.19 3374 568260 386195 78786559
Cholelithiasis 56.95 10.19 603 571031 52061 79120693
PCO2 decreased 56.95 10.19 90 571544 3064 79169690
Psoriatic arthropathy 56.76 10.19 327 571307 77672 79095082
Chronic sinusitis 56.76 10.19 12 571622 13014 79159740
Urinary tract discomfort 56.47 10.19 45 571589 696 79172058
Pollakiuria 56.36 10.19 459 571175 36858 79135896
Osteonecrosis 55.97 10.19 85 571549 31010 79141744
Pancytopenia 55.94 10.19 843 570791 164902 79007852
Hepatic function abnormal 55.65 10.19 302 571332 72805 79099949
Genital infection fungal 54.98 10.19 28 571606 185 79172569
Dialysis 54.88 10.19 270 571364 18192 79154562
Injection site erythema 54.70 10.19 332 571302 77865 79094889
Grip strength decreased 54.37 10.19 46 571588 21823 79150931
Glucose urine present 54.30 10.19 65 571569 1691 79171063
Haemophagocytic lymphohistiocytosis 54.21 10.19 46 571588 21791 79150963
Hospitalisation 54.10 10.19 424 571210 93812 79078942
Arthritis 54.02 10.19 544 571090 114336 79058418
Cardiovascular disorder 53.86 10.19 264 571370 17761 79154993
Tenosynovitis 53.80 10.19 22 571612 15532 79157222
Sopor 53.68 10.19 413 571221 32597 79140157
Eating disorder 53.42 10.19 291 571343 20406 79152348
Diabetic foot infection 53.10 10.19 45 571589 762 79171992
Nausea 52.61 10.19 7723 563911 949473 78223281
Gastroenteritis 52.44 10.19 421 571213 33661 79139093
Glycosylated haemoglobin decreased 52.15 10.19 42 571592 660 79172094
Pancreatitis chronic 52.02 10.19 99 571535 3920 79168834
Clostridium difficile infection 51.98 10.19 146 571488 42539 79130215
Injection site reaction 51.92 10.19 209 571425 54576 79118178
Glycosuria 51.90 10.19 71 571563 2117 79170637
Blood triglycerides increased 51.75 10.19 292 571342 20748 79152006
Drug ineffective for unapproved indication 51.43 10.19 191 571443 51047 79121707
High density lipoprotein decreased 51.05 10.19 107 571527 4548 79168206
Autoimmune disorder 50.56 10.19 28 571606 16584 79156170
Flushing 49.81 10.19 399 571235 87869 79084885
Parkinsonism 49.63 10.19 243 571391 16341 79156413
Alveolar osteitis 49.31 10.19 44 571590 801 79171953
Tubulointerstitial nephritis 49.23 10.19 454 571180 37781 79134973
BK virus infection 48.08 10.19 4 571630 8800 79163954
Adverse event 47.35 10.19 246 571388 59968 79112786
Device expulsion 47.22 10.19 70 571564 25791 79146963
Anhidrosis 47.15 10.19 26 571608 206 79172548
Atrial fibrillation 47.12 10.19 1799 569835 196087 78976667
Multiple sclerosis relapse 47.01 10.19 173 571461 46360 79126394
Needle issue 46.91 10.19 202 571432 12866 79159888
Leukocytosis 46.72 10.19 497 571137 42958 79129796
Incorrect route of product administration 46.71 10.19 114 571520 34815 79137939
Haematuria 46.68 10.19 723 570911 68113 79104641
Prerenal failure 46.52 10.19 90 571544 3608 79169146
Staphylococcal infection 46.50 10.19 237 571397 58058 79114696
Pain in jaw 46.34 10.19 172 571462 45979 79126775
Blood ketone body 46.34 10.19 22 571612 122 79172632
Bone erosion 46.29 10.19 36 571598 17811 79154943
Kussmaul respiration 46.17 10.19 32 571602 395 79172359
Therapeutic response decreased 46.15 10.19 285 571349 66568 79106186
Naevus flammeus 46.12 10.19 19 571615 70 79172684
Hypophagia 46.07 10.19 513 571121 44854 79127900
Myopathy 45.80 10.19 278 571356 20285 79152469
Antipsychotic drug level decreased 45.79 10.19 50 571584 1174 79171580
Asthenia 45.11 10.19 4256 567378 507433 78665321
Herpes zoster 44.92 10.19 438 571196 92645 79080109
Adjustment disorder with depressed mood 44.83 10.19 6 571628 9080 79163674
Blindness transient 44.69 10.19 103 571531 4673 79168081
Sedation 44.28 10.19 206 571428 51689 79121065
Thirst 44.22 10.19 256 571378 18363 79154391
Amylase increased 43.94 10.19 178 571456 11031 79161723
Lung disorder 43.69 10.19 368 571266 80189 79092565
Osmolar gap increased 43.32 10.19 20 571614 103 79172651
C-reactive protein increased 43.27 10.19 657 570977 128370 79044384
Stevens-Johnson syndrome 42.66 10.19 141 571493 39025 79133729
Thrombotic microangiopathy 42.57 10.19 49 571585 20120 79152634
Lymphocyte count decreased 41.97 10.19 185 571449 47104 79125650
Coma 41.97 10.19 981 570653 99668 79073086
Red blood cell sedimentation rate increased 41.83 10.19 178 571456 45764 79126990
Insulin C-peptide decreased 41.82 10.19 17 571617 60 79172694
Pleural effusion 41.72 10.19 761 570873 144501 79028253
Neuropathy vitamin B12 deficiency 41.62 10.19 18 571616 77 79172677
Pancreatic neoplasm 41.38 10.19 52 571582 1424 79171330
Mouth ulceration 41.29 10.19 139 571495 38255 79134499
Clostridium difficile colitis 41.12 10.19 108 571526 32175 79140579
Base excess negative 40.97 10.19 13 571621 16 79172738
Unintentional medical device removal 40.78 10.19 4 571630 7708 79165046
Multiple-drug resistance 40.75 10.19 7 571627 8801 79163953
Bradyarrhythmia 40.56 10.19 91 571543 4055 79168699
Dysarthria 40.55 10.19 696 570938 66926 79105828
Bladder transitional cell carcinoma 40.30 10.19 70 571564 2580 79170174
Type 2 diabetes mellitus 40.29 10.19 604 571030 56518 79116236
Hypoaesthesia 40.24 10.19 978 570656 178374 78994380
Disability 40.18 10.19 38 571596 17082 79155672
Immunosuppressant drug level increased 39.99 10.19 8 571626 9019 79163735
Lymphopenia 39.87 10.19 101 571533 30456 79142298
Hyponatraemia 39.80 10.19 1606 570028 176242 78996512
Basilar artery thrombosis 39.64 10.19 28 571606 357 79172397
Aphasia 39.38 10.19 510 571124 46222 79126532
Blood calcium decreased 39.36 10.19 108 571526 31711 79141043
Enthesopathy 39.22 10.19 17 571617 11591 79161163
Hemiparesis 39.21 10.19 392 571242 33341 79139413
Neuropathy peripheral 39.11 10.19 745 570889 140560 79032194
Coma scale abnormal 39.08 10.19 144 571490 8534 79164220
Dystonia 38.99 10.19 58 571576 21341 79151413
Ischaemic stroke 38.99 10.19 386 571248 32745 79140009
Liver disorder 38.74 10.19 332 571302 72085 79100669
Pernicious anaemia 38.74 10.19 33 571601 563 79172191
Balanoposthitis 38.70 10.19 41 571593 929 79171825
Tunnel vision 38.64 10.19 52 571582 1526 79171228
Dysuria 38.40 10.19 545 571089 50406 79122348
Anion gap abnormal 38.10 10.19 34 571600 619 79172135
Liver injury 37.71 10.19 244 571390 56370 79116384
Medication error 37.44 10.19 696 570938 67946 79104808
Rheumatoid nodule 37.20 10.19 42 571592 17396 79155358
Oral herpes 37.18 10.19 89 571545 27365 79145389
Cerebral venous thrombosis 37.11 10.19 69 571565 2684 79170070
Hypoglycaemic unconsciousness 36.93 10.19 44 571590 1139 79171615
Joint stiffness 36.68 10.19 159 571475 40671 79132083
Coordination abnormal 36.64 10.19 231 571403 17081 79155673
Polymyalgia rheumatica 36.19 10.19 92 571542 4445 79168309
Malaise 36.06 10.19 4025 567609 485844 78686910
Cytomegalovirus infection reactivation 36.04 10.19 9 571625 8707 79164047
Foot deformity 35.92 10.19 74 571560 24000 79148754
Acute myeloid leukaemia 35.88 10.19 108 571526 30777 79141977
Body temperature decreased 35.67 10.19 370 571264 31775 79140979
Lumbosacral radiculoplexus neuropathy 35.47 10.19 15 571619 60 79172694
Drug dependence 35.27 10.19 161 571473 40608 79132146
Wrong patient received product 35.15 10.19 92 571542 4526 79168228
Decreased appetite 35.07 10.19 2880 568754 339538 78833216
Electrocardiogram T wave peaked 35.04 10.19 39 571595 936 79171818
Ascites 35.02 10.19 359 571275 75203 79097551
Hypertensive crisis 34.97 10.19 262 571372 20508 79152246
Diabetic foot 34.73 10.19 79 571555 3553 79169201
Anxiety 34.71 10.19 1442 570192 247070 78925684
Complications of transplanted kidney 34.47 10.19 3 571631 6363 79166391
Athetosis 34.37 10.19 18 571616 127 79172627
Blood creatine phosphokinase increased 34.29 10.19 665 570969 65425 79107329
5-hydroxyindolacetic acid in urine increased 34.25 10.19 22 571612 237 79172517
Sedation complication 34.24 10.19 37 571597 15632 79157122
Urine ketone body 34.14 10.19 20 571614 180 79172574
Blood mercury abnormal 33.75 10.19 21 571613 213 79172541
Bladder pain 33.30 10.19 60 571574 2277 79170477
Plasma cell myeloma 33.25 10.19 234 571400 53025 79119729
Peripheral venous disease 33.20 10.19 39 571595 15870 79156884
Nephrogenic systemic fibrosis 33.09 10.19 3 571631 6157 79166597
Atrioventricular block complete 32.93 10.19 218 571416 16392 79156362
Interstitial lung disease 32.93 10.19 588 571046 112012 79060742
Tumour lysis syndrome 32.90 10.19 77 571557 23862 79148892
Drug reaction with eosinophilia and systemic symptoms 32.84 10.19 298 571336 63946 79108808
Neoplasm progression 32.79 10.19 226 571408 51456 79121298
Product substitution issue 32.69 10.19 253 571381 20003 79152751
Hypocalcaemia 32.57 10.19 521 571113 49403 79123351
Injury 32.40 10.19 377 571257 77119 79095635
Dyslipidaemia 32.37 10.19 167 571467 11466 79161288
Lupus-like syndrome 32.24 10.19 31 571603 13826 79158928
Confusional state 32.14 10.19 2672 568962 315325 78857429
Osteonecrosis of jaw 32.11 10.19 180 571454 43046 79129708
Appendicitis 31.81 10.19 63 571571 20731 79152023
Hyperlipasaemia 31.74 10.19 42 571592 1212 79171542
Lower limb fracture 31.65 10.19 75 571559 23140 79149614
Hyperventilation 31.41 10.19 126 571508 7773 79164981
Wheezing 31.39 10.19 618 571016 116046 79056708
Aggression 31.27 10.19 225 571409 50733 79122021
Unresponsive to stimuli 31.24 10.19 568 571066 55220 79117534
Pulmonary toxicity 31.09 10.19 28 571606 12886 79159868
Immune effector cell-associated neurotoxicity syndrome 31.01 10.19 3 571631 5845 79166909
Congenital hydrocephalus 30.97 10.19 14 571620 68 79172686
Oedematous pancreatitis 30.93 10.19 40 571594 1128 79171626
X-ray abnormal 30.78 10.19 3 571631 5810 79166944
Dry eye 30.68 10.19 148 571486 36783 79135971
Depression 30.68 10.19 1256 570378 215534 78957220
Chorea 30.62 10.19 59 571575 2358 79170396
Device related infection 30.53 10.19 134 571500 34160 79138594
Peritonitis 30.49 10.19 101 571533 27935 79144819
Bundle branch block left 30.47 10.19 163 571471 11350 79161404
Vitreous haemorrhage 30.36 10.19 76 571558 3637 79169117
Allergic reaction to excipient 30.35 10.19 23 571611 329 79172425
Colorectal cancer 30.28 10.19 12 571622 8635 79164119
Night sweats 30.08 10.19 234 571400 51861 79120893
Choreoathetosis 30.02 10.19 46 571588 1524 79171230
Wound infection 30.00 10.19 81 571553 23910 79148844
Nocardiosis 29.89 10.19 3 571631 5676 79167078
Joint dislocation 29.82 10.19 47 571587 16892 79155862
Sensory loss 29.80 10.19 177 571457 12814 79159940
Bone density decreased 29.74 10.19 31 571603 13316 79159438
Myelodysplastic syndrome 29.73 10.19 114 571520 30187 79142567
Glomerular filtration rate abnormal 29.72 10.19 47 571587 1601 79171153
Hypoglycaemic seizure 29.68 10.19 33 571601 791 79171963
Loss of personal independence in daily activities 29.57 10.19 537 571097 102043 79070711
Pneumothorax 29.47 10.19 104 571530 28219 79144535
Body mass index increased 29.32 10.19 51 571583 1882 79170872
Obstructive pancreatitis 29.27 10.19 34 571600 856 79171898
Malignant mediastinal neoplasm 29.25 10.19 43 571591 1372 79171382
Blood pressure systolic increased 29.19 10.19 657 570977 66329 79106425
Azotaemia 29.00 10.19 127 571507 8149 79164605
Motor dysfunction 28.98 10.19 193 571441 14540 79158214
Enterococcal infection 28.97 10.19 42 571592 15618 79157136
Insulin-like growth factor increased 28.92 10.19 50 571584 1836 79170918
Tongue oedema 28.68 10.19 114 571520 7003 79165751
Antipsychotic drug level increased 28.65 10.19 101 571533 5856 79166898
Device dislocation 28.63 10.19 93 571541 25877 79146877
Dysentery 28.50 10.19 39 571595 1163 79171591
Gastrointestinal disorder 28.34 10.19 663 570971 121542 79051212
Pulseless electrical activity 28.16 10.19 186 571448 13974 79158780
Rales 28.07 10.19 242 571392 19759 79152995
Type V hyperlipidaemia 28.06 10.19 36 571598 1007 79171747
Constipation 27.99 10.19 1702 569932 281348 78891406
Animal scratch 27.92 10.19 43 571591 1431 79171323
Musculoskeletal disorder 27.90 10.19 71 571563 21377 79151377
Aplastic anaemia 27.60 10.19 54 571580 17851 79154903
Blood insulin decreased 27.56 10.19 9 571625 13 79172741
No adverse event 27.55 10.19 155 571479 37037 79135717
Status epilepticus 27.38 10.19 90 571544 24951 79147803
Paraesthesia 27.25 10.19 1011 570623 175312 78997442
Therapy partial responder 27.23 10.19 52 571582 17345 79155409
Drug use disorder 27.18 10.19 14 571620 8637 79164117
Retroperitoneal fibrosis 27.13 10.19 29 571605 664 79172090
Neutrophilia 27.09 10.19 121 571513 7830 79164924
Unevaluable event 27.05 10.19 261 571373 55324 79117430
Conjunctivitis 27.04 10.19 94 571540 25621 79147133
Low density lipoprotein abnormal 26.98 10.19 24 571610 435 79172319
Anovulatory cycle 26.98 10.19 15 571619 121 79172633
Hepatojugular reflux 26.95 10.19 28 571606 620 79172134
Hypoxia 26.85 10.19 550 571084 102693 79070061
Haemofiltration 26.83 10.19 13 571621 76 79172678
Insomnia 26.81 10.19 1460 570174 243710 78929044
Pulmonary haemorrhage 26.71 10.19 40 571594 14677 79158077
Loss of consciousness 26.53 10.19 1465 570169 166478 79006276
Hypervolaemia 26.44 10.19 188 571446 42502 79130252
Device use error 26.31 10.19 9 571625 7092 79165662
Multiple organ dysfunction syndrome 26.23 10.19 1083 570551 119163 79053591
Cold sweat 26.11 10.19 226 571408 18473 79154281
Cytopenia 26.11 10.19 68 571566 20315 79152439
Hydrops foetalis 26.05 10.19 30 571604 748 79172006
Microcytic anaemia 25.87 10.19 90 571544 5184 79167570
Hepatitis B reactivation 25.86 10.19 6 571628 6102 79166652
Starvation ketoacidosis 25.80 10.19 15 571619 133 79172621
Erythromelalgia 25.72 10.19 17 571617 193 79172561
Cholestatic liver injury 25.71 10.19 86 571548 4855 79167899
Necrotising myositis 25.45 10.19 38 571596 1230 79171524
Transferrin saturation decreased 25.41 10.19 36 571598 1110 79171644
Deformity 25.39 10.19 19 571615 9586 79163168
Prescribed overdose 25.37 10.19 163 571471 37720 79135034
Gangrene 25.16 10.19 129 571505 8835 79163919
Apolipoprotein A-I decreased 25.12 10.19 9 571625 20 79172734
Complication associated with device 25.08 10.19 55 571579 17441 79155313
Retinitis 25.00 10.19 5 571629 5638 79167116
Neoplasm malignant 24.98 10.19 130 571504 31680 79141074
Cytomegalovirus test positive 24.87 10.19 6 571628 5941 79166813
Altered state of consciousness 24.83 10.19 447 571187 43375 79129379
Macular oedema 24.79 10.19 91 571543 5383 79167371
Swollen tongue 24.74 10.19 436 571198 42134 79130620
Acquired phimosis 24.74 10.19 11 571623 51 79172703
Erythema 24.72 10.19 1328 570306 221962 78950792
Aspartate aminotransferase increased 24.65 10.19 781 570853 137860 79034894
Infusion site erythema 24.64 10.19 19 571615 9441 79163313
Cardiotoxicity 24.49 10.19 31 571603 12208 79160546
Oedema 24.43 10.19 661 570973 118919 79053835
Respiratory syncytial virus infection 24.34 10.19 19 571615 9383 79163371
Bacteraemia 24.21 10.19 137 571497 32687 79140067
Mydriasis 24.05 10.19 57 571577 17586 79155168
Cytomegalovirus chorioretinitis 24.04 10.19 5 571629 5485 79167269
Pancreatic pseudocyst 24.04 10.19 39 571595 1358 79171396
Febrile bone marrow aplasia 24.01 10.19 35 571599 12985 79159769
Intestinal perforation 23.99 10.19 56 571578 17370 79155384
Blood chloride decreased 23.89 10.19 119 571515 8058 79164696
Adrenal cyst 23.79 10.19 15 571619 156 79172598
Ultrasound antenatal screen 23.68 10.19 27 571607 666 79172088
Oxygen saturation decreased 23.67 10.19 724 570910 128323 79044431
Hypoparathyroidism 23.62 10.19 34 571600 1064 79171690
Ileus 23.59 10.19 102 571532 26109 79146645
Erectile dysfunction 23.58 10.19 183 571451 14481 79158273
Vitamin B1 deficiency 23.52 10.19 27 571607 671 79172083
Wound complication 23.46 10.19 84 571550 4909 79167845
Metabolic syndrome 23.37 10.19 57 571577 2683 79170071
Rhinovirus infection 23.35 10.19 14 571620 7939 79164815
Haemoptysis 23.18 10.19 273 571361 55726 79117028
Throat irritation 23.13 10.19 185 571449 40761 79131993
Left ventricular dysfunction 22.99 10.19 226 571408 19135 79153619
Substance abuse 22.84 10.19 25 571609 10501 79162253
Low density lipoprotein increased 22.77 10.19 122 571512 8500 79164254
Resuscitation 22.66 10.19 52 571582 2352 79170402
Adrenal adenoma 22.66 10.19 36 571598 1231 79171523
Haemorrhage 22.64 10.19 489 571145 90629 79082125
Fixed eruption 22.63 10.19 59 571575 2895 79169859
Immunodeficiency 22.60 10.19 80 571554 21688 79151066
Aplasia pure red cell 22.58 10.19 14 571620 7796 79164958
Balanitis candida 22.57 10.19 13 571621 113 79172641
Temperature perception test abnormal 22.57 10.19 8 571626 17 79172737
Melaena 22.54 10.19 584 571050 60306 79112448
Clostridium test positive 22.53 10.19 9 571625 6445 79166309
Atelectasis 22.53 10.19 137 571497 32120 79140634
Product administered to patient of inappropriate age 22.45 10.19 6 571628 5547 79167207
Drug-disease interaction 22.43 10.19 33 571601 1054 79171700
Non-alcoholic steatohepatitis 22.37 10.19 50 571584 2222 79170532
Postmenopausal haemorrhage 22.31 10.19 40 571594 1512 79171242
Graft versus host disease in skin 21.98 10.19 8 571626 6065 79166689
Albuminuria 21.98 10.19 27 571607 722 79172032
Pulmonary valve disease 21.98 10.19 18 571616 290 79172464
Nipple inflammation 21.89 10.19 10 571624 50 79172704
Back pain 21.80 10.19 1880 569754 302300 78870454
Synovial cyst 21.74 10.19 24 571610 10041 79162713
Actinic elastosis 21.74 10.19 10 571624 51 79172703
Colitis 21.68 10.19 382 571252 72925 79099829
Chills 21.68 10.19 933 570701 159301 79013453
PO2 increased 21.65 10.19 40 571594 1548 79171206
Rhinitis allergic 21.64 10.19 34 571600 12235 79160519
Ear infection 21.63 10.19 151 571483 34281 79138473
Electrolyte imbalance 21.56 10.19 326 571308 30555 79142199
Liver palpable 21.47 10.19 19 571615 342 79172412
Coeliac disease 21.44 10.19 30 571604 11321 79161433
Orbital swelling 21.43 10.19 10 571624 53 79172701
Female genital tract fistula 21.41 10.19 8 571626 5967 79166787
Enterocolitis 21.32 10.19 45 571589 14467 79158287
Atrioventricular block first degree 21.27 10.19 158 571476 12333 79160421
Trisomy 18 21.27 10.19 24 571610 585 79172169
Blood iron decreased 21.27 10.19 186 571448 15248 79157506
Anaemia macrocytic 21.24 10.19 88 571546 5509 79167245
Granuloma 21.19 10.19 17 571617 8280 79164474
Blood pressure fluctuation 21.12 10.19 346 571288 66799 79105955
Feeling hot 21.12 10.19 301 571333 59433 79113321
Central obesity 21.11 10.19 42 571592 1719 79171035
Abnormal loss of weight 21.10 10.19 117 571517 8259 79164495
Respiratory tract infection 21.08 10.19 235 571399 48454 79124300
Diabetic complication 21.06 10.19 35 571599 1244 79171510
Liver function test increased 20.98 10.19 183 571451 39590 79133164
Hypokinesia 20.96 10.19 219 571415 18841 79153913
Hypogammaglobulinaemia 20.90 10.19 38 571596 12913 79159841
Pancreatic neuroendocrine tumour 20.90 10.19 25 571609 650 79172104
Alanine aminotransferase increased 20.89 10.19 952 570682 161618 79011136
Body mass index abnormal 20.82 10.19 16 571618 234 79172520
Tinnitus 20.80 10.19 210 571424 44123 79128631
Bacterial infection 20.74 10.19 135 571499 31145 79141609
Temperature regulation disorder 20.70 10.19 8 571626 5845 79166909
Sleep disorder 20.65 10.19 462 571172 85215 79087539
Pneumatosis intestinalis 20.63 10.19 10 571624 6387 79166367
Drug specific antibody present 20.55 10.19 11 571623 6641 79166113
Arrhythmia 20.49 10.19 580 571054 60692 79112062
Cardiogenic shock 20.48 10.19 418 571216 41496 79131258
Dyspnoea at rest 20.44 10.19 105 571529 7197 79165557
Pneumonia aspiration 20.44 10.19 347 571287 66620 79106134
Exercise tolerance decreased 20.43 10.19 123 571511 8948 79163806
Diabetic ulcer 20.43 10.19 16 571618 241 79172513
Road traffic accident 20.42 10.19 207 571427 43457 79129297
Venoocclusive disease 20.37 10.19 4 571630 4569 79168185
Burkholderia pseudomallei infection 20.29 10.19 10 571624 61 79172693
Diabetic coma 20.28 10.19 34 571600 1217 79171537
Hallucination 20.21 10.19 464 571170 85281 79087473
Urosepsis 20.20 10.19 284 571350 26211 79146543
Intercapillary glomerulosclerosis 20.16 10.19 10 571624 62 79172692
Device difficult to use 20.09 10.19 41 571593 13344 79159410
Viral infection 20.09 10.19 204 571430 42812 79129942
Ulcer 20.05 10.19 129 571505 29843 79142911
Cerebral haematoma 20.05 10.19 111 571523 7831 79164923
Mechanical ventilation complication 20.03 10.19 9 571625 43 79172711
Leukocyturia 19.93 10.19 44 571590 1939 79170815
Large intestine perforation 19.91 10.19 47 571587 14520 79158234
Thrombosis 19.85 10.19 455 571179 83645 79089109
Neuroendocrine tumour 19.79 10.19 35 571599 1309 79171445
Glomerular filtration rate increased 19.75 10.19 33 571601 1178 79171576
Lactate pyruvate ratio abnormal 19.73 10.19 5 571629 0 79172754
Birt-Hogg-Dube syndrome 19.73 10.19 5 571629 0 79172754
Therapeutic drug monitoring analysis incorrectly performed 19.72 10.19 25 571609 691 79172063
Angina unstable 19.66 10.19 193 571441 16334 79156420
Overweight 19.65 10.19 70 571564 4080 79168674
Sepsis 19.64 10.19 1663 569971 267765 78904989
Pneumonia viral 19.60 10.19 22 571612 9136 79163618
Diabetes mellitus management 19.56 10.19 6 571628 6 79172748
Pelvic fracture 19.52 10.19 36 571598 12168 79160586
Pruritus 19.52 10.19 2504 569130 392144 78780610
IIIrd nerve paresis 19.46 10.19 14 571620 184 79172570
Suicidal ideation 19.46 10.19 408 571226 75932 79096822
Neuropathic arthropathy 19.33 10.19 18 571616 347 79172407
Urine output increased 19.32 10.19 47 571587 2209 79170545
Drug level below therapeutic 19.28 10.19 25 571609 9745 79163009
Hyperinsulinaemic hypoglycaemia 19.27 10.19 13 571621 153 79172601
Drug tolerance decreased 19.27 10.19 40 571594 12938 79159816
Serotonin syndrome 19.23 10.19 218 571416 44809 79127945
Skin turgor decreased 19.09 10.19 26 571608 772 79171982
Food allergy 19.09 10.19 30 571604 10794 79161960
Cleft lip 19.08 10.19 6 571628 7 79172747
Ear congestion 19.08 10.19 55 571579 2864 79169890
Necrotising fasciitis 19.08 10.19 90 571544 5960 79166794
Cytomegalovirus colitis 19.06 10.19 5 571629 4680 79168074
Ischaemic cardiomyopathy 19.06 10.19 107 571527 7588 79165166
Pseudomonas infection 19.02 10.19 81 571553 20822 79151932
Femur fracture 19.01 10.19 181 571453 38471 79134283
Methaemoglobinaemia 18.99 10.19 8 571626 5549 79167205
Injection site bruising 18.92 10.19 195 571439 40807 79131947
Hyperinsulinaemia 18.91 10.19 14 571620 193 79172561
Upper respiratory tract infection 18.86 10.19 503 571131 90665 79082089
Albumin urine present 18.83 10.19 24 571610 667 79172087
Hepatic vein dilatation 18.77 10.19 15 571619 233 79172521
Live birth 18.72 10.19 70 571564 18674 79154080
Renal oncocytoma 18.70 10.19 10 571624 74 79172680
Cutaneous vasculitis 18.65 10.19 112 571522 8140 79164614
Cleft lip and palate 18.63 10.19 24 571610 674 79172080
Injection site mass 18.60 10.19 224 571410 19960 79152794
Cystitis haemorrhagic 18.59 10.19 23 571611 9149 79163605
Differential white blood cell count abnormal 18.57 10.19 44 571590 2033 79170721
Nipple disorder 18.49 10.19 14 571620 200 79172554
Duodenal ulcer 18.44 10.19 189 571445 16180 79156574
Diffuse large B-cell lymphoma 18.42 10.19 37 571597 12112 79160642
Drug dose omission by device 18.36 10.19 11 571623 6239 79166515
Brain oedema 18.33 10.19 106 571528 25157 79147597
Electrocardiogram abnormal 18.26 10.19 192 571442 16545 79156209
Blood triglycerides abnormal 18.20 10.19 20 571614 473 79172281
Joint effusion 18.17 10.19 67 571567 17947 79154807
Haemorrhoids 18.17 10.19 128 571506 29000 79143754
Hepatic neoplasm 18.16 10.19 60 571574 3366 79169388
Parainfluenzae virus infection 18.14 10.19 9 571625 5673 79167081
Leukoencephalopathy 18.14 10.19 18 571616 7911 79164843
Rash erythematous 18.07 10.19 298 571336 57471 79115283
Pneumonitis 18.04 10.19 317 571317 60543 79112211
Renal artery thrombosis 18.00 10.19 20 571614 479 79172275
Bundle branch block right 17.87 10.19 140 571494 11111 79161643
Musculoskeletal pain 17.86 10.19 578 571056 101776 79070978
Prothrombin consumption time prolonged 17.84 10.19 8 571626 38 79172716
Helicobacter gastritis 17.84 10.19 48 571586 2401 79170353
Pulmonary tuberculosis 17.83 10.19 18 571616 7847 79164907
Device malfunction 17.79 10.19 86 571548 21362 79151392
Injection site warmth 17.76 10.19 51 571583 14756 79157998
Drug withdrawal syndrome 17.76 10.19 161 571473 34557 79138197
Mucosal dryness 17.69 10.19 61 571573 3498 79169256
Diabetic hyperosmolar coma 17.62 10.19 25 571609 772 79171982
Oral candidiasis 17.61 10.19 132 571502 29496 79143258
Tongue disorder 17.61 10.19 47 571587 13928 79158826
Blepharospasm 17.61 10.19 10 571624 5841 79166913
Herbal interaction 17.58 10.19 20 571614 492 79172262
Prostatomegaly 17.58 10.19 60 571574 3423 79169331
Skin disorder 17.54 10.19 157 571477 33786 79138968
Transfusion 17.42 10.19 86 571548 21244 79151510
Insulin C-peptide increased 17.40 10.19 11 571623 115 79172639
Scrotal cyst 17.40 10.19 5 571629 3 79172751
Malignant spinal cord compression 17.39 10.19 12 571622 147 79172607
Pyelonephritis 17.38 10.19 223 571411 20165 79152589
Food aversion 17.38 10.19 29 571605 1034 79171720
Peripheral arterial occlusive disease 17.36 10.19 110 571524 8148 79164606
Urticaria 17.36 10.19 1119 570515 184082 78988672
Intestinal stenosis 17.33 10.19 3 571631 3751 79169003
Inappropriate antidiuretic hormone secretion 17.31 10.19 275 571359 26038 79146716
Hypertriglyceridaemia 17.28 10.19 153 571481 12587 79160167
Hyperoxaluria 17.24 10.19 16 571618 307 79172447
Blood growth hormone abnormal 17.20 10.19 8 571626 42 79172712
Labelled drug-disease interaction medication error 17.16 10.19 16 571618 309 79172445
Mitochondrial enzyme deficiency 17.16 10.19 7 571627 25 79172729
Basal cell carcinoma 17.14 10.19 178 571456 37197 79135557
Decreased bronchial secretion 17.13 10.19 9 571625 64 79172690
Miosis 17.09 10.19 57 571577 15732 79157022
Fear of injection 17.06 10.19 17 571617 7457 79165297
Peripheral sensory neuropathy 17.06 10.19 43 571591 12990 79159764
Product appearance confusion 17.05 10.19 8 571626 43 79172711
Pericardial disease 16.97 10.19 21 571613 566 79172188
Low density lipoprotein decreased 16.96 10.19 31 571603 1190 79171564
Genital swelling 16.95 10.19 16 571618 314 79172440
Intestinal obstruction 16.94 10.19 212 571422 42808 79129946
Lymphoma 16.93 10.19 66 571568 17394 79155360
Herpes simplex 16.91 10.19 39 571595 12148 79160606
Anal incontinence 16.90 10.19 202 571432 17966 79154788
Pancreatitis necrotising 16.89 10.19 64 571570 3844 79168910
Lymphadenopathy 16.88 10.19 274 571360 52973 79119781
Coronary artery bypass 16.85 10.19 87 571547 5975 79166779
Injection site swelling 16.84 10.19 237 571397 46895 79125859
Drug half-life increased 16.73 10.19 12 571622 157 79172597
Intentional self-injury 16.73 10.19 150 571484 32269 79140485
Malabsorption 16.71 10.19 76 571558 4956 79167798
Calculus urinary 16.71 10.19 47 571587 2413 79170341
Generalised tonic-clonic seizure 16.69 10.19 218 571416 43692 79129062
Prostatitis 16.69 10.19 67 571567 4135 79168619
Red blood cell count decreased 16.60 10.19 301 571333 57212 79115542
Encephalitis toxic 16.59 10.19 15 571619 278 79172476
Pancreatic mass 16.57 10.19 35 571599 1496 79171258
Muscle necrosis 16.56 10.19 34 571600 1424 79171330
Hypoperfusion 16.55 10.19 49 571585 2590 79170164
Myoglobin blood increased 16.54 10.19 55 571579 3096 79169658
Device issue 16.48 10.19 120 571514 26988 79145766
Eyelid bleeding 16.46 10.19 9 571625 70 79172684
Neck pain 16.43 10.19 413 571221 75004 79097750
Hormone receptor positive HER2 negative breast cancer 16.41 10.19 11 571623 128 79172626
Brain stem infarction 16.41 10.19 41 571593 1960 79170794
Purpura 16.37 10.19 78 571556 19449 79153305
Neuropathy, ataxia, retinitis pigmentosa syndrome 16.34 10.19 8 571626 48 79172706
Cardiac failure chronic 16.30 10.19 136 571498 10999 79161755
Pneumonia fungal 16.27 10.19 35 571599 11175 79161579
Staphylococcal bacteraemia 16.24 10.19 40 571594 12178 79160576
Blindness cortical 16.24 10.19 27 571607 960 79171794
Autoimmune myositis 16.16 10.19 15 571619 288 79172466
Virologic failure 16.08 10.19 5 571629 4186 79168568
Uveitis 16.07 10.19 64 571570 16766 79155988
CD30 expression 16.07 10.19 8 571626 50 79172704
Catheter site infection 16.04 10.19 15 571619 6780 79165974
Epistaxis 15.99 10.19 645 570989 110870 79061884
Jaundice 15.94 10.19 498 571136 52851 79119903
Pleural fibrosis 15.93 10.19 5 571629 4162 79168592
Blood cholesterol 15.90 10.19 22 571612 663 79172091
Fall 15.90 10.19 3833 567801 483796 78688958
Post-traumatic amnestic disorder 15.82 10.19 8 571626 52 79172702
Skin haemorrhage 15.80 10.19 143 571491 11838 79160916
Macular degeneration 15.79 10.19 36 571598 11260 79161494
Atrioventricular node dysfunction 15.78 10.19 4 571630 0 79172754
Pancreatic enzymes abnormal 15.78 10.19 4 571630 0 79172754
Amnesia 15.78 10.19 338 571296 62719 79110035
Scleroderma 15.76 10.19 10 571624 5500 79167254
Deep vein thrombosis 15.75 10.19 707 570927 120212 79052542
Gastrointestinal toxicity 15.75 10.19 21 571613 8088 79164666
Genitourinary symptom 15.68 10.19 14 571620 255 79172499
Peripheral vascular disorder 15.68 10.19 105 571529 7925 79164829
Cryptococcosis 15.67 10.19 3 571631 3490 79169264
Akathisia 15.66 10.19 46 571588 13213 79159541
Paradoxical drug reaction 15.66 10.19 17 571617 7168 79165586
Bone disorder 15.64 10.19 77 571557 19036 79153718
Pulmonary arterial hypertension 15.64 10.19 129 571505 28237 79144517
Bronchial secretion retention 15.56 10.19 5 571629 4099 79168655
Anaphylactic reaction 15.55 10.19 469 571165 83274 79089480
Fibrillary glomerulonephritis 15.45 10.19 8 571626 55 79172699
Genital rash 15.43 10.19 27 571607 1001 79171753
Nodular rash 15.42 10.19 15 571619 306 79172448
Proctitis 15.42 10.19 14 571620 6418 79166336
Ankylosing spondylitis 15.42 10.19 41 571593 12164 79160590
Chronic obstructive pulmonary disease 15.23 10.19 481 571153 84938 79087816
Treatment noncompliance 15.12 10.19 486 571148 51782 79120972
Phimosis 15.12 10.19 20 571614 577 79172177
Clonus 15.11 10.19 16 571618 6824 79165930
Myalgia 15.11 10.19 1536 570098 184105 78988649
Pyelonephritis acute 15.08 10.19 84 571550 5939 79166815
Blood lactate dehydrogenase increased 15.06 10.19 194 571440 38976 79133778
Cholecystitis chronic 15.04 10.19 122 571512 9784 79162970
Osteopenia 15.02 10.19 74 571560 18290 79154464
Foreign body aspiration 15.00 10.19 15 571619 317 79172437
Wrong technique in product usage process 14.92 10.19 409 571225 73466 79099288
Periarthritis calcarea 14.91 10.19 9 571625 86 79172668
Laryngitis viral 14.87 10.19 8 571626 60 79172694
Diet failure 14.86 10.19 7 571627 38 79172716
Breast cancer female 14.86 10.19 38 571596 11423 79161331
Intracranial pressure increased 14.74 10.19 23 571611 8299 79164455
Cardiovascular insufficiency 14.73 10.19 51 571583 2930 79169824
Palmar-plantar erythrodysaesthesia syndrome 14.71 10.19 159 571475 32975 79139779
Cutaneous T-cell dyscrasia 14.65 10.19 8 571626 62 79172692
Fluid intake reduced 14.64 10.19 86 571548 6202 79166552
Carcinoid tumour 14.63 10.19 19 571615 538 79172216
Pneumonia bacterial 14.63 10.19 80 571554 19251 79153503
Prescription drug used without a prescription 14.55 10.19 63 571571 4022 79168732
Peripheral circulatory failure 14.55 10.19 28 571606 1118 79171636
Product quality issue 14.51 10.19 332 571302 33608 79139146
Vitamin B1 decreased 14.47 10.19 19 571615 544 79172210
Intervertebral disc degeneration 14.47 10.19 61 571573 15724 79157030
Foetal death 14.47 10.19 22 571612 8022 79164732
Clear cell renal cell carcinoma 14.45 10.19 46 571588 2530 79170224
Vascular encephalopathy 14.45 10.19 20 571614 603 79172151
Lip swelling 14.45 10.19 390 571244 40521 79132233
Coma uraemic 14.43 10.19 7 571627 41 79172713
Product administration error 14.40 10.19 314 571320 31532 79141222
Disseminated intravascular coagulation 14.35 10.19 176 571458 35666 79137088
Pharyngitis streptococcal 14.30 10.19 35 571599 10679 79162075
Shock hypoglycaemic 14.24 10.19 13 571621 244 79172510
Osmolar gap abnormal 14.24 10.19 9 571625 94 79172660
Renal abscess 14.24 10.19 27 571607 1066 79171688
Ureterolithiasis 14.21 10.19 60 571574 3788 79168966
Wrong dose 14.19 10.19 35 571599 1659 79171095
Hyperkinetic heart syndrome 14.12 10.19 10 571624 128 79172626
Diabetic gangrene 14.07 10.19 12 571622 205 79172549
Neutropenic sepsis 14.06 10.19 125 571509 26939 79145815
Pancreatitis haemorrhagic 14.05 10.19 23 571611 807 79171947
Secondary immunodeficiency 14.05 10.19 3 571631 3231 79169523
Physical examination abnormal 14.03 10.19 14 571620 295 79172459
Mitral valve incompetence 14 10.19 285 571349 28280 79144474
Coronary artery stenosis 13.99 10.19 144 571490 12340 79160414
Asthma-chronic obstructive pulmonary disease overlap syndrome 13.97 10.19 3 571631 3218 79169536
Body temperature increased 13.94 10.19 229 571405 44191 79128563
Left atrial dilatation 13.93 10.19 52 571582 3101 79169653
Cardiopulmonary failure 13.93 10.19 90 571544 6711 79166043
Cognitive disorder 13.90 10.19 388 571246 69538 79103216
Skin papilloma 13.89 10.19 13 571621 5873 79166881
Postoperative wound infection 13.88 10.19 47 571587 12914 79159840
Cerebral infarction 13.81 10.19 427 571207 45249 79127505
Creatinine renal clearance 13.81 10.19 6 571628 26 79172728
Blood urine present 13.79 10.19 222 571412 21075 79151679
Blood cholesterol abnormal 13.77 10.19 54 571580 3296 79169458
Eructation 13.77 10.19 129 571505 10780 79161974
Sciatica 13.74 10.19 162 571472 33060 79139694
Small intestinal obstruction 13.72 10.19 127 571507 27145 79145609
Analgesic drug level increased 13.70 10.19 3 571631 3175 79169579
Intraductal papillary-mucinous carcinoma of pancreas 13.69 10.19 5 571629 12 79172742
Muscular weakness 13.68 10.19 1334 570300 159395 79013359
Expired product administered 13.65 10.19 92 571542 6959 79165795
Diabetic vascular disorder 13.63 10.19 9 571625 102 79172652
Bladder neoplasm 13.63 10.19 35 571599 1702 79171052
Jaundice hepatocellular 13.62 10.19 10 571624 136 79172618
Oesophagitis 13.60 10.19 110 571524 24179 79148575
Diabetic cheiroarthropathy 13.56 10.19 4 571630 3 79172751
Retinal artery thrombosis 13.55 10.19 9 571625 103 79172651
Hypochromic anaemia 13.54 10.19 47 571587 2704 79170050
Mitral valve thickening 13.52 10.19 16 571618 411 79172343
Blood sodium decreased 13.51 10.19 323 571311 32932 79139822
Infusion site extravasation 13.51 10.19 33 571601 10075 79162679
Upper-airway cough syndrome 13.50 10.19 41 571593 11652 79161102
Infusion site pain 13.48 10.19 54 571580 14122 79158632
Respiratory arrest 13.40 10.19 312 571322 57238 79115516
Neuralgia 13.34 10.19 164 571470 33220 79139534
Autoimmune pancreatitis 13.33 10.19 20 571614 650 79172104
Extrasystoles 13.30 10.19 95 571539 7324 79165430
Blood growth hormone increased 13.29 10.19 21 571613 715 79172039
Decreased vibratory sense 13.27 10.19 20 571614 653 79172101
Tooth disorder 13.27 10.19 122 571512 26111 79146643
Hypomania 13.22 10.19 21 571613 7523 79165231
Premature labour 13.20 10.19 25 571609 8365 79164389
Urethral intrinsic sphincter deficiency 13.15 10.19 5 571629 14 79172740
Pain in extremity 13.15 10.19 2356 569278 362182 78810572
Blood lactic acid abnormal 13.14 10.19 6 571628 30 79172724
Carbohydrate metabolism disorder 13.14 10.19 6 571628 30 79172724
Cerebellar ischaemia 13.12 10.19 12 571622 226 79172528
Drug dose titration not performed 13.11 10.19 22 571612 788 79171966
Embolism venous 13.11 10.19 7 571627 4232 79168522
Flatulence 13.08 10.19 400 571234 42324 79130430
Pancreatic atrophy 13.07 10.19 19 571615 600 79172154
Catheter site erythema 13.05 10.19 11 571623 5229 79167525
Hereditary angioedema with normal C1 esterase inhibitor 13.04 10.19 4 571630 4 79172750
Venous aneurysm 13.04 10.19 4 571630 4 79172750
Muscle twitching 13.03 10.19 114 571520 24650 79148104
Enterococcal bacteraemia 13.02 10.19 3 571631 3065 79169689
Poisoning 13.01 10.19 254 571380 25018 79147736
Mycobacterial infection 12.99 10.19 5 571629 3663 79169091
Transient ischaemic attack 12.99 10.19 481 571153 52214 79120540
Mitochondrial encephalomyopathy 12.98 10.19 6 571628 31 79172723
Pancreatic failure 12.97 10.19 33 571601 1595 79171159
Genital infection 12.94 10.19 11 571623 187 79172567
Acute lymphocytic leukaemia recurrent 12.94 10.19 9 571625 4715 79168039
Spinal compression fracture 12.93 10.19 70 571564 16888 79155866
Pneumonia cytomegaloviral 12.92 10.19 10 571624 4959 79167795
Hyponatraemic encephalopathy 12.91 10.19 14 571620 326 79172428
Hyperphagia 12.91 10.19 44 571590 2508 79170246
Finger deformity 12.91 10.19 21 571613 7453 79165301
Endometriosis male 12.90 10.19 5 571629 15 79172739
Multiple sclerosis 12.90 10.19 100 571534 22182 79150572
Carcinoid tumour of the stomach 12.90 10.19 11 571623 188 79172566
Red blood cells urine positive 12.89 10.19 10 571624 4953 79167801
Discoloured vomit 12.88 10.19 31 571603 1447 79171307
Base excess 12.87 10.19 8 571626 81 79172673
Bronchostenosis 12.87 10.19 20 571614 671 79172083
Anaphylactic shock 12.86 10.19 181 571453 35815 79136939
Memory impairment 12.83 10.19 662 570972 111072 79061682
Varicella zoster virus infection 12.79 10.19 8 571626 4433 79168321
Haemolytic anaemia 12.78 10.19 189 571445 17631 79155123
Optic neuritis 12.78 10.19 31 571603 9489 79163265
Obliterative bronchiolitis 12.77 10.19 3 571631 3025 79169729
Rebound effect 12.77 10.19 20 571614 7206 79165548
Heart sounds 12.76 10.19 24 571610 942 79171812
Blood cholesterol decreased 12.76 10.19 34 571600 1691 79171063
Wound secretion 12.74 10.19 82 571552 6106 79166648
Metastases to fallopian tube 12.74 10.19 7 571627 55 79172699
Gingival oedema 12.74 10.19 7 571627 55 79172699
Device occlusion 12.73 10.19 43 571591 11823 79160931
Foot amputation 12.72 10.19 24 571610 944 79171810
Urine albumin/creatinine ratio increased 12.70 10.19 18 571616 555 79172199
pH urine decreased 12.67 10.19 5 571629 16 79172738
Alcoholic ketoacidosis 12.67 10.19 5 571629 16 79172738
Product solubility abnormal 12.65 10.19 24 571610 948 79171806
Lupus nephritis 12.65 10.19 3 571631 3005 79169749
Illness 12.62 10.19 246 571388 46265 79126489
Crying 12.61 10.19 105 571529 22938 79149816
Food craving 12.60 10.19 33 571601 1624 79171130
Aplasia 12.57 10.19 23 571611 7797 79164957
Respiratory disorder 12.56 10.19 236 571398 44620 79128134
Septic shock 12.55 10.19 736 570898 122065 79050689
Intestinal ischaemia 12.55 10.19 148 571486 13122 79159632
Blood pressure systolic decreased 12.53 10.19 128 571506 10948 79161806
Left ventricular hypertrophy 12.50 10.19 129 571505 11062 79161692
Cholangiocarcinoma 12.50 10.19 43 571591 2463 79170291
Central venous catheterisation 12.48 10.19 4 571630 3285 79169469
Disorientation 12.48 10.19 560 571074 62216 79110538
Crush syndrome 12.47 10.19 11 571623 197 79172557
Bladder papilloma 12.44 10.19 5 571629 17 79172737
Photophobia 12.42 10.19 91 571543 20437 79152317
Ototoxicity 12.39 10.19 4 571630 3270 79169484
Blindness 12.24 10.19 278 571356 28105 79144649
Sinus tachycardia 12.24 10.19 349 571285 36559 79136195
Venous pressure jugular 12.23 10.19 5 571629 18 79172736
Cornea verticillata 12.22 10.19 10 571624 161 79172593
Bone pain 12.21 10.19 305 571329 55437 79117317
Faecal calprotectin increased 12.20 10.19 13 571621 5528 79167226
Bladder sphincter atony 12.16 10.19 9 571625 124 79172630
Cardiac failure congestive 12.13 10.19 1182 570452 141220 79031534
Drug-induced liver injury 12.11 10.19 585 571049 65532 79107222
Malnutrition 12.10 10.19 103 571531 22399 79150355
Hypovitaminosis 12.05 10.19 26 571608 1128 79171626
Glycosylated haemoglobin 12.02 10.19 5 571629 19 79172735
Blood glucose 11.99 10.19 6 571628 38 79172716
Vascular purpura 11.99 10.19 49 571585 3049 79169705
Plasmapheresis 11.95 10.19 19 571615 650 79172104
Helicobacter test false negative 11.95 10.19 7 571627 63 79172691
Conduction disorder 11.95 10.19 52 571582 3327 79169427
Gamma-glutamyltransferase abnormal 11.93 10.19 18 571616 588 79172166
Acid base balance abnormal 11.88 10.19 14 571620 358 79172396
Blood ketone body present 11.87 10.19 8 571626 94 79172660
Spinal fusion surgery 11.86 10.19 12 571622 5226 79167528
Autonomic seizure 11.84 10.19 3 571631 0 79172754
Diabetic dyslipidaemia 11.84 10.19 3 571631 0 79172754
Transitional cell carcinoma urethra 11.84 10.19 3 571631 0 79172754
Babinski reflex test 11.84 10.19 3 571631 0 79172754
Embolic cerebellar infarction 11.82 10.19 5 571629 20 79172734
Blood glucose normal 11.82 10.19 5 571629 20 79172734
Dizziness 11.80 10.19 4075 567559 522366 78650388
Medullary thyroid cancer 11.79 10.19 12 571622 259 79172495
Neurofibrosarcoma 11.77 10.19 11 571623 213 79172541
Aortic stenosis 11.76 10.19 93 571541 7402 79165352
Cellulitis of male external genital organ 11.74 10.19 6 571628 40 79172714
Anaesthetic complication 11.73 10.19 3 571631 2856 79169898
Blood albumin decreased 11.72 10.19 114 571520 24129 79148625
Electroencephalogram abnormal 11.69 10.19 13 571621 5421 79167333
Renal replacement therapy 11.67 10.19 10 571624 172 79172582
Oxygen saturation immeasurable 11.62 10.19 6 571628 41 79172713
Glucose urine 11.62 10.19 6 571628 41 79172713
Psychiatric decompensation 11.60 10.19 7 571627 3956 79168798
Blood pressure inadequately controlled 11.60 10.19 80 571554 6097 79166657
Lipids abnormal 11.60 10.19 18 571616 603 79172151
Delirium 11.60 10.19 492 571142 84135 79088619
Stenosis 11.59 10.19 41 571593 2381 79170373
Neuropathic ulcer 11.59 10.19 8 571626 98 79172656
Serum serotonin increased 11.52 10.19 13 571621 317 79172437
Genital infection female 11.50 10.19 7 571627 68 79172686
Hepatosplenomegaly 11.50 10.19 16 571618 6053 79166701
Blood urea increased 11.46 10.19 443 571191 48347 79124407
Hypertensive angiopathy 11.46 10.19 8 571626 100 79172654
Prolonged expiration 11.44 10.19 27 571607 1244 79171510
Respiratory rate increased 11.42 10.19 218 571416 21382 79151372
Walking aid user 11.42 10.19 36 571598 10112 79162642
Blood bicarbonate abnormal 11.41 10.19 9 571625 137 79172617
Red cell distribution width abnormal 11.41 10.19 11 571623 222 79172532
Cushingoid 11.39 10.19 33 571601 9519 79163235
Myositis 11.38 10.19 197 571437 18971 79153783
Haemoglobin decreased 11.37 10.19 1406 570228 220713 78952041
Fluid retention 11.29 10.19 398 571236 69411 79103343
Endometrial hyperplasia 11.28 10.19 18 571616 618 79172136
Psychogenic tremor 11.28 10.19 5 571629 23 79172731
Catheter site haemorrhage 11.27 10.19 12 571622 5105 79167649
Colitis ulcerative 11.27 10.19 178 571456 34564 79138190
Product preparation error 11.25 10.19 15 571619 5778 79166976
Drug abuser 11.25 10.19 16 571618 5997 79166757
Pancreatic enzymes increased 11.22 10.19 28 571606 1337 79171417
Squamous cell carcinoma of skin 11.22 10.19 57 571577 13976 79158778
Leukaemia recurrent 11.21 10.19 3 571631 2771 79169983
Cardiac discomfort 11.21 10.19 27 571607 1261 79171493
Dry mouth 11.18 10.19 516 571118 87503 79085251
Systemic infection 11.18 10.19 113 571521 9639 79163115
Schizophrenia 11.17 10.19 164 571470 15276 79157478
Diabetic macroangiopathy 11.09 10.19 9 571625 143 79172611
Lichen sclerosus 11.08 10.19 23 571611 971 79171783
Drug tolerance 11.06 10.19 29 571605 8646 79164108
Obesity 11.06 10.19 330 571304 34795 79137959
Chronic pigmented purpura 11.05 10.19 11 571623 231 79172523
Blood creatine increased 11.05 10.19 110 571524 9345 79163409
Viral mutation identified 11.04 10.19 7 571627 3851 79168903
Scleritis 11.03 10.19 9 571625 4347 79168407
Injection site hypertrophy 11.01 10.19 7 571627 74 79172680
Fungaemia 11.00 10.19 10 571624 4581 79168173
Amputation 10.88 10.19 20 571614 771 79171983
Renal cyst 10.87 10.19 157 571477 14575 79158179
Subacute cutaneous lupus erythematosus 10.84 10.19 6 571628 3555 79169199
Intercepted product preparation error 10.83 10.19 6 571628 3554 79169200
Genital tract inflammation 10.83 10.19 6 571628 48 79172706
Epilepsy 10.82 10.19 217 571417 40643 79132111
Ear pain 10.80 10.19 168 571466 32701 79140053
Pneumonia pseudomonal 10.79 10.19 16 571618 5895 79166859
Sinus arrest 10.79 10.19 53 571581 3569 79169185
Intracranial haematoma 10.77 10.19 22 571612 918 79171836
Bacterial sepsis 10.77 10.19 27 571607 8171 79164583
Adrenomegaly 10.77 10.19 14 571620 397 79172357
Haematocrit decreased 10.75 10.19 346 571288 60966 79111788
Hyperaesthesia 10.73 10.19 48 571586 12174 79160580
Tachyarrhythmia 10.71 10.19 86 571548 6876 79165878
Arteriosclerosis 10.71 10.19 187 571447 18040 79154714
Ventricular dyssynchrony 10.70 10.19 7 571627 78 79172676
Lactate pyruvate ratio increased 10.70 10.19 7 571627 78 79172676
Total cholesterol/HDL ratio abnormal 10.70 10.19 7 571627 78 79172676
Ventricular enlargement 10.70 10.19 19 571615 713 79172041
Metastases to central nervous system 10.69 10.19 71 571563 16304 79156450
Blood urea abnormal 10.68 10.19 27 571607 1300 79171454
Drug level decreased 10.68 10.19 60 571574 14342 79158412
Skin induration 10.67 10.19 10 571624 4515 79168239
Fistula 10.67 10.19 52 571582 12888 79159866
Sexual dysfunction 10.64 10.19 25 571609 7738 79165016
Upper respiratory tract inflammation 10.64 10.19 8 571626 4027 79168727
Thyroid cancer recurrent 10.64 10.19 5 571629 27 79172727
Dyskinesia 10.63 10.19 242 571392 44531 79128223
Gallbladder oedema 10.62 10.19 12 571622 293 79172461
Panniculitis 10.61 10.19 49 571585 12322 79160432
Soft tissue disorder 10.59 10.19 6 571628 3509 79169245
Stenotrophomonas infection 10.59 10.19 7 571627 3766 79168988
Essential hypertension 10.56 10.19 77 571557 5976 79166778
Vascular device infection 10.51 10.19 38 571596 10238 79162516
Increased tendency to bruise 10.50 10.19 39 571595 10425 79162329
Oculogyric crisis 10.50 10.19 4 571630 2948 79169806
Hemianopia homonymous 10.50 10.19 27 571607 1314 79171440
Opportunistic infection 10.49 10.19 4 571630 2946 79169808
Stress fracture 10.47 10.19 19 571615 6461 79166293
Cortisol increased 10.47 10.19 16 571618 529 79172225
Serum ferritin abnormal 10.45 10.19 14 571620 409 79172345
Diabetic eye disease 10.45 10.19 9 571625 156 79172598
Idiopathic intracranial hypertension 10.45 10.19 5 571629 3217 79169537
Coronary artery occlusion 10.43 10.19 161 571473 15154 79157600
Oral fungal infection 10.43 10.19 7 571627 3736 79169018
Anal fissure 10.41 10.19 25 571609 7678 79165076
Bronchial wall thickening 10.41 10.19 3 571631 2638 79170116
Hepatic enzyme decreased 10.40 10.19 9 571625 157 79172597
Haemorrhage urinary tract 10.39 10.19 40 571594 2421 79170333
IIIrd nerve paralysis 10.37 10.19 25 571609 1168 79171586
Thirst decreased 10.37 10.19 12 571622 301 79172453
Orbital oedema 10.35 10.19 14 571620 413 79172341
Therapeutic drug monitoring analysis not performed 10.34 10.19 34 571600 1902 79170852
Atrial enlargement 10.32 10.19 23 571611 1020 79171734
Locomotive syndrome 10.32 10.19 4 571630 12 79172742
Non-high-density lipoprotein cholesterol decreased 10.32 10.19 4 571630 12 79172742
Albumin globulin ratio abnormal 10.32 10.19 4 571630 12 79172742
Orthopnoea 10.27 10.19 114 571520 9959 79162795
Lip oedema 10.26 10.19 79 571555 6237 79166517
Blood osmolarity increased 10.24 10.19 18 571616 670 79172084
Stem cell transplant 10.22 10.19 7 571627 3697 79169057
Tumour compression 10.21 10.19 9 571625 161 79172593
Enterochromaffin cell hyperplasia 10.20 10.19 7 571627 85 79172669
Respiratory acidosis 10.19 10.19 124 571510 11076 79161678

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC A10BA02 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Biguanides
ATC A10BD02 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD03 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD05 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD07 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD08 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD10 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD11 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD13 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD14 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD15 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD16 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD17 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD18 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD20 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD22 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD23 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD25 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD26 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD27 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
FDA CS M0002471 Biguanides
FDA EPC N0000175565 Biguanide
MeSH PA D007004 Hypoglycemic Agents
CHEBI has role CHEBI:35526 antidiabetic
CHEBI has role CHEBI:35703 Xenobiotic
CHEBI has role CHEBI:78298 environmental contaminants
CHEBI has role CHEBI:176497 geroprotectors

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Diabetes mellitus type 2 indication 44054006 DOID:9352
Induction of ovulation in polycystic ovarian syndrome indication 237055002 DOID:11612
Controlled ovarian stimulation indication 732970000
Treatment Refractory Type 2 Diabetes Mellitus indication
Gestational diabetes mellitus off-label use 11687002 DOID:11714
Polycystic ovaries off-label use 69878008
Weight loss off-label use 89362005
Polycystic ovary syndrome off-label use 237055002 DOID:11612
Prevention of Type 2 Diabetes Mellitus off-label use
Alcoholism contraindication 7200002
Weight gain finding contraindication 8943002
Asthenia contraindication 13791008
Pulmonary edema contraindication 19242006 DOID:11396
Myocardial infarction contraindication 22298006 DOID:5844
Acute vomiting contraindication 23971007
Severe adrenal insufficiency contraindication 24867002
Alcohol intoxication contraindication 25702006
Shock contraindication 27942005
Dehydration contraindication 34095006
Macular retinal edema contraindication 37231002 DOID:4449
Infectious disease contraindication 40733004
Body fluid retention contraindication 43498006
End stage renal disease contraindication 46177005 DOID:784
Chronic heart failure contraindication 48447003
Lymphocytopenia contraindication 48813009 DOID:614
Hepatic porphyria contraindication 55056006 DOID:3133
Ketoacidosis contraindication 56051008
Acute nephropathy contraindication 58574008
Metabolic acidosis contraindication 59455009
Hepatic failure contraindication 59927004
Hemolytic anemia contraindication 61261009 DOID:583
Glucose-6-phosphate dehydrogenase deficiency anemia contraindication 62403005
Acute infectious disease contraindication 63171007
Osteoporosis contraindication 64859006 DOID:11476
Hypopituitarism contraindication 74728003 DOID:9406
Cardiogenic shock contraindication 89138009
Kidney disease contraindication 90708001 DOID:557
Lactic acidosis contraindication 91273001 DOID:3650
Fracture of bone contraindication 125605004
Liver function tests abnormal contraindication 166603001
Cobalamin deficiency contraindication 190634004
Angina pectoris contraindication 194828000
Decompensated cardiac failure contraindication 195111005
Acute pancreatitis contraindication 197456007 DOID:2913
Impaired renal function disorder contraindication 197663003
Cerebrovascular accident contraindication 230690007
Disease of liver contraindication 235856003 DOID:409
Drug-induced hepatitis contraindication 235876009
Hypoglycemic disorder contraindication 237630007
Sepsis syndrome contraindication 238150007
Edema contraindication 267038008
Osteopenia contraindication 312894000
Primary adrenocortical insufficiency contraindication 373662000
Adrenal cortical hypofunction contraindication 386584007 DOID:10493
Fever contraindication 386661006
Surgical procedure contraindication 387713003
Malignant tumor of urinary bladder contraindication 399326009 DOID:11054
Severe diarrhea contraindication 409587002
Breastfeeding (mother) contraindication 413712001
Disorder of coronary artery contraindication 414024009
Myocardial ischemia contraindication 414795007 DOID:3393
Traumatic injury contraindication 417746004
Fever greater than 100.4 Fahrenheit contraindication 426000000
Severe Hypoxemia contraindication
Severe Autonomic Insufficiency contraindication
Radiography with IV Iodinated Contrast Agent contraindication
Prolonged-Severe Nausea and Vomiting contraindication




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 12.63 Basic
pKa2 3.34 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
1GM;EQ 2.5MG BASE KOMBIGLYZE XR ASTRAZENECA AB N200678 Nov. 5, 2010 RX TABLET, EXTENDED RELEASE ORAL RE44186 July 31, 2023 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHEN TREATMENT WITH BOTH SAXAGLIPTIN AND METFORMIN IS APPROPRIATE
1GM;EQ 2.5MG BASE KOMBIGLYZE XR ASTRAZENECA AB N200678 Nov. 5, 2010 RX TABLET, EXTENDED RELEASE ORAL RE44186 July 31, 2023 METHOD FOR TREATING TYPE II DIABETES MELLITUS BY ADMINISTERING SAXAGLIPTIN IN COMBINATION WITH METFORMIN
1GM;EQ 5MG BASE KOMBIGLYZE XR ASTRAZENECA AB N200678 Nov. 5, 2010 RX TABLET, EXTENDED RELEASE ORAL RE44186 July 31, 2023 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHEN TREATMENT WITH BOTH SAXAGLIPTIN AND METFORMIN IS APPROPRIATE
1GM;EQ 5MG BASE KOMBIGLYZE XR ASTRAZENECA AB N200678 Nov. 5, 2010 RX TABLET, EXTENDED RELEASE ORAL RE44186 July 31, 2023 METHOD FOR TREATING TYPE II DIABETES MELLITUS BY ADMINISTERING SAXAGLIPTIN IN COMBINATION WITH METFORMIN
500MG;EQ 5MG BASE KOMBIGLYZE XR ASTRAZENECA AB N200678 Nov. 5, 2010 RX TABLET, EXTENDED RELEASE ORAL RE44186 July 31, 2023 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHEN TREATMENT WITH BOTH SAXAGLIPTIN AND METFORMIN IS APPROPRIATE
500MG;EQ 5MG BASE KOMBIGLYZE XR ASTRAZENECA AB N200678 Nov. 5, 2010 RX TABLET, EXTENDED RELEASE ORAL RE44186 July 31, 2023 METHOD FOR TREATING TYPE II DIABETES MELLITUS BY ADMINISTERING SAXAGLIPTIN IN COMBINATION WITH METFORMIN
10MG;1GM;EQ 5MG BASE QTERNMET XR ASTRAZENECA AB N210874 May 2, 2019 DISCN TABLET, EXTENDED RELEASE ORAL RE44186 July 31, 2023 TREATMENT OF TYPE 2 DIABETES MELLITUS
2.5MG;1GM;EQ 2.5MG BASE QTERNMET XR ASTRAZENECA AB N210874 May 2, 2019 DISCN TABLET, EXTENDED RELEASE ORAL RE44186 July 31, 2023 TREATMENT OF TYPE 2 DIABETES MELLITUS
5MG;1GM;EQ 2.5MG BASE QTERNMET XR ASTRAZENECA AB N210874 May 2, 2019 DISCN TABLET, EXTENDED RELEASE ORAL RE44186 July 31, 2023 TREATMENT OF TYPE 2 DIABETES MELLITUS
5MG;1GM;EQ 5MG BASE QTERNMET XR ASTRAZENECA AB N210874 May 2, 2019 DISCN TABLET, EXTENDED RELEASE ORAL RE44186 July 31, 2023 TREATMENT OF TYPE 2 DIABETES MELLITUS
2.5MG;1GM JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL 8119648 Aug. 12, 2023 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR
2.5MG;1GM JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL 8178541 Aug. 12, 2023 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN AND/OR A SULFONYLUREA
2.5MG;500MG JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL 8119648 Aug. 12, 2023 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR
2.5MG;500MG JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL 8178541 Aug. 12, 2023 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN AND/OR A SULFONYLUREA
2.5MG;850MG JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL 8119648 Aug. 12, 2023 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR
2.5MG;850MG JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL 8178541 Aug. 12, 2023 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN AND/OR A SULFONYLUREA
2.5MG;1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL 8119648 Aug. 12, 2023 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR
2.5MG;1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL 8178541 Aug. 12, 2023 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN AND, OPTIONALLY, A SULFONYLUREA
5MG;1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL 8119648 Aug. 12, 2023 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR
5MG;1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL 8178541 Aug. 12, 2023 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN AND, OPTIONALLY, A SULFONYLUREA
10MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 8119648 Aug. 12, 2023 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN AND METFORMIN
10MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 8178541 Aug. 12, 2023 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN AND METFORMIN
12.5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 8119648 Aug. 12, 2023 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN AND METFORMIN
12.5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 8178541 Aug. 12, 2023 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN AND METFORMIN
25MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 8119648 Aug. 12, 2023 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN AND METFORMIN
25MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 8178541 Aug. 12, 2023 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN AND METFORMIN
5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 8119648 Aug. 12, 2023 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN AND METFORMIN
5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 8178541 Aug. 12, 2023 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN AND METFORMIN
EQ 12.5MG BASE;1GM KAZANO TAKEDA PHARMS USA N203414 Jan. 25, 2013 RX TABLET ORAL 8173663 March 15, 2025 METHOD OF TREATING DIABETES COMPRISING ADMINISTERING A COMPOUND SUCH AS ALOGLIPTIN
EQ 12.5MG BASE;500MG KAZANO TAKEDA PHARMS USA N203414 Jan. 25, 2013 RX TABLET ORAL 8173663 March 15, 2025 METHOD OF TREATING DIABETES COMPRISING ADMINISTERING A COMPOUND SUCH AS ALOGLIPTIN
150MG;1GM INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 8222219 April 11, 2025 REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
150MG;1GM INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 8222219 April 11, 2025 REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
150MG;1GM INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 8222219 April 11, 2025 TREATMENT OF TYPE 2 DIABETES MELLITUS
150MG;500MG INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 8222219 April 11, 2025 REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
150MG;500MG INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 8222219 April 11, 2025 REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
150MG;500MG INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 8222219 April 11, 2025 TREATMENT OF TYPE 2 DIABETES MELLITUS
50MG;1GM INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 8222219 April 11, 2025 REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
50MG;1GM INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 8222219 April 11, 2025 REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
50MG;1GM INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 8222219 April 11, 2025 TREATMENT OF TYPE 2 DIABETES MELLITUS
50MG;500MG INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 8222219 April 11, 2025 REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
50MG;500MG INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 8222219 April 11, 2025 REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
50MG;500MG INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 8222219 April 11, 2025 TREATMENT OF TYPE 2 DIABETES MELLITUS
150MG;1GM INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 8222219 April 11, 2025 REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
150MG;1GM INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 8222219 April 11, 2025 REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
150MG;1GM INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 8222219 April 11, 2025 TREATMENT OF TYPE 2 DIABETES MELLITUS
150MG;500MG INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 8222219 April 11, 2025 REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
150MG;500MG INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 8222219 April 11, 2025 REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
150MG;500MG INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 8222219 April 11, 2025 TREATMENT OF TYPE 2 DIABETES MELLITUS
50MG;1GM INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 8222219 April 11, 2025 REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
50MG;1GM INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 8222219 April 11, 2025 REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
50MG;1GM INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 8222219 April 11, 2025 TREATMENT OF TYPE 2 DIABETES MELLITUS
50MG;500MG INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 8222219 April 11, 2025 REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
50MG;500MG INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 8222219 April 11, 2025 REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
50MG;500MG INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 8222219 April 11, 2025 TREATMENT OF TYPE 2 DIABETES MELLITUS
10MG;1GM XIGDUO XR ASTRAZENECA AB N205649 Oct. 29, 2014 RX TABLET, EXTENDED RELEASE ORAL 6515117 Oct. 4, 2025 TREATMENT OF TYPE 2 DIABETES MELLITUS
10MG;500MG XIGDUO XR ASTRAZENECA AB N205649 Oct. 29, 2014 RX TABLET, EXTENDED RELEASE ORAL 6515117 Oct. 4, 2025 TREATMENT OF TYPE 2 DIABETES MELLITUS
2.5MG;1GM XIGDUO XR ASTRAZENECA AB N205649 July 28, 2017 RX TABLET, EXTENDED RELEASE ORAL 6515117 Oct. 4, 2025 TREATMENT OF TYPE 2 DIABETES MELLITUS
5MG;1GM XIGDUO XR ASTRAZENECA AB N205649 Oct. 29, 2014 RX TABLET, EXTENDED RELEASE ORAL 6515117 Oct. 4, 2025 TREATMENT OF TYPE 2 DIABETES MELLITUS
5MG;500MG XIGDUO XR ASTRAZENECA AB N205649 Oct. 29, 2014 RX TABLET, EXTENDED RELEASE ORAL 6515117 Oct. 4, 2025 TREATMENT OF TYPE 2 DIABETES MELLITUS
10MG;1GM;EQ 5MG BASE QTERNMET XR ASTRAZENECA AB N210874 May 2, 2019 DISCN TABLET, EXTENDED RELEASE ORAL 6515117 Oct. 4, 2025 TREATMENT OF TYPE 2 DIABETES MELLITUS
2.5MG;1GM;EQ 2.5MG BASE QTERNMET XR ASTRAZENECA AB N210874 May 2, 2019 DISCN TABLET, EXTENDED RELEASE ORAL 6515117 Oct. 4, 2025 TREATMENT OF TYPE 2 DIABETES MELLITUS
5MG;1GM;EQ 2.5MG BASE QTERNMET XR ASTRAZENECA AB N210874 May 2, 2019 DISCN TABLET, EXTENDED RELEASE ORAL 6515117 Oct. 4, 2025 TREATMENT OF TYPE 2 DIABETES MELLITUS
5MG;1GM;EQ 5MG BASE QTERNMET XR ASTRAZENECA AB N210874 May 2, 2019 DISCN TABLET, EXTENDED RELEASE ORAL 6515117 Oct. 4, 2025 TREATMENT OF TYPE 2 DIABETES MELLITUS
1GM;EQ 50MG BASE JANUMET MSD SUB MERCK N022044 March 30, 2007 RX TABLET ORAL 7326708 Nov. 24, 2026 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR
500MG;EQ 50MG BASE JANUMET MSD SUB MERCK N022044 March 30, 2007 RX TABLET ORAL 7326708 Nov. 24, 2026 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR
1GM;EQ 100MG BASE JANUMET XR MERCK SHARP DOHME N202270 Feb. 2, 2012 RX TABLET, EXTENDED RELEASE ORAL 7326708 Nov. 24, 2026 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND METFORMIN HCL EXTENDED RELEASE IS APPROPRIATE
1GM;EQ 50MG BASE JANUMET XR MERCK SHARP DOHME N202270 Feb. 2, 2012 RX TABLET, EXTENDED RELEASE ORAL 7326708 Nov. 24, 2026 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND METFORMIN HCL EXTENDED RELEASE IS APPROPRIATE
500MG;EQ 50MG BASE JANUMET XR MERCK SHARP DOHME N202270 Feb. 2, 2012 RX TABLET, EXTENDED RELEASE ORAL 7326708 Nov. 24, 2026 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND METFORMIN HCL EXTENDED RELEASE IS APPROPRIATE
2.5MG;1GM JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL 8673927 May 4, 2027 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
2.5MG;500MG JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL 8673927 May 4, 2027 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
2.5MG;850MG JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL 8673927 May 4, 2027 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
2.5MG;1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL 8673927 May 4, 2027 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
2.5MG;1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL 9173859 May 4, 2027 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
5MG;1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL 8673927 May 4, 2027 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
5MG;1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL 9173859 May 4, 2027 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
10MG;1GM XIGDUO XR ASTRAZENECA AB N205649 Oct. 29, 2014 RX TABLET, EXTENDED RELEASE ORAL 8501698 June 20, 2027 TREATMENT OF TYPE 2 DIABETES MELLITUS
10MG;500MG XIGDUO XR ASTRAZENECA AB N205649 Oct. 29, 2014 RX TABLET, EXTENDED RELEASE ORAL 8501698 June 20, 2027 TREATMENT OF TYPE 2 DIABETES MELLITUS
2.5MG;1GM XIGDUO XR ASTRAZENECA AB N205649 July 28, 2017 RX TABLET, EXTENDED RELEASE ORAL 8501698 June 20, 2027 TREATMENT OF TYPE 2 DIABETES MELLITUS
5MG;1GM XIGDUO XR ASTRAZENECA AB N205649 Oct. 29, 2014 RX TABLET, EXTENDED RELEASE ORAL 8501698 June 20, 2027 TREATMENT OF TYPE 2 DIABETES MELLITUS
5MG;500MG XIGDUO XR ASTRAZENECA AB N205649 Oct. 29, 2014 RX TABLET, EXTENDED RELEASE ORAL 8501698 June 20, 2027 TREATMENT OF TYPE 2 DIABETES MELLITUS
10MG;1GM;EQ 5MG BASE QTERNMET XR ASTRAZENECA AB N210874 May 2, 2019 DISCN TABLET, EXTENDED RELEASE ORAL 8501698 June 20, 2027 TREATMENT OF TYPE 2 DIABETES MELLITUS
2.5MG;1GM;EQ 2.5MG BASE QTERNMET XR ASTRAZENECA AB N210874 May 2, 2019 DISCN TABLET, EXTENDED RELEASE ORAL 8501698 June 20, 2027 TREATMENT OF TYPE 2 DIABETES MELLITUS
5MG;1GM;EQ 2.5MG BASE QTERNMET XR ASTRAZENECA AB N210874 May 2, 2019 DISCN TABLET, EXTENDED RELEASE ORAL 8501698 June 20, 2027 TREATMENT OF TYPE 2 DIABETES MELLITUS
5MG;1GM;EQ 5MG BASE QTERNMET XR ASTRAZENECA AB N210874 May 2, 2019 DISCN TABLET, EXTENDED RELEASE ORAL 8501698 June 20, 2027 TREATMENT OF TYPE 2 DIABETES MELLITUS
150MG;1GM INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 8513202 Dec. 3, 2027 REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
150MG;1GM INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 8513202 Dec. 3, 2027 REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
150MG;1GM INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 8513202 Dec. 3, 2027 TREATMENT OF TYPE 2 DIABETES MELLITUS
150MG;500MG INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 8513202 Dec. 3, 2027 REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
150MG;500MG INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 8513202 Dec. 3, 2027 REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
150MG;500MG INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 8513202 Dec. 3, 2027 TREATMENT OF TYPE 2 DIABETES MELLITUS
50MG;1GM INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 8513202 Dec. 3, 2027 REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
50MG;1GM INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 8513202 Dec. 3, 2027 REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
50MG;1GM INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 8513202 Dec. 3, 2027 TREATMENT OF TYPE 2 DIABETES MELLITUS
50MG;500MG INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 8513202 Dec. 3, 2027 REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
50MG;500MG INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 8513202 Dec. 3, 2027 REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
50MG;500MG INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 8513202 Dec. 3, 2027 TREATMENT OF TYPE 2 DIABETES MELLITUS
150MG;1GM INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 8513202 Dec. 3, 2027 REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
150MG;1GM INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 8513202 Dec. 3, 2027 REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
150MG;1GM INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 8513202 Dec. 3, 2027 TREATMENT OF TYPE 2 DIABETES MELLITUS
150MG;500MG INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 8513202 Dec. 3, 2027 REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
150MG;500MG INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 8513202 Dec. 3, 2027 REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
150MG;500MG INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 8513202 Dec. 3, 2027 TREATMENT OF TYPE 2 DIABETES MELLITUS
50MG;1GM INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 8513202 Dec. 3, 2027 REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
50MG;1GM INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 8513202 Dec. 3, 2027 REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
50MG;1GM INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 8513202 Dec. 3, 2027 TREATMENT OF TYPE 2 DIABETES MELLITUS
50MG;500MG INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 8513202 Dec. 3, 2027 REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
50MG;500MG INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 8513202 Dec. 3, 2027 REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
50MG;500MG INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 8513202 Dec. 3, 2027 TREATMENT OF TYPE 2 DIABETES MELLITUS
EQ 12.5MG BASE;1GM KAZANO TAKEDA PHARMS USA N203414 Jan. 25, 2013 RX TABLET ORAL 7807689 June 27, 2028 METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN
EQ 12.5MG BASE;500MG KAZANO TAKEDA PHARMS USA N203414 Jan. 25, 2013 RX TABLET ORAL 7807689 June 27, 2028 METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN
1GM;EQ 50MG BASE JANUMET MSD SUB MERCK N022044 March 30, 2007 RX TABLET ORAL 8414921 July 21, 2028 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH INSULIN
500MG;EQ 50MG BASE JANUMET MSD SUB MERCK N022044 March 30, 2007 RX TABLET ORAL 8414921 July 21, 2028 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH INSULIN
150MG;1GM INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 7943582 Feb. 26, 2029 REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
150MG;1GM INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 7943582 Feb. 26, 2029 REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
150MG;1GM INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 7943582 Feb. 26, 2029 TREATMENT OF TYPE 2 DIABETES MELLITUS
150MG;500MG INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 7943582 Feb. 26, 2029 REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
150MG;500MG INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 7943582 Feb. 26, 2029 REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
150MG;500MG INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 7943582 Feb. 26, 2029 TREATMENT OF TYPE 2 DIABETES MELLITUS
50MG;1GM INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 7943582 Feb. 26, 2029 REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
50MG;1GM INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 7943582 Feb. 26, 2029 REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
50MG;1GM INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 7943582 Feb. 26, 2029 TREATMENT OF TYPE 2 DIABETES MELLITUS
50MG;500MG INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 7943582 Feb. 26, 2029 REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
50MG;500MG INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 7943582 Feb. 26, 2029 REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
50MG;500MG INVOKAMET JANSSEN PHARMS N204353 Aug. 8, 2014 RX TABLET ORAL 7943582 Feb. 26, 2029 TREATMENT OF TYPE 2 DIABETES MELLITUS
150MG;1GM INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 7943582 Feb. 26, 2029 REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
150MG;1GM INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 7943582 Feb. 26, 2029 REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
150MG;1GM INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 7943582 Feb. 26, 2029 TREATMENT OF TYPE 2 DIABETES MELLITUS
150MG;500MG INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 7943582 Feb. 26, 2029 REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
150MG;500MG INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 7943582 Feb. 26, 2029 REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
150MG;500MG INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 7943582 Feb. 26, 2029 TREATMENT OF TYPE 2 DIABETES MELLITUS
50MG;1GM INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 7943582 Feb. 26, 2029 REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
50MG;1GM INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 7943582 Feb. 26, 2029 REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
50MG;1GM INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 7943582 Feb. 26, 2029 TREATMENT OF TYPE 2 DIABETES MELLITUS
50MG;500MG INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 7943582 Feb. 26, 2029 REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
50MG;500MG INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 7943582 Feb. 26, 2029 REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
50MG;500MG INVOKAMET XR JANSSEN PHARMS N205879 Sept. 20, 2016 RX TABLET, EXTENDED RELEASE ORAL 7943582 Feb. 26, 2029 TREATMENT OF TYPE 2 DIABETES MELLITUS
2.5MG;1GM JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL 10022379 April 2, 2029 USE OF A PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN, METFORMIN AND A BASIC AMINO ACID TO TREAT TYPE 2 DIABETES MELLITUS
2.5MG;500MG JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL 10022379 April 2, 2029 USE OF A PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN, METFORMIN AND A BASIC AMINO ACID TO TREAT TYPE 2 DIABETES MELLITUS
2.5MG;850MG JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL 10022379 April 2, 2029 USE OF A PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN, METFORMIN AND A BASIC AMINO ACID TO TREAT TYPE 2 DIABETES MELLITUS
2.5MG;1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL 10022379 April 2, 2029 USE OF A PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN, METFORMIN AND A BASIC AMINO ACID TO TREAT TYPE 2 DIABETES MELLITUS
5MG;1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL 10022379 April 2, 2029 USE OF A PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN, METFORMIN AND A BASIC AMINO ACID TO TREAT TYPE 2 DIABETES MELLITUS
10MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10022379 April 2, 2029 METHOD OF TREATING TYPE 2 DIABETES USING A PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN, METFORMIN, EMPAGLIFLOZIN AND A BASIC AMINO ACID
12.5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10022379 April 2, 2029 METHOD OF TREATING TYPE 2 DIABETES USING A PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN, METFORMIN, EMPAGLIFLOZIN AND A BASIC AMINO ACID
25MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10022379 April 2, 2029 METHOD OF TREATING TYPE 2 DIABETES USING A PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN, METFORMIN, EMPAGLIFLOZIN AND A BASIC AMINO ACID
5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10022379 April 2, 2029 METHOD OF TREATING TYPE 2 DIABETES USING A PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN, METFORMIN, EMPAGLIFLOZIN AND A BASIC AMINO ACID
10MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 8551957 Oct. 14, 2029 METHOD OF TREATING TYPE 2 DIABETES MELLITUS USING A PHARMACEUTICAL COMPOSITION COMPRISING EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN
12.5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 8551957 Oct. 14, 2029 METHOD OF TREATING TYPE 2 DIABETES MELLITUS USING A PHARMACEUTICAL COMPOSITION COMPRISING EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN
25MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 8551957 Oct. 14, 2029 METHOD OF TREATING TYPE 2 DIABETES MELLITUS USING A PHARMACEUTICAL COMPOSITION COMPRISING EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN
5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 8551957 Oct. 14, 2029 METHOD OF TREATING TYPE 2 DIABETES MELLITUS USING A PHARMACEUTICAL COMPOSITION COMPRISING EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN
10MG;1GM XIGDUO XR ASTRAZENECA AB N205649 Oct. 29, 2014 RX TABLET, EXTENDED RELEASE ORAL 8685934 May 26, 2030 TREATMENT OF TYPE 2 DIABETES MELLITUS IN A PATIENT, WHEREIN GLYCEMIC CONTROL (HBA1C < 7.0%) IS NOT ACHIEVABLE USING ONE OR MORE OF INSULIN, METFORMIN, PIOGLITAZONE, OR ROSIGLITAZONE
10MG;500MG XIGDUO XR ASTRAZENECA AB N205649 Oct. 29, 2014 RX TABLET, EXTENDED RELEASE ORAL 8685934 May 26, 2030 TREATMENT OF TYPE 2 DIABETES MELLITUS IN A PATIENT, WHEREIN GLYCEMIC CONTROL (HBA1C < 7.0%) IS NOT ACHIEVABLE USING ONE OR MORE OF INSULIN, METFORMIN, PIOGLITAZONE, OR ROSIGLITAZONE
2.5MG;1GM XIGDUO XR ASTRAZENECA AB N205649 July 28, 2017 RX TABLET, EXTENDED RELEASE ORAL 8685934 May 26, 2030 TREATMENT OF TYPE 2 DIABETES MELLITUS IN A PATIENT, WHEREIN GLYCEMIC CONTROL (HBA1C < 7.0%) IS NOT ACHIEVABLE USING ONE OR MORE OF INSULIN, METFORMIN, PIOGLITAZONE, OR ROSIGLITAZONE
5MG;1GM XIGDUO XR ASTRAZENECA AB N205649 Oct. 29, 2014 RX TABLET, EXTENDED RELEASE ORAL 8685934 May 26, 2030 TREATMENT OF TYPE 2 DIABETES MELLITUS IN A PATIENT, WHEREIN GLYCEMIC CONTROL (HBA1C < 7.0%) IS NOT ACHIEVABLE USING ONE OR MORE OF INSULIN, METFORMIN, PIOGLITAZONE, OR ROSIGLITAZONE
5MG;500MG XIGDUO XR ASTRAZENECA AB N205649 Oct. 29, 2014 RX TABLET, EXTENDED RELEASE ORAL 8685934 May 26, 2030 TREATMENT OF TYPE 2 DIABETES MELLITUS IN A PATIENT, WHEREIN GLYCEMIC CONTROL (HBA1C < 7.0%) IS NOT ACHIEVABLE USING ONE OR MORE OF INSULIN, METFORMIN, PIOGLITAZONE, OR ROSIGLITAZONE
2.5MG;1GM JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL 8846695 June 4, 2030 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
2.5MG;500MG JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL 8846695 June 4, 2030 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
2.5MG;850MG JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL 8846695 June 4, 2030 METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
10MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10406172 June 15, 2030 METHOD OF TREATING A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE THERAPY WITH METFORMIN USING A PHARMACEUTICAL COMPOSITION COMPRISING EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN
12.5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10406172 June 15, 2030 METHOD OF TREATING A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE THERAPY WITH METFORMIN USING A PHARMACEUTICAL COMPOSITION COMPRISING EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN
25MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10406172 June 15, 2030 METHOD OF TREATING A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE THERAPY WITH METFORMIN USING A PHARMACEUTICAL COMPOSITION COMPRISING EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN
5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10406172 June 15, 2030 METHOD OF TREATING A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE THERAPY WITH METFORMIN USING A PHARMACEUTICAL COMPOSITION COMPRISING EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN
2.5MG;1GM SEGLUROMET MSD SUB MERCK N209806 Dec. 19, 2017 RX TABLET ORAL 8080580 July 13, 2030 AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES
2.5MG;500MG SEGLUROMET MSD SUB MERCK N209806 Dec. 19, 2017 RX TABLET ORAL 8080580 July 13, 2030 AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES
7.5MG;1GM SEGLUROMET MSD SUB MERCK N209806 Dec. 19, 2017 RX TABLET ORAL 8080580 July 13, 2030 AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES
7.5MG;500MG SEGLUROMET MSD SUB MERCK N209806 Dec. 19, 2017 RX TABLET ORAL 8080580 July 13, 2030 AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES
2.5MG;1GM SEGLUROMET MSD SUB MERCK N209806 Dec. 19, 2017 RX TABLET ORAL 9439902 Oct. 21, 2030 AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES
2.5MG;500MG SEGLUROMET MSD SUB MERCK N209806 Dec. 19, 2017 RX TABLET ORAL 9439902 Oct. 21, 2030 AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES
7.5MG;1GM SEGLUROMET MSD SUB MERCK N209806 Dec. 19, 2017 RX TABLET ORAL 9439902 Oct. 21, 2030 AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES
7.5MG;500MG SEGLUROMET MSD SUB MERCK N209806 Dec. 19, 2017 RX TABLET ORAL 9439902 Oct. 21, 2030 AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES
10MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 10596120 March 7, 2032 TREATMENT OF A TREATMENT-NAÏVE PATIENT WITH INADEQUATELY CONTROLLED TYPE 2 DIABETES USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN
10MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 10596120 March 7, 2032 TREATMENT OF A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE METFORMIN THERAPY USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN
12.5MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 10596120 March 7, 2032 TREATMENT OF A TREATMENT-NAÏVE PATIENT WITH INADEQUATELY CONTROLLED TYPE 2 DIABETES USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN
12.5MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 10596120 March 7, 2032 TREATMENT OF A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE METFORMIN THERAPY USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN
25MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 10596120 March 7, 2032 TREATMENT OF A TREATMENT-NAÏVE PATIENT WITH INADEQUATELY CONTROLLED TYPE 2 DIABETES USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN
25MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 10596120 March 7, 2032 TREATMENT OF A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE METFORMIN THERAPY USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN
5MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 10596120 March 7, 2032 TREATMENT OF A TREATMENT-NAÏVE PATIENT WITH INADEQUATELY CONTROLLED TYPE 2 DIABETES USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN
5MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 10596120 March 7, 2032 TREATMENT OF A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE METFORMIN THERAPY USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN
10MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10596120 March 7, 2032 TREATMENT OF A TREATMENT-NAIVE PATIENT WITH INADEQUATELY CONTROLLED TYPE 2 DIABETES USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN
10MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10596120 March 7, 2032 TREATMENT OF A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE METFORMIN THERAPY USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN
10MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 11564886 March 7, 2032 TREATMENT OF A TYPE 2 DIABETES PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE METFORMIN THERAPY USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN
12.5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10596120 March 7, 2032 TREATMENT OF A TREATMENT-NAIVE PATIENT WITH INADEQUATELY CONTROLLED TYPE 2 DIABETES USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN
12.5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10596120 March 7, 2032 TREATMENT OF A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE METFORMIN THERAPY USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN
12.5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 11564886 March 7, 2032 TREATMENT OF A TYPE 2 DIABETES PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE METFORMIN THERAPY USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN
25MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10596120 March 7, 2032 TREATMENT OF A TREATMENT-NAIVE PATIENT WITH INADEQUATELY CONTROLLED TYPE 2 DIABETES USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN
25MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10596120 March 7, 2032 TREATMENT OF A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE METFORMIN THERAPY USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN
5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10596120 March 7, 2032 TREATMENT OF A TREATMENT-NAIVE PATIENT WITH INADEQUATELY CONTROLLED TYPE 2 DIABETES USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN
5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10596120 March 7, 2032 TREATMENT OF A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE METFORMIN THERAPY USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN
5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 11564886 March 7, 2032 TREATMENT OF A TYPE 2 DIABETES PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE METFORMIN THERAPY USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN
2.5MG;1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL 9555001 March 6, 2033 METHOD OF TREATING TYPE 2 DIABETES IN PATIENTS WHO HAVE NOT BEEN PREVIOUSLY TREATED WITH AN ANTIHYPERGLYCEMIC AGENT BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
2.5MG;1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL 9555001 March 6, 2033 METHOD OF TREATING TYPE 2 DIABETES IN PATIENTS WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE THERAPY WITH ONE OR MORE CONVENTIONAL ANTIHYPERGLYCEMIC AGENTS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
5MG;1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL 9555001 March 6, 2033 METHOD OF TREATING TYPE 2 DIABETES IN PATIENTS WHO HAVE NOT BEEN PREVIOUSLY TREATED WITH AN ANTIHYPERGLYCEMIC AGENT BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
5MG;1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL 9555001 March 6, 2033 METHOD OF TREATING TYPE 2 DIABETES IN PATIENTS WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE THERAPY WITH ONE OR MORE CONVENTIONAL ANTIHYPERGLYCEMIC AGENTS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
12.5MG;1GM SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 10258637 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
12.5MG;1GM SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 11090323 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATENT WITH RENAL IMPAIRMENT (EGFR<60 ML/MIN/1.73 M2) BY INITIATION OF EMPAGLIFLOZIN AND METFORMIN HCL IF EGFR>=45 ML/MIN/1.73 M2 AND DISCONTINUATION IF EGFR<30 ML/MIN/1.73 M2
12.5MG;500MG SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 10258637 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
12.5MG;500MG SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 11090323 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATENT WITH RENAL IMPAIRMENT (EGFR<60 ML/MIN/1.73 M2) BY INITIATION OF EMPAGLIFLOZIN AND METFORMIN HCL IF EGFR>=45 ML/MIN/1.73 M2 AND DISCONTINUATION IF EGFR<30 ML/MIN/1.73 M2
5MG;1GM SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 10258637 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
5MG;1GM SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 11090323 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATENT WITH RENAL IMPAIRMENT (EGFR<60 ML/MIN/1.73 M2) BY INITIATION OF EMPAGLIFLOZIN AND METFORMIN HCL IF EGFR>=45 ML/MIN/1.73 M2 AND DISCONTINUATION IF EGFR<30 ML/MIN/1.73 M2
5MG;500MG SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 10258637 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
5MG;500MG SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 11090323 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATENT WITH RENAL IMPAIRMENT (EGFR<60 ML/MIN/1.73 M2) BY INITIATION OF EMPAGLIFLOZIN AND METFORMIN HCL IF EGFR>=45 ML/MIN/1.73 M2 AND DISCONTINUATION IF EGFR<30 ML/MIN/1.73 M2
10MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 10258637 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
10MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 11090323 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATENT WITH RENAL IMPAIRMENT (EGFR<60 ML/MIN/1.73 M2) BY INITIATION OF EMPAGLIFLOZIN AND METFORMIN HCL IF EGFR>=45 ML/MIN/1.73 M2 AND DISCONTINUATION IF EGFR<30 ML/MIN/1.73 M2
12.5MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 10258637 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
12.5MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 11090323 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATENT WITH RENAL IMPAIRMENT (EGFR<60 ML/MIN/1.73 M2) BY INITIATION OF EMPAGLIFLOZIN AND METFORMIN HCL IF EGFR>=45 ML/MIN/1.73 M2 AND DISCONTINUATION IF EGFR<30 ML/MIN/1.73 M2
25MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 10258637 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
25MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 11090323 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATENT WITH RENAL IMPAIRMENT (EGFR<60 ML/MIN/1.73 M2) BY INITIATION OF EMPAGLIFLOZIN AND METFORMIN HCL IF EGFR>=45 ML/MIN/1.73 M2 AND DISCONTINUATION IF EGFR<30 ML/MIN/1.73 M2
5MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 10258637 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
5MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 11090323 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATENT WITH RENAL IMPAIRMENT (EGFR<60 ML/MIN/1.73 M2) BY INITIATION OF EMPAGLIFLOZIN AND METFORMIN HCL IF EGFR>=45 ML/MIN/1.73 M2 AND DISCONTINUATION IF EGFR<30 ML/MIN/1.73 M2
10MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10258637 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN IN COMBINATION WITH LINAGLIPTIN AND METFORMIN
10MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 11090323 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (EGFR<60 ML/MIN/1.73 M2) BY INITIATION OF EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN HCL IF EGFR>=45 ML/MIN/1.73 M2 AND DISCONTINUATION IF EGFR <30 ML/MIN/1.73 M2
12.5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10258637 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN IN COMBINATION WITH LINAGLIPTIN AND METFORMIN
12.5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 11090323 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (EGFR<60 ML/MIN/1.73 M2) BY INITIATION OF EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN HCL IF EGFR>=45 ML/MIN/1.73 M2 AND DISCONTINUATION IF EGFR <30 ML/MIN/1.73 M2
25MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10258637 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN IN COMBINATION WITH LINAGLIPTIN AND METFORMIN
25MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 11090323 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (EGFR<60 ML/MIN/1.73 M2) BY INITIATION OF EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN HCL IF EGFR>=45 ML/MIN/1.73 M2 AND DISCONTINUATION IF EGFR <30 ML/MIN/1.73 M2
5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 10258637 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN IN COMBINATION WITH LINAGLIPTIN AND METFORMIN
5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 11090323 April 3, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (EGFR<60 ML/MIN/1.73 M2) BY INITIATION OF EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN HCL IF EGFR>=45 ML/MIN/1.73 M2 AND DISCONTINUATION IF EGFR <30 ML/MIN/1.73 M2
12.5MG;1GM SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 9949997 May 17, 2034 METHOD FOR REDUCING THE RISK OF CARDIOVASCULAR DEATH AND HOSPITALIZATION FOR HEART FAILURE IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ONCE DAILY ADMINISTRATION OF EMPAGLIFLOZIN
12.5MG;1GM SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 9949997 May 17, 2034 METHOD FOR REDUCING THE RISK OF CARDIOVASCULAR DEATH IN ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS AND CARDIOVASCULAR DISEASE BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
12.5MG;500MG SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 9949997 May 17, 2034 METHOD FOR REDUCING THE RISK OF CARDIOVASCULAR DEATH AND HOSPITALIZATION FOR HEART FAILURE IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ONCE DAILY ADMINISTRATION OF EMPAGLIFLOZIN
12.5MG;500MG SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 9949997 May 17, 2034 METHOD FOR REDUCING THE RISK OF CARDIOVASCULAR DEATH IN ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS AND CARDIOVASCULAR DISEASE BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
5MG;1GM SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 9949997 May 17, 2034 METHOD FOR REDUCING THE RISK OF CARDIOVASCULAR DEATH AND HOSPITALIZATION FOR HEART FAILURE IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ONCE DAILY ADMINISTRATION OF EMPAGLIFLOZIN
5MG;1GM SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 9949997 May 17, 2034 METHOD FOR REDUCING THE RISK OF CARDIOVASCULAR DEATH IN ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS AND CARDIOVASCULAR DISEASE BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
5MG;500MG SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 9949997 May 17, 2034 METHOD FOR REDUCING THE RISK OF CARDIOVASCULAR DEATH AND HOSPITALIZATION FOR HEART FAILURE IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ONCE DAILY ADMINISTRATION OF EMPAGLIFLOZIN
5MG;500MG SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL 9949997 May 17, 2034 METHOD FOR REDUCING THE RISK OF CARDIOVASCULAR DEATH IN ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS AND CARDIOVASCULAR DISEASE BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
10MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 9949997 May 17, 2034 METHOD FOR REDUCING THE RISK OF CARDIOVASCULAR DEATH AND HOSPITALIZATION FOR HEART FAILURE IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ONCE DAILY ADMINISTRATION OF EMPAGLIFLOZIN
10MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 9949997 May 17, 2034 METHOD FOR REDUCING THE RISK OF CARDIOVASCULAR DEATH IN ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS AND CARDIOVASCULAR DISEASE BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
12.5MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 9949997 May 17, 2034 METHOD FOR REDUCING THE RISK OF CARDIOVASCULAR DEATH AND HOSPITALIZATION FOR HEART FAILURE IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ONCE DAILY ADMINISTRATION OF EMPAGLIFLOZIN
12.5MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 9949997 May 17, 2034 METHOD FOR REDUCING THE RISK OF CARDIOVASCULAR DEATH IN ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS AND CARDIOVASCULAR DISEASE BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
25MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 9949997 May 17, 2034 METHOD FOR REDUCING THE RISK OF CARDIOVASCULAR DEATH AND HOSPITALIZATION FOR HEART FAILURE IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ONCE DAILY ADMINISTRATION OF EMPAGLIFLOZIN
25MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 9949997 May 17, 2034 METHOD FOR REDUCING THE RISK OF CARDIOVASCULAR DEATH IN ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS AND CARDIOVASCULAR DISEASE BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
5MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 9949997 May 17, 2034 METHOD FOR REDUCING THE RISK OF CARDIOVASCULAR DEATH AND HOSPITALIZATION FOR HEART FAILURE IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ONCE DAILY ADMINISTRATION OF EMPAGLIFLOZIN
5MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 9949997 May 17, 2034 METHOD FOR REDUCING THE RISK OF CARDIOVASCULAR DEATH IN ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS AND CARDIOVASCULAR DISEASE BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
10MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 9949998 June 11, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
12.5MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 9949998 June 11, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
25MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 9949998 June 11, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
5MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL 9949998 June 11, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN
10MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 9949998 June 11, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN IN COMBINATION WITH LINAGLIPTIN AND METFORMIN
12.5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 9949998 June 11, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN IN COMBINATION WITH LINAGLIPTIN AND METFORMIN
25MG;5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 9949998 June 11, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN IN COMBINATION WITH LINAGLIPTIN AND METFORMIN
5MG;2.5MG;1GM TRIJARDY XR BOEHRINGER INGELHEIM N212614 Jan. 27, 2020 RX TABLET, EXTENDED RELEASE ORAL 9949998 June 11, 2034 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN IN COMBINATION WITH LINAGLIPTIN AND METFORMIN

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
1GM;EQ 50MG BASE JANUMET MSD SUB MERCK N022044 March 30, 2007 RX TABLET ORAL Feb. 12, 2023 PEDIATRIC EXCLUSIVITY
500MG;EQ 50MG BASE JANUMET MSD SUB MERCK N022044 March 30, 2007 RX TABLET ORAL Feb. 12, 2023 PEDIATRIC EXCLUSIVITY
1GM;EQ 100MG BASE JANUMET XR MERCK SHARP DOHME N202270 Feb. 2, 2012 RX TABLET, EXTENDED RELEASE ORAL Feb. 12, 2023 PEDIATRIC EXCLUSIVITY
1GM;EQ 50MG BASE JANUMET XR MERCK SHARP DOHME N202270 Feb. 2, 2012 RX TABLET, EXTENDED RELEASE ORAL Feb. 12, 2023 PEDIATRIC EXCLUSIVITY
500MG;EQ 50MG BASE JANUMET XR MERCK SHARP DOHME N202270 Feb. 2, 2012 RX TABLET, EXTENDED RELEASE ORAL Feb. 12, 2023 PEDIATRIC EXCLUSIVITY
2.5MG;1GM JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL March 30, 2023 ADDITION OF INFORMATION TO CLINICAL STUDIES SECTION REGARDING CARDIOVASCULAR OUTCOME
2.5MG;500MG JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL March 30, 2023 ADDITION OF INFORMATION TO CLINICAL STUDIES SECTION REGARDING CARDIOVASCULAR OUTCOME
2.5MG;850MG JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL March 30, 2023 ADDITION OF INFORMATION TO CLINICAL STUDIES SECTION REGARDING CARDIOVASCULAR OUTCOME
2.5MG;1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL March 30, 2023 ADDITION OF INFORMATION TO CLINICAL STUDIES SECTION REGARDING CARDIOVASCULAR OUTCOME
5MG;1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL March 30, 2023 ADDITION OF INFORMATION TO CLINICAL STUDIES SECTION REGARDING CARDIOVASCULAR OUTCOME
1GM;EQ 50MG BASE JANUMET MSD SUB MERCK N022044 March 30, 2007 RX TABLET ORAL Dec. 4, 2023 ADDITION OF CLINICAL INFORMATION OBTAINED FROM A PEDIATRIC TRIAL TO SECTION 8.4 OF THE LABELING
500MG;EQ 50MG BASE JANUMET MSD SUB MERCK N022044 March 30, 2007 RX TABLET ORAL Dec. 4, 2023 ADDITION OF CLINICAL INFORMATION OBTAINED FROM A PEDIATRIC TRIAL TO SECTION 8.4 OF THE LABELING
1GM;EQ 50MG BASE JANUMET XR MERCK SHARP DOHME N202270 Feb. 2, 2012 RX TABLET, EXTENDED RELEASE ORAL Dec. 4, 2023 ADDITION OF CLINICAL INFORMATION OBTAINED FROM A PEDIATRIC TRIAL TO SECTION 8.4 OF THE LABELING
500MG;EQ 50MG BASE JANUMET XR MERCK SHARP DOHME N202270 Feb. 2, 2012 RX TABLET, EXTENDED RELEASE ORAL Dec. 4, 2023 ADDITION OF CLINICAL INFORMATION OBTAINED FROM A PEDIATRIC TRIAL TO SECTION 8.4 OF THE LABELING
1GM;EQ 50MG BASE JANUMET MSD SUB MERCK N022044 March 30, 2007 RX TABLET ORAL June 4, 2024 PEDIATRIC EXCLUSIVITY
500MG;EQ 50MG BASE JANUMET MSD SUB MERCK N022044 March 30, 2007 RX TABLET ORAL June 4, 2024 PEDIATRIC EXCLUSIVITY
1GM;EQ 50MG BASE JANUMET XR MERCK SHARP DOHME N202270 Feb. 2, 2012 RX TABLET, EXTENDED RELEASE ORAL June 4, 2024 PEDIATRIC EXCLUSIVITY
500MG;EQ 50MG BASE JANUMET XR MERCK SHARP DOHME N202270 Feb. 2, 2012 RX TABLET, EXTENDED RELEASE ORAL June 4, 2024 PEDIATRIC EXCLUSIVITY
2.5MG;1GM SEGLUROMET MSD SUB MERCK N209806 Dec. 19, 2017 RX TABLET ORAL Sept. 17, 2024 REVISION TO THE LABELING TO INCLUDE RESULTS FROM CLINICAL STUDY, MK-8835-004/B1521021, VERTIS CV
2.5MG;500MG SEGLUROMET MSD SUB MERCK N209806 Dec. 19, 2017 RX TABLET ORAL Sept. 17, 2024 REVISION TO THE LABELING TO INCLUDE RESULTS FROM CLINICAL STUDY, MK-8835-004/B1521021, VERTIS CV
7.5MG;1GM SEGLUROMET MSD SUB MERCK N209806 Dec. 19, 2017 RX TABLET ORAL Sept. 17, 2024 REVISION TO THE LABELING TO INCLUDE RESULTS FROM CLINICAL STUDY, MK-8835-004/B1521021, VERTIS CV
7.5MG;500MG SEGLUROMET MSD SUB MERCK N209806 Dec. 19, 2017 RX TABLET ORAL Sept. 17, 2024 REVISION TO THE LABELING TO INCLUDE RESULTS FROM CLINICAL STUDY, MK-8835-004/B1521021, VERTIS CV
2.5MG;1GM JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL June 20, 2026 REVISIONS TO THE PEDIATRIC USE SUBSECTION OF LABELING TO INCLUDE THE RESULTS FROM CLINICAL STUDY 1218-0091, CONDUCTED TO FULFILL A PEDIATRIC WRITTEN REQUEST
2.5MG;500MG JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL June 20, 2026 REVISIONS TO THE PEDIATRIC USE SUBSECTION OF LABELING TO INCLUDE THE RESULTS FROM CLINICAL STUDY 1218-0091, CONDUCTED TO FULFILL A PEDIATRIC WRITTEN REQUEST
2.5MG;850MG JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL June 20, 2026 REVISIONS TO THE PEDIATRIC USE SUBSECTION OF LABELING TO INCLUDE THE RESULTS FROM CLINICAL STUDY 1218-0091, CONDUCTED TO FULFILL A PEDIATRIC WRITTEN REQUEST
12.5MG;1GM SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL June 20, 2026 NEW PATIENT POPULATION
12.5MG;500MG SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL June 20, 2026 NEW PATIENT POPULATION
5MG;1GM SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL June 20, 2026 NEW PATIENT POPULATION
5MG;500MG SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL June 20, 2026 NEW PATIENT POPULATION
2.5MG;1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL June 20, 2026 REVISIONS TO THE PEDIATRIC USE SUBSECTION OF LABELING TO INCLUDE THE RESULTS FROM CLINICAL STUDY 1218-0091, CONDUCTED TO FULFILL A PEDIATRIC WRITTEN REQUEST
5MG;1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL June 20, 2026 REVISIONS TO THE PEDIATRIC USE SUBSECTION OF LABELING TO INCLUDE THE RESULTS FROM CLINICAL STUDY 1218-0091, CONDUCTED TO FULFILL A PEDIATRIC WRITTEN REQUEST
10MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL June 20, 2026 REVISIONS TO THE LABELING TO INCLUDE RESULTS FROM PROTOCOL 1218- 0091
12.5MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL June 20, 2026 REVISIONS TO THE LABELING TO INCLUDE RESULTS FROM PROTOCOL 1218- 0091
25MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL June 20, 2026 REVISIONS TO THE LABELING TO INCLUDE RESULTS FROM PROTOCOL 1218- 0091
5MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL June 20, 2026 REVISIONS TO THE LABELING TO INCLUDE RESULTS FROM PROTOCOL 1218- 0091
2.5MG;1GM JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL Dec. 20, 2026 PEDIATRIC EXCLUSIVITY
2.5MG;500MG JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL Dec. 20, 2026 PEDIATRIC EXCLUSIVITY
2.5MG;850MG JENTADUETO BOEHRINGER INGELHEIM N201281 Jan. 30, 2012 RX TABLET ORAL Dec. 20, 2026 PEDIATRIC EXCLUSIVITY
12.5MG;1GM SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL Dec. 20, 2026 PEDIATRIC EXCLUSIVITY
12.5MG;500MG SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL Dec. 20, 2026 PEDIATRIC EXCLUSIVITY
5MG;1GM SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL Dec. 20, 2026 PEDIATRIC EXCLUSIVITY
5MG;500MG SYNJARDY BOEHRINGER INGELHEIM N206111 Aug. 26, 2015 RX TABLET ORAL Dec. 20, 2026 PEDIATRIC EXCLUSIVITY
2.5MG;1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL Dec. 20, 2026 PEDIATRIC EXCLUSIVITY
5MG;1GM JENTADUETO XR BOEHRINGER INGELHEIM N208026 May 27, 2016 RX TABLET, EXTENDED RELEASE ORAL Dec. 20, 2026 PEDIATRIC EXCLUSIVITY
10MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL Dec. 20, 2026 PEDIATRIC EXCLUSIVITY
12.5MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL Dec. 20, 2026 PEDIATRIC EXCLUSIVITY
25MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL Dec. 20, 2026 PEDIATRIC EXCLUSIVITY
5MG;1GM SYNJARDY XR BOEHRINGER INGELHEIM N208658 Dec. 9, 2016 RX TABLET, EXTENDED RELEASE ORAL Dec. 20, 2026 PEDIATRIC EXCLUSIVITY

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Mitochondrial complex I (NADH dehydrogenase) Enzyme INHIBITOR CHEMBL CHEMBL
5'-AMP-activated protein kinase subunit beta-1 Kinase WOMBAT-PK
Dipeptidyl peptidase 4 Enzyme IC50 4.54 CHEMBL
Solute carrier family 22 member 1 Transporter IC50 2.70 WOMBAT-PK
Solute carrier family 22 member 2 Transporter IC50 3.40 WOMBAT-PK
Solute carrier family 22 member 3 Transporter Km 2.50 WOMBAT-PK

External reference:

IDSource
4023979 VUID
N0000021984 NUI
D00944 KEGG_DRUG
1115-70-4 SECONDARY_CAS_RN
4020898 VANDF
4023979 VANDF
C0025598 UMLSCUI
CHEBI:6801 CHEBI
MF8 PDB_CHEM_ID
CHEMBL1431 ChEMBL_ID
4091 PUBCHEM_CID
DB00331 DRUGBANK_ID
CHEMBL1703 ChEMBL_ID
D008687 MESH_DESCRIPTOR_UI
965 INN_ID
4779 IUPHAR_LIGAND_ID
9100L32L2N UNII
151827 RXNORM
41717 MMSL
5063 MMSL
592 MMSL
d03807 MMSL
003483 NDDF
004534 NDDF
109081006 SNOMEDCT_US
109083009 SNOMEDCT_US
372567009 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
JANUMET XR HUMAN PRESCRIPTION DRUG LABEL 2 0006-0078 TABLET, FILM COATED, EXTENDED RELEASE 500 mg ORAL NDA 30 sections
JANUMET XR HUMAN PRESCRIPTION DRUG LABEL 2 0006-0078 TABLET, FILM COATED, EXTENDED RELEASE 500 mg ORAL NDA 30 sections
JANUMET XR HUMAN PRESCRIPTION DRUG LABEL 2 0006-0078 TABLET, FILM COATED, EXTENDED RELEASE 500 mg ORAL NDA 30 sections
JANUMET XR HUMAN PRESCRIPTION DRUG LABEL 2 0006-0080 TABLET, FILM COATED, EXTENDED RELEASE 1000 mg ORAL NDA 30 sections
JANUMET XR HUMAN PRESCRIPTION DRUG LABEL 2 0006-0080 TABLET, FILM COATED, EXTENDED RELEASE 1000 mg ORAL NDA 30 sections
JANUMET XR HUMAN PRESCRIPTION DRUG LABEL 2 0006-0080 TABLET, FILM COATED, EXTENDED RELEASE 1000 mg ORAL NDA 30 sections
JANUMET XR HUMAN PRESCRIPTION DRUG LABEL 2 0006-0081 TABLET, FILM COATED, EXTENDED RELEASE 1000 mg ORAL NDA 30 sections
JANUMET XR HUMAN PRESCRIPTION DRUG LABEL 2 0006-0081 TABLET, FILM COATED, EXTENDED RELEASE 1000 mg ORAL NDA 30 sections
JANUMET XR HUMAN PRESCRIPTION DRUG LABEL 2 0006-0081 TABLET, FILM COATED, EXTENDED RELEASE 1000 mg ORAL NDA 30 sections
JANUMET HUMAN PRESCRIPTION DRUG LABEL 2 0006-0575 TABLET, FILM COATED 500 mg ORAL NDA 29 sections
JANUMET HUMAN PRESCRIPTION DRUG LABEL 2 0006-0575 TABLET, FILM COATED 500 mg ORAL NDA 29 sections
JANUMET HUMAN PRESCRIPTION DRUG LABEL 2 0006-0575 TABLET, FILM COATED 500 mg ORAL NDA 29 sections
JANUMET HUMAN PRESCRIPTION DRUG LABEL 2 0006-0577 TABLET, FILM COATED 1000 mg ORAL NDA 29 sections
JANUMET HUMAN PRESCRIPTION DRUG LABEL 2 0006-0577 TABLET, FILM COATED 1000 mg ORAL NDA 29 sections
JANUMET HUMAN PRESCRIPTION DRUG LABEL 2 0006-0577 TABLET, FILM COATED 1000 mg ORAL NDA 29 sections
SEGLUROMET HUMAN PRESCRIPTION DRUG LABEL 2 0006-5369 TABLET, FILM COATED 500 mg ORAL NDA 30 sections
SEGLUROMET HUMAN PRESCRIPTION DRUG LABEL 2 0006-5369 TABLET, FILM COATED 500 mg ORAL NDA 30 sections
SEGLUROMET HUMAN PRESCRIPTION DRUG LABEL 2 0006-5369 TABLET, FILM COATED 500 mg ORAL NDA 30 sections
SEGLUROMET HUMAN PRESCRIPTION DRUG LABEL 2 0006-5370 TABLET, FILM COATED 500 mg ORAL NDA 30 sections
SEGLUROMET HUMAN PRESCRIPTION DRUG LABEL 2 0006-5370 TABLET, FILM COATED 500 mg ORAL NDA 30 sections
SEGLUROMET HUMAN PRESCRIPTION DRUG LABEL 2 0006-5370 TABLET, FILM COATED 500 mg ORAL NDA 30 sections
SEGLUROMET HUMAN PRESCRIPTION DRUG LABEL 2 0006-5373 TABLET, FILM COATED 1000 mg ORAL NDA 30 sections
SEGLUROMET HUMAN PRESCRIPTION DRUG LABEL 2 0006-5373 TABLET, FILM COATED 1000 mg ORAL NDA 30 sections
SEGLUROMET HUMAN PRESCRIPTION DRUG LABEL 2 0006-5373 TABLET, FILM COATED 1000 mg ORAL NDA 30 sections
SEGLUROMET HUMAN PRESCRIPTION DRUG LABEL 2 0006-5374 TABLET, FILM COATED 1000 mg ORAL NDA 30 sections
SEGLUROMET HUMAN PRESCRIPTION DRUG LABEL 2 0006-5374 TABLET, FILM COATED 1000 mg ORAL NDA 30 sections
SEGLUROMET HUMAN PRESCRIPTION DRUG LABEL 2 0006-5374 TABLET, FILM COATED 1000 mg ORAL NDA 30 sections
Glipizide and Metformin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 2 0093-7455 TABLET, FILM COATED 250 mg ORAL ANDA 27 sections
Glipizide and Metformin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 2 0093-7456 TABLET, FILM COATED 500 mg ORAL ANDA 27 sections
Glipizide and Metformin Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 2 0093-7457 TABLET, FILM COATED 500 mg ORAL ANDA 27 sections